{"matching_results": 30958, "aggregations": [{"type": "term", "field": "host", "results": [{"key": "americanbankingnews.com", "matching_results": 1590, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 1316}, {"key": "negative", "matching_results": 255}, {"key": "neutral", "matching_results": 19}]}]}, {"key": "watchlistnews.com", "matching_results": 878, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 760}, {"key": "negative", "matching_results": 118}]}]}, {"key": "tickerreport.com", "matching_results": 867, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 787}, {"key": "negative", "matching_results": 80}]}]}, {"key": "dailypolitical.com", "matching_results": 824, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 716}, {"key": "negative", "matching_results": 108}]}]}, {"key": "freelancer.com.co", "matching_results": 808, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 727}, {"key": "negative", "matching_results": 65}, {"key": "neutral", "matching_results": 16}]}]}, {"key": "wkrb13.com", "matching_results": 794, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 691}, {"key": "negative", "matching_results": 103}]}]}, {"key": "zolmax.com", "matching_results": 772, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 671}, {"key": "negative", "matching_results": 100}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "theolympiareport.com", "matching_results": 706, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 578}, {"key": "negative", "matching_results": 127}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "thelincolnianonline.com", "matching_results": 550, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 453}, {"key": "negative", "matching_results": 97}]}]}, {"key": "marketscreener.com", "matching_results": 520, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 363}, {"key": "negative", "matching_results": 154}, {"key": "neutral", "matching_results": 3}]}]}]}], "results": [{"id": "ZLuFdKv4F3aRa-x0CIaJlx9PqFvacDQFxrOK4GIjM1bnlxX0VZQw8ZI751gReD0g", "result_metadata": {"score": 37.632774}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co", "relevance": 0.949873, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.506728, "label": "positive"}, "text": "Mitsubishi", "relevance": 0.445733, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "Mitsubishi", "keywords": [{"text": "Mitsubishi"}], "entities": [{"type": "Company", "text": "Mitsubishi"}]}, "sentence": "Mitsubishi UFJ Fin.", "object": {"text": "Fin", "keywords": [{"text": "Fin"}]}, "action": {"verb": {"text": "UFJ", "tense": "present"}, "text": "UFJ", "normalized": "UFJ"}}], "concepts": [{"text": "Mitsubishi", "relevance": 0.909247, "dbpedia_resource": "http://dbpedia.org/resource/Mitsubishi"}, {"text": "Mitsubishi UFJ Financial Group", "relevance": 0.854345, "dbpedia_resource": "http://dbpedia.org/resource/Mitsubishi_UFJ_Financial_Group"}, {"text": "Companies based in Osaka Prefecture", "relevance": 0.662889, "dbpedia_resource": "http://dbpedia.org/resource/Companies_based_in_Osaka_Prefecture"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.644805, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.615638, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.971291}, {"text": "Fin", "sentiment": {"score": 0.506728, "label": "positive"}, "relevance": 0.86126}, {"text": "Mitsubishi", "sentiment": {"score": 0.506728, "label": "positive"}, "relevance": 0.838167}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.487755}]}, "crawl_date": "2018-11-08T08:48:50Z", "url": "https://www.moneyam.com/action/news/showArticle?id=6199598", "host": "moneyam.com", "text": "(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Takeda Pharmaceutical Co.", "country": "GB", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-08T08:29:00Z", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mitsubishi UFJ Financial Group", "relevance": 0.835935, "type": "Company", "disambiguation": {"subtype": [], "name": "Mitsubishi UFJ Financial Group", "dbpedia_resource": "http://dbpedia.org/resource/Mitsubishi_UFJ_Financial_Group"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mitsubishi UFJ Kokusai Asset Management Co.", "relevance": 0.740544, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mitsubishi UFJ Trust", "relevance": 0.737465, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co. Ltd.", "relevance": 0.460665, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "MU Investments Co.", "relevance": 0.451325, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.403974, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.350098, "type": "JobTitle"}], "sentiment": {"document": {"score": -0.383144, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Mitsubishi", "keywords": [{"text": "Mitsubishi"}], "entities": [{"type": "Company", "text": "Mitsubishi UFJ Trust"}]}, "sentence": " Mitsubishi UFJ Trust and Banking Corporation Mitsubishi UFJ Kokusai Asset Management Co., Ltd.", "object": {"text": "Trust", "keywords": [{"text": "Trust"}]}, "action": {"verb": {"text": "UFJ", "tense": "present"}, "text": "UFJ", "normalized": "UFJ"}}, {"subject": {"text": "Mitsubishi UFJ Trust and Banking Corporation Mitsubishi", "keywords": [{"text": "Mitsubishi UFJ Trust"}, {"text": "Banking Corporation"}], "entities": [{"type": "Company", "text": "Mitsubishi UFJ Trust"}, {"type": "Company", "text": "Mitsubishi UFJ Kokusai Asset Management Co."}]}, "sentence": " Mitsubishi UFJ Trust and Banking Corporation Mitsubishi UFJ Kokusai Asset Management Co., Ltd.", "object": {"text": "Kokusai Asset Management Co., Ltd", "keywords": [{"text": "Asset Management Co."}]}, "action": {"verb": {"text": "UFJ", "tense": "present"}, "text": "UFJ", "normalized": "UFJ"}}, {"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \"N/A\" NO", "object": {"text": "a cash offer or possible cash offer", "keywords": [{"text": "possible cash offer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}], "concepts": [{"text": "Mitsubishi", "relevance": 0.970883, "dbpedia_resource": "http://dbpedia.org/resource/Mitsubishi"}, {"text": "Mitsubishi UFJ Financial Group", "relevance": 0.949945, "dbpedia_resource": "http://dbpedia.org/resource/Mitsubishi_UFJ_Financial_Group"}, {"text": "Financial services", "relevance": 0.841192, "dbpedia_resource": "http://dbpedia.org/resource/Financial_services"}, {"text": "Investment", "relevance": 0.726561, "dbpedia_resource": "http://dbpedia.org/resource/Investment"}], "categories": [{"score": 0.562411, "label": "/finance/financial news"}, {"score": 0.468672, "label": "/finance/investing"}, {"score": 0.468672, "label": "/finance/investing/beginning investing"}], "relations": [], "keywords": [{"text": "Mitsubishi UFJ Financial", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.945102}, {"text": "opening position disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.804902}, {"text": "offeror/offeree Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.753546}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.730105}, {"text": "MU Investments Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.728883}, {"text": "Asset Management Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.723545}, {"text": "possible cash offer", "sentiment": {"score": 0.396801, "label": "positive"}, "relevance": 0.713939}, {"text": "latest practicable date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.684658}, {"text": "short positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52256}, {"text": "vehicle companies", "sentiment": {"score": -0.502364, "label": "negative"}, "relevance": 0.517344}, {"text": "Date position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.492986}, {"text": "Banking Corporation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.484801}, {"text": "separate form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.477722}, {"text": "relevant securities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.475548}, {"text": "Co. Ltd.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.468615}, {"text": "N/A", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.453665}, {"text": "state", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.302924}, {"text": "beneficiaries", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.291878}, {"text": "nominee", "sentiment": {"score": -0.502364, "label": "negative"}, "relevance": 0.288707}, {"text": "discloser", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.28601}, {"text": "trust", "sentiment": {"score": 0.575723, "label": "positive"}, "relevance": 0.285807}, {"text": "trustee", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.283504}, {"text": "disclosures", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.282942}, {"text": "naming", "sentiment": {"score": -0.502364, "label": "negative"}, "relevance": 0.270849}, {"text": "controller", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.268176}, {"text": "respect", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.253917}, {"text": "relation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.253043}, {"text": "Group", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.250826}, {"text": "Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.250765}, {"text": "Owner", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.250642}, {"text": "interests", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.25052}, {"text": "settlor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.246559}, {"text": "addition", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.244964}]}, "extracted_metadata": {"sha1": "b96a2fe4dcaad8a4280e9fafce8f3e567a080c19", "filename": "1541666930235.zip-7669d10c9209feca3f148dd2c9fb9db7.xml", "file_type": "json"}, "title": "Mitsubishi UFJ Fin. Form 8.3 - Takeda Pharmaceutical Co. Ltd", "forum_title": "MoneyAM News"}, {"id": "CnPawL1llvJ6DO0ZmKAKV2p7fMQFD0kd47KgS_kZwxCbEJDf-pq6RxjLURKs2cXI", "result_metadata": {"score": 36.730064}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.363752, "label": "negative"}, "text": "Market Development", "relevance": 0.33, "type": "JobTitle"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Marketing", "relevance": 0.902134, "dbpedia_resource": "http://dbpedia.org/resource/Marketing"}, {"text": "Economics", "relevance": 0.791193, "dbpedia_resource": "http://dbpedia.org/resource/Economics"}], "categories": [{"score": 0.612665, "label": "/health and fitness"}, {"score": 0.464234, "label": "/business and industrial/business operations/management/business process"}, {"score": 0.421841, "label": "/finance/financial news"}], "relations": [{"type": "employedBy", "sentence": "Anti-Obesity Drugs Market Precise Analysis on Business Overview, Product Scope and Ongoing Market Development 2024", "score": 0.409652, "arguments": [{"text": "Anti", "location": [0, 4], "entities": [{"type": "Person", "text": "Anti"}]}, {"text": "Obesity Drugs Market Precise Analysis", "location": [5, 42], "entities": [{"type": "Organization", "text": "Obesity Drugs Market Precise Analysis"}]}]}], "keywords": [{"text": "Drugs Market Precise", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.941531}, {"text": "Ongoing Market Development", "sentiment": {"score": -0.363753, "label": "negative"}, "relevance": 0.673506}, {"text": "Product Scope", "sentiment": {"score": -0.363753, "label": "negative"}, "relevance": 0.471617}, {"text": "Business Overview", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.310737}]}, "crawl_date": "2018-11-07T20:55:43Z", "url": "http://www.sbwire.com/press-releases/anti-obesity-drugs-market/release-1078954.htm", "host": "sbwire.com", "text": "Global Anti-Obesity Drugs Market: Competitive Landscape Snapshot The leading companies operating in the global anti-obesity drugs market include Boehringer Ingelheim GmbH, Arena Pharmaceuticals Inc., Takeda Pharmaceuticals Company Limited, Zydus Cadila, Rhythm Pharmaceuticals, Merck & Co.", "main_image_url": "http://media.releasewire.com/photos/show/?id=69214", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-07T20:57:00Z", "enriched_text": {"entities": [{"count": 4, "sentiment": {"score": -0.390419, "label": "negative"}, "text": "obesity", "relevance": 0.462044, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}, {"count": 1, "sentiment": {"score": -0.363753, "label": "negative"}, "text": "Market Development", "relevance": 0.402714, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": -0.206956, "label": "negative"}, "text": "North America", "relevance": 0.264622, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 2, "sentiment": {"score": 0.785375, "label": "positive"}, "text": "U.S.", "relevance": 0.260806, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "World Health Organization", "relevance": 0.237966, "type": "Organization", "disambiguation": {"subtype": [], "name": "World Health Organization", "dbpedia_resource": "http://dbpedia.org/resource/World_Health_Organization"}}, {"count": 1, "sentiment": {"score": -0.511131, "label": "negative"}, "text": "Centers for Disease Control and Prevention", "relevance": 0.234224, "type": "Organization", "disambiguation": {"subtype": ["GovernmentAgency", "GovernmentalBody"], "name": "Centers for Disease Control and Prevention", "dbpedia_resource": "http://dbpedia.org/resource/Centers_for_Disease_Control_and_Prevention"}}, {"count": 1, "sentiment": {"score": -0.217533, "label": "negative"}, "text": "Boehringer Ingelheim GmbH", "relevance": 0.210997, "type": "Company", "disambiguation": {"subtype": [], "name": "Boehringer Ingelheim", "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}}, {"count": 1, "sentiment": {"score": -0.433844, "label": "negative"}, "text": "underweight", "relevance": 0.20306, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia Pacific", "relevance": 0.191812, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.221008, "label": "negative"}, "text": "Zydus Cadila", "relevance": 0.183764, "type": "Person"}, {"count": 1, "sentiment": {"score": 0.785375, "label": "positive"}, "text": "FDA.", "relevance": 0.180372, "type": "Organization"}, {"count": 1, "sentiment": {"score": -0.455703, "label": "negative"}, "text": "Rhythm Pharmaceuticals", "relevance": 0.180214, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.484451, "label": "negative"}, "text": "Takeda Pharmaceuticals Company Limited", "relevance": 0.178179, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novo Nordisk A/S", "relevance": 0.177904, "type": "Company", "disambiguation": {"subtype": [], "name": "Novo Nordisk", "dbpedia_resource": "http://dbpedia.org/resource/Novo_Nordisk"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roche AG", "relevance": 0.172651, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer Inc.", "relevance": 0.169052, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline PLC", "relevance": 0.165583, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": -0.569302, "label": "negative"}, "text": "Arena Pharmaceuticals Inc.", "relevance": 0.160461, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Merck & Co. Inc.", "relevance": 0.158864, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Orexigen Therapeutics Inc.", "relevance": 0.14718, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eisai Co. Ltd.", "relevance": 0.14088, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Zafgen", "relevance": 0.140599, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Norgine B.V.", "relevance": 0.140482, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "68.8%", "relevance": 0.140482, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "13%", "relevance": 0.140482, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "39%", "relevance": 0.140482, "type": "Quantity"}], "sentiment": {"document": {"score": 0.170911, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Overview The World Health Organization", "keywords": [{"text": "World Health Organization"}], "entities": [{"type": "Organization", "text": "World Health Organization", "disambiguation": {"subtype": [], "name": "World Health Organization", "dbpedia_resource": "http://dbpedia.org/resource/World_Health_Organization"}}]}, "sentence": " Global Anti-Obesity Drugs Market: Overview The World Health Organization reveals that global obesity has more than doubled since 1980, with over 1.9 billion adults overweight in 2014, of which, more than 600 million were obese.", "object": {"text": "that global obesity has more than doubled since 1980, with over 1.9 billion adults overweight in 2014, of which, more than 600 million were obese", "keywords": [{"text": "global obesity"}, {"text": "obese"}, {"text": "adults"}]}, "action": {"verb": {"text": "reveal", "tense": "present"}, "text": "reveals", "normalized": "reveal"}}, {"subject": {"text": "global obesity", "keywords": [{"text": "global obesity"}]}, "sentence": " Global Anti-Obesity Drugs Market: Overview The World Health Organization reveals that global obesity has more than doubled since 1980, with over 1.9 billion adults overweight in 2014, of which, more than 600 million were obese.", "action": {"verb": {"text": "double", "tense": "past"}, "text": "has more than doubled", "normalized": "have more than double"}}, {"subject": {"text": "an estimated 39% of adults", "keywords": [{"text": "adults"}], "entities": [{"type": "Quantity", "text": "39"}]}, "sentence": " Percentage-wise, an estimated 39% of adults were overweight and 13% were obese in 2014.", "object": {"text": "overweight", "keywords": [{"text": "overweight"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "were", "normalized": "be"}}, {"subject": {"text": "an estimated 39% of adults were overweight and 13%", "keywords": [{"text": "overweight"}, {"text": "adults"}], "entities": [{"type": "Quantity", "text": "13"}, {"type": "Quantity", "text": "39"}]}, "sentence": " Percentage-wise, an estimated 39% of adults were overweight and 13% were obese in 2014.", "object": {"text": "obese", "keywords": [{"text": "obese"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "were", "normalized": "be"}}, {"subject": {"text": "An additional 42 million children below the age of five", "keywords": [{"text": "children"}, {"text": "age"}]}, "sentence": " An additional 42 million children below the age of five were found to be overweight or obese in 2013.", "object": {"text": "overweight or obese", "keywords": [{"text": "overweight"}, {"text": "obese"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "were found to be", "normalized": "be find to be"}}, {"subject": {"text": "by the Centers for Disease Control and Prevention", "keywords": [{"text": "Disease Control"}, {"text": "Centers"}, {"text": "Prevention"}], "entities": [{"type": "Organization", "text": "Centers for Disease Control and Prevention", "disambiguation": {"subtype": ["GovernmentAgency", "GovernmentalBody"], "name": "Centers for Disease Control and Prevention", "dbpedia_resource": "http://dbpedia.org/resource/Centers_for_Disease_Control_and_Prevention"}}]}, "sentence": " Based on two surveys conducted by the Centers for Disease Control and Prevention, an astounding 68.8% of the U.S. adult population is considered to be overweight or obese.", "object": {"text": "two surveys", "keywords": [{"text": "surveys"}]}, "action": {"verb": {"text": "conduct", "tense": "past"}, "text": "conducted", "normalized": "conduct"}}, {"subject": {"text": "an astounding 68.8% of the U.S. adult population", "keywords": [{"text": "U.S. adult population"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Quantity", "text": "68.8"}]}, "sentence": " Based on two surveys conducted by the Centers for Disease Control and Prevention, an astounding 68.8% of the U.S. adult population is considered to be overweight or obese.", "object": {"text": "considered to be overweight or obese", "keywords": [{"text": "obese"}, {"text": "overweight"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "an astounding 68.8% of the U.S. adult population", "keywords": [{"text": "U.S. adult population"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Quantity", "text": "68.8"}]}, "sentence": " Based on two surveys conducted by the Centers for Disease Control and Prevention, an astounding 68.8% of the U.S. adult population is considered to be overweight or obese.", "object": {"text": "to be overweight or obese", "keywords": [{"text": "obese"}, {"text": "overweight"}]}, "action": {"verb": {"text": "consider", "tense": "past"}, "text": "considered", "normalized": "consider"}}, {"subject": {"text": "an astounding 68.8% of the U.S. adult population", "keywords": [{"text": "U.S. adult population"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Quantity", "text": "68.8"}]}, "sentence": " Based on two surveys conducted by the Centers for Disease Control and Prevention, an astounding 68.8% of the U.S. adult population is considered to be overweight or obese.", "object": {"text": "overweight or obese", "keywords": [{"text": "overweight"}, {"text": "obese"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "is considered to be", "normalized": "be consider to be"}}, {"subject": {"text": "It"}, "sentence": " It is no surprise, then, that today, most of the world's population lives in countries where obesity and overweight are claiming more lives than underweight and malnutrition.", "object": {"text": "no surprise, then, that today, most of the world's population lives in countries where obesity and overweight are claiming more lives than underweight and malnutrition", "keywords": [{"text": "underweight"}, {"text": "malnutrition"}, {"text": "overweight"}, {"text": "surprise"}], "entities": [{"type": "HealthCondition", "text": "obesity", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}, {"type": "HealthCondition", "text": "underweight"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "https://www.transparencymarketresearch.com/anti-obesity-drugs-market.html This alarming rise in the prevalence of obesity, particularly in the developed region of North America,", "keywords": [{"text": "alarming rise"}, {"text": "developed region"}, {"text": "North America"}, {"text": "prevalence"}], "entities": [{"type": "HealthCondition", "text": "obesity", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}, {"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "sentence": " View Report: https://www.transparencymarketresearch.com/anti-obesity-drugs-market.html This alarming rise in the prevalence of obesity, particularly in the developed region of North America, has been single-handedly propelling the anti-obesity drugs market.", "object": {"text": "the anti-obesity drugs market", "keywords": [{"text": "anti-obesity drugs"}, {"text": "market"}], "entities": []}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has been single-handedly propelling", "normalized": "have be single-handedly propel"}}, {"subject": {"text": "https://www.transparencymarketresearch.com/anti-obesity-drugs-market.html This alarming rise in the prevalence of obesity, particularly in the developed region of North America,", "keywords": [{"text": "alarming rise"}, {"text": "developed region"}, {"text": "North America"}, {"text": "prevalence"}], "entities": [{"type": "HealthCondition", "text": "obesity", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}, {"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "sentence": " View Report: https://www.transparencymarketresearch.com/anti-obesity-drugs-market.html This alarming rise in the prevalence of obesity, particularly in the developed region of North America, has been single-handedly propelling the anti-obesity drugs market.", "object": {"text": "single-handedly propelling the anti-obesity drugs market", "keywords": [{"text": "anti-obesity drugs"}, {"text": "market"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "https://www.transparencymarketresearch.com/anti-obesity-drugs-market.html This alarming rise in the prevalence of obesity, particularly in the developed region of North America,", "keywords": [{"text": "alarming rise"}, {"text": "developed region"}, {"text": "North America"}, {"text": "prevalence"}], "entities": [{"type": "HealthCondition", "text": "obesity", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}, {"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "sentence": " View Report: https://www.transparencymarketresearch.com/anti-obesity-drugs-market.html This alarming rise in the prevalence of obesity, particularly in the developed region of North America, has been single-handedly propelling the anti-obesity drugs market.", "object": {"text": "the anti-obesity drugs market", "keywords": [{"text": "anti-obesity drugs"}, {"text": "market"}], "entities": []}, "action": {"verb": {"text": "propel", "tense": "present"}, "text": "propelling", "normalized": "propel"}}, {"subject": {"text": "These"}, "sentence": " These contain a host of pharmacological agents that control or reduce weight by altering either the absorption of calories or regulating appetite.", "object": {"text": "a host of pharmacological agents that control or reduce weight by altering either the absorption of calories or regulating appetite", "keywords": [{"text": "pharmacological agents"}, {"text": "calories"}, {"text": "appetite"}, {"text": "absorption"}]}, "action": {"verb": {"text": "contain", "tense": "present"}, "text": "contain", "normalized": "contain"}}, {"subject": {"text": "a host of pharmacological agents", "keywords": [{"text": "pharmacological agents"}, {"text": "host"}]}, "sentence": " These contain a host of pharmacological agents that control or reduce weight by altering either the absorption of calories or regulating appetite.", "object": {"text": "weight", "keywords": [{"text": "weight"}]}, "action": {"verb": {"text": "control", "tense": "present"}, "text": "control", "normalized": "control"}}, {"subject": {"text": "pharmacological agents", "keywords": [{"text": "pharmacological agents"}]}, "sentence": " These contain a host of pharmacological agents that control or reduce weight by altering either the absorption of calories or regulating appetite.", "object": {"text": "weight", "keywords": [{"text": "weight"}]}, "action": {"verb": {"text": "reduce", "tense": "present"}, "text": "reduce", "normalized": "reduce"}}, {"subject": {"text": "a host of pharmacological agents", "keywords": [{"text": "pharmacological agents"}, {"text": "host"}]}, "sentence": " These contain a host of pharmacological agents that control or reduce weight by altering either the absorption of calories or regulating appetite.", "object": {"text": "either the absorption of calories", "keywords": [{"text": "calories"}, {"text": "absorption"}]}, "action": {"verb": {"text": "alter", "tense": "present"}, "text": "altering", "normalized": "alter"}}, {"subject": {"text": "This comprehensive research publication", "keywords": [{"text": "comprehensive research publication"}]}, "sentence": " This comprehensive research publication offers clients an exhaustive database of accurate, authentic, objective, and the most recent information on the global anti-obesity drugs market.", "object": {"text": "an exhaustive database of accurate, authentic, objective, and the most recent information on the global anti-obesity drugs market", "keywords": [{"text": "global anti-obesity drugs"}, {"text": "exhaustive database"}, {"text": "recent information"}, {"text": "market"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "The overall market", "keywords": [{"text": "overall market"}]}, "sentence": " The overall market is segmented based on several key criteria and each segment is thoroughly evaluated to identify the leading and weakest categories.", "object": {"text": "segmented based on several key criteria", "keywords": [{"text": "key criteria"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "each segment", "keywords": [{"text": "segment"}]}, "sentence": " The overall market is segmented based on several key criteria and each segment is thoroughly evaluated to identify the leading and weakest categories.", "object": {"text": "thoroughly evaluated to identify the leading and weakest categories", "keywords": [{"text": "weakest categories"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "each segment", "keywords": [{"text": "segment"}]}, "sentence": " The overall market is segmented based on several key criteria and each segment is thoroughly evaluated to identify the leading and weakest categories.", "object": {"text": "to identify the leading and weakest categories", "keywords": [{"text": "weakest categories"}]}, "action": {"verb": {"text": "evaluate", "tense": "past"}, "text": "evaluated", "normalized": "evaluate"}}, {"subject": {"text": "each segment", "keywords": [{"text": "segment"}]}, "sentence": " The overall market is segmented based on several key criteria and each segment is thoroughly evaluated to identify the leading and weakest categories.", "object": {"text": "the leading and weakest categories", "keywords": [{"text": "weakest categories"}]}, "action": {"verb": {"text": "identify", "tense": "future"}, "text": "is thoroughly evaluated to identify", "normalized": "be thoroughly evaluate to identify"}}, {"subject": {"text": "Statistical data and inputs from industry experts", "keywords": [{"text": "inputs"}, {"text": "Statistical data"}, {"text": "industry experts"}]}, "sentence": " Statistical data and inputs from industry experts support the qualitative data offered in the report and help clients devise actionable and profitable decisions for the future.", "object": {"text": "the qualitative data offered in the report", "keywords": [{"text": "qualitative data"}, {"text": "report"}]}, "action": {"verb": {"text": "support", "tense": "present"}, "text": "support", "normalized": "support"}}, {"subject": {"text": "the qualitative data", "keywords": [{"text": "qualitative data"}]}, "sentence": " Statistical data and inputs from industry experts support the qualitative data offered in the report and help clients devise actionable and profitable decisions for the future.", "action": {"verb": {"text": "offer", "tense": "past"}, "text": "offered", "normalized": "offer"}}, {"subject": {"text": "clients", "keywords": [{"text": "clients"}]}, "sentence": " Statistical data and inputs from industry experts support the qualitative data offered in the report and help clients devise actionable and profitable decisions for the future.", "object": {"text": "actionable and profitable decisions", "keywords": [{"text": "decisions"}]}, "action": {"verb": {"text": "devise", "tense": "present"}, "text": "devise", "normalized": "devise"}}, {"subject": {"text": "Key Trends and Regional Outlook The global market for anti-obesity drugs", "keywords": [{"text": "Key Trends"}, {"text": "Regional Outlook"}, {"text": "anti-obesity drugs"}, {"text": "global market"}], "entities": []}, "sentence": " Global Anti-Obesity Drugs Market: Key Trends and Regional Outlook The global market for anti-obesity drugs has been expanding at a significant pace in recent years.", "object": {"text": "expanding at a significant pace", "keywords": [{"text": "significant pace"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "Key Trends and Regional Outlook The global market for anti-obesity drugs", "keywords": [{"text": "Key Trends"}, {"text": "Regional Outlook"}, {"text": "anti-obesity drugs"}, {"text": "global market"}], "entities": []}, "sentence": " Global Anti-Obesity Drugs Market: Key Trends and Regional Outlook The global market for anti-obesity drugs has been expanding at a significant pace in recent years.", "action": {"verb": {"text": "expand", "tense": "past"}, "text": "has been expanding", "normalized": "have be expand"}}, {"subject": {"text": "the obvious driving factor", "keywords": [{"text": "obvious driving factor"}]}, "sentence": " With the obvious driving factor being the surge in obesity levels around the globe, this market is also propelled by the strong pipeline of anti-obesity drugs.", "object": {"text": "the surge in obesity levels around the globe", "keywords": [{"text": "obesity levels"}, {"text": "surge"}, {"text": "globe"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "being", "normalized": "be"}}, {"subject": {"text": "by the strong pipeline of anti-obesity drugs", "keywords": [{"text": "strong pipeline"}, {"text": "anti-obesity drugs"}]}, "sentence": " With the obvious driving factor being the surge in obesity levels around the globe, this market is also propelled by the strong pipeline of anti-obesity drugs.", "object": {"text": "this market", "keywords": [{"text": "market"}], "entities": []}, "action": {"verb": {"text": "propel", "tense": "past"}, "text": "is also propelled", "normalized": "be also propel"}}, {"subject": {"text": "The anti-obesity drugs market in North America", "keywords": [{"text": "anti-obesity drugs market"}, {"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "sentence": " Request //www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=12461 The anti-obesity drugs market in North America has been flourishing over the years owing to the high level of awareness among the population about obesity and the various risks arising from the medical condition, increased healthcare expenditure, the presence of favorable reimbursement policies, extensive research and development activities in the field, and the increased involvement of government as well as non-government organizations in generating awareness and funding research.", "object": {"text": "been flourishing"}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Request //www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=12461 The anti-obesity drugs market in North America", "keywords": [{"text": "anti-obesity drugs market"}, {"text": "Request //www.transparencymarketresearch.com/sample/sample.php"}, {"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "sentence": " Request //www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=12461 The anti-obesity drugs market in North America has been flourishing over the years owing to the high level of awareness among the population about obesity and the various risks arising from the medical condition, increased healthcare expenditure, the presence of favorable reimbursement policies, extensive research and development activities in the field, and the increased involvement of government as well as non-government organizations in generating awareness and funding research.", "object": {"text": "flourishing"}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "The anti-obesity drugs market in North America", "keywords": [{"text": "anti-obesity drugs market"}, {"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "sentence": " Request //www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=12461 The anti-obesity drugs market in North America has been flourishing over the years owing to the high level of awareness among the population about obesity and the various risks arising from the medical condition, increased healthcare expenditure, the presence of favorable reimbursement policies, extensive research and development activities in the field, and the increased involvement of government as well as non-government organizations in generating awareness and funding research.", "action": {"verb": {"text": "flourish", "tense": "past"}, "text": "has been flourishing", "normalized": "have be flourish"}}, {"subject": {"text": "the various risks", "keywords": [{"text": "various risks"}]}, "sentence": " Request //www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=12461 The anti-obesity drugs market in North America has been flourishing over the years owing to the high level of awareness among the population about obesity and the various risks arising from the medical condition, increased healthcare expenditure, the presence of favorable reimbursement policies, extensive research and development activities in the field, and the increased involvement of government as well as non-government organizations in generating awareness and funding research.", "object": {"text": "from the medical condition", "keywords": [{"text": "medical condition"}]}, "action": {"verb": {"text": "arise", "tense": "present"}, "text": "arising", "normalized": "arise"}}, {"subject": {"text": "The Asia Pacific market for anti-obesity drugs", "keywords": [{"text": "anti-obesity drugs"}, {"text": "Asia Pacific market"}], "entities": [{"type": "Company", "text": "Asia Pacific"}]}, "sentence": " The Asia Pacific market for anti-obesity drugs is anticipated to gain momentum in the coming years thanks to the rise in obese population, resulting from increased spending on processed and packaged foods and the growing consumption of sugar-sweetened beverages.", "object": {"text": "anticipated to gain momentum in the coming years", "keywords": [{"text": "momentum"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Asia Pacific market for anti-obesity drugs", "keywords": [{"text": "anti-obesity drugs"}, {"text": "Asia Pacific market"}], "entities": [{"type": "Company", "text": "Asia Pacific"}]}, "sentence": " The Asia Pacific market for anti-obesity drugs is anticipated to gain momentum in the coming years thanks to the rise in obese population, resulting from increased spending on processed and packaged foods and the growing consumption of sugar-sweetened beverages.", "object": {"text": "momentum", "keywords": [{"text": "momentum"}]}, "action": {"verb": {"text": "gain", "tense": "future"}, "text": "is anticipated to gain", "normalized": "be anticipate to gain"}}, {"subject": {"text": "from increased spending on processed and packaged foods", "keywords": [{"text": "spending"}, {"text": "foods"}]}, "sentence": " The Asia Pacific market for anti-obesity drugs is anticipated to gain momentum in the coming years thanks to the rise in obese population, resulting from increased spending on processed and packaged foods and the growing consumption of sugar-sweetened beverages.", "object": {"text": "obese population", "keywords": [{"text": "obese population"}]}, "action": {"verb": {"text": "result", "tense": "present"}, "text": "resulting", "normalized": "result"}}, {"subject": {"text": "Improving healthcare infrastructure and mounting healthcare expenditure", "keywords": [{"text": "healthcare expenditure"}, {"text": "healthcare infrastructure"}]}, "sentence": " Improving healthcare infrastructure and mounting healthcare expenditure is also expected to drive the market for anti-obesity drugs in APAC.", "object": {"text": "the market", "keywords": [{"text": "market"}], "entities": []}, "action": {"verb": {"text": "drive", "tense": "future"}, "text": "is also expected to drive", "normalized": "be also expect to drive"}}, {"subject": {"text": "companies", "keywords": [{"text": "companies"}]}, "sentence": " Global Anti-Obesity Drugs Market: Competitive Landscape Snapshot The leading companies operating in the global anti-obesity drugs market include Boehringer Ingelheim GmbH, Arena Pharmaceuticals Inc., Takeda Pharmaceuticals Company Limited, Zydus Cadila, Rhythm Pharmaceuticals, Merck & Co. Inc., Eisai Co. Ltd., Novo Nordisk A/S, Orexigen Therapeutics Inc., Zafgen, GlaxoSmithKline PLC, Norgine B.V., Pfizer Inc., and F. Hoffmann-La Roche AG.", "action": {"verb": {"text": "operate", "tense": "present"}, "text": "operating", "normalized": "operate"}}, {"subject": {"text": "Boehringer Ingelheim GmbH, Arena Pharmaceuticals Inc., Takeda Pharmaceuticals Company Limited, Zydus Cadila, Rhythm Pharmaceuticals, Merck & Co. Inc., Eisai Co. Ltd., Novo Nordisk A/S, Orexigen Therapeutics Inc., Zafgen, GlaxoSmithKline PLC, Norgine B.V., Pfizer Inc., and F. Hoffmann-La Roche AG", "keywords": [{"text": "Takeda Pharmaceuticals Company"}, {"text": "Arena Pharmaceuticals Inc."}, {"text": "Boehringer Ingelheim GmbH"}, {"text": "Novo Nordisk A/S"}], "entities": [{"type": "Company", "text": "Boehringer Ingelheim GmbH", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Boehringer Ingelheim", "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}}, {"type": "Company", "text": "Arena Pharmaceuticals Inc."}, {"type": "Company", "text": "Takeda Pharmaceuticals Company Limited"}, {"type": "Person", "text": "Zydus Cadila"}, {"type": "Company", "text": "Rhythm Pharmaceuticals"}, {"type": "Company", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Company", "text": "Eisai Co. Ltd."}, {"type": "Company", "text": "Novo Nordisk A/S", "disambiguation": {"subtype": ["Company"], "name": "Novo Nordisk", "dbpedia_resource": "http://dbpedia.org/resource/Novo_Nordisk"}}, {"type": "Company", "text": "Orexigen Therapeutics Inc."}, {"type": "Company", "text": "Zafgen"}, {"type": "Company", "text": "GlaxoSmithKline PLC", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"type": "Company", "text": "Norgine B.V."}, {"type": "Company", "text": "Pfizer Inc.", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"type": "Company", "text": "Roche AG"}]}, "sentence": " Global Anti-Obesity Drugs Market: Competitive Landscape Snapshot The leading companies operating in the global anti-obesity drugs market include Boehringer Ingelheim GmbH, Arena Pharmaceuticals Inc., Takeda Pharmaceuticals Company Limited, Zydus Cadila, Rhythm Pharmaceuticals, Merck & Co. Inc., Eisai Co. Ltd., Novo Nordisk A/S, Orexigen Therapeutics Inc., Zafgen, GlaxoSmithKline PLC, Norgine B.V., Pfizer Inc., and F. Hoffmann-La Roche AG.", "object": {"text": "The leading companies operating in the global anti-obesity drugs market", "keywords": [{"text": "global anti-obesity drugs"}, {"text": "companies"}, {"text": "market"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "to the increasing prevalence of obesity in several parts of the world", "keywords": [{"text": "prevalence"}, {"text": "obesity"}, {"text": "parts"}, {"text": "world"}], "entities": [{"type": "HealthCondition", "text": "obesity", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}]}, "sentence": " Owing to the increasing prevalence of obesity in several parts of the world, the degree of competition among players in the anti-obesity drugs market has been on the rise.", "object": {"text": "the degree of competition among players in the anti-obesity drugs market", "keywords": [{"text": "anti-obesity drugs"}, {"text": "degree"}, {"text": "competition"}, {"text": "players"}], "entities": []}, "action": {"verb": {"text": "Owing", "tense": "present"}, "text": "Owing", "normalized": "Owing"}}, {"subject": {"text": "the degree of competition among players in the anti-obesity drugs market", "keywords": [{"text": "anti-obesity drugs"}, {"text": "degree"}, {"text": "competition"}, {"text": "players"}], "entities": []}, "sentence": " Owing to the increasing prevalence of obesity in several parts of the world, the degree of competition among players in the anti-obesity drugs market has been on the rise.", "object": {"text": "on the rise", "keywords": [{"text": "rise"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "has been", "normalized": "have be"}}, {"subject": {"text": "This"}, "sentence": " This gives players a greater chance of approval from regulatory bodies such as the US FDA. //www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=12461 Companies around the globe are also focused on the development as well as successful commercialization of anti-obesity drugs that are both clinically effective and safe in the long run and also have the potential to generate massive sales and reach blockbuster status.", "object": {"text": "a greater chance of approval from regulatory bodies such as the US FDA. //www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=12461 Companies around the globe are also focused on the development as well as successful commercialization of anti-obesity drugs that are both clinically effective and safe in the long run and also have the potential to generate massive sales and reach blockbuster status", "keywords": [{"text": "successful commercialization"}, {"text": "blockbuster status"}, {"text": "greater chance"}, {"text": "regulatory bodies"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Organization", "text": "FDA."}]}, "action": {"verb": {"text": "give", "tense": "present"}, "text": "gives", "normalized": "give"}}, {"subject": {"text": "successful commercialization of anti-obesity drugs", "keywords": [{"text": "successful commercialization"}, {"text": "anti-obesity drugs"}]}, "sentence": " This gives players a greater chance of approval from regulatory bodies such as the US FDA. //www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=12461 Companies around the globe are also focused on the development as well as successful commercialization of anti-obesity drugs that are both clinically effective and safe in the long run and also have the potential to generate massive sales and reach blockbuster status.", "object": {"text": "both clinically effective and safe"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "anti-obesity drugs", "keywords": [{"text": "anti-obesity drugs"}]}, "sentence": " This gives players a greater chance of approval from regulatory bodies such as the US FDA. //www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=12461 Companies around the globe are also focused on the development as well as successful commercialization of anti-obesity drugs that are both clinically effective and safe in the long run and also have the potential to generate massive sales and reach blockbuster status.", "object": {"text": "the potential to generate massive sales and reach blockbuster status", "keywords": [{"text": "blockbuster status"}, {"text": "massive sales"}, {"text": "potential"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "The current portfolio of prescription weight-loss drugs and emerging anti-obesity drugs in pre-clinical or clinical trials", "keywords": [{"text": "prescription weight-loss drugs"}, {"text": "anti-obesity drugs"}, {"text": "current portfolio"}, {"text": "clinical trials"}]}, "sentence": " The current portfolio of prescription weight-loss drugs and emerging anti-obesity drugs in pre-clinical or clinical trials acts as a significant force driving the global anti-obesity drugs market.", "object": {"text": "as a significant force driving the global anti-obesity drugs market", "keywords": [{"text": "global anti-obesity drugs"}, {"text": "significant force"}, {"text": "market"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acts", "normalized": "act"}}], "concepts": [{"text": "Obesity", "relevance": 0.979759, "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}, {"text": "Cancer", "relevance": 0.701757, "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}, {"text": "Weight loss", "relevance": 0.65414, "dbpedia_resource": "http://dbpedia.org/resource/Weight_loss"}, {"text": "Nutrition", "relevance": 0.632707, "dbpedia_resource": "http://dbpedia.org/resource/Nutrition"}, {"text": "Body shape", "relevance": 0.606418, "dbpedia_resource": "http://dbpedia.org/resource/Body_shape"}, {"text": "Boehringer Ingelheim", "relevance": 0.578933, "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}, {"text": "Adipose tissue", "relevance": 0.555396, "dbpedia_resource": "http://dbpedia.org/resource/Adipose_tissue"}, {"text": "Overweight", "relevance": 0.5522, "dbpedia_resource": "http://dbpedia.org/resource/Overweight"}, {"text": "Dieting", "relevance": 0.514, "dbpedia_resource": "http://dbpedia.org/resource/Dieting"}, {"text": "Physical exercise", "relevance": 0.490927, "dbpedia_resource": "http://dbpedia.org/resource/Physical_exercise"}, {"text": "Malnutrition", "relevance": 0.476023, "dbpedia_resource": "http://dbpedia.org/resource/Malnutrition"}, {"text": "Hoffmann\u2013La Roche", "relevance": 0.472013, "dbpedia_resource": "http://dbpedia.org/resource/Hoffmann\u2013La_Roche"}, {"text": "Ingelheim am Rhein", "relevance": 0.469814, "dbpedia_resource": "http://dbpedia.org/resource/Ingelheim_am_Rhein"}, {"text": "Appetite", "relevance": 0.468684, "dbpedia_resource": "http://dbpedia.org/resource/Appetite"}, {"text": "Medicine", "relevance": 0.466491, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Pharmacology", "relevance": 0.46343, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Bariatrics", "relevance": 0.460113, "dbpedia_resource": "http://dbpedia.org/resource/Bariatrics"}, {"text": "Body mass index", "relevance": 0.457229, "dbpedia_resource": "http://dbpedia.org/resource/Body_mass_index"}, {"text": "Sedentary lifestyle", "relevance": 0.454175, "dbpedia_resource": "http://dbpedia.org/resource/Sedentary_lifestyle"}, {"text": "Binge eating disorder", "relevance": 0.431611, "dbpedia_resource": "http://dbpedia.org/resource/Binge_eating_disorder"}, {"text": "Novo Nordisk", "relevance": 0.398404, "dbpedia_resource": "http://dbpedia.org/resource/Novo_Nordisk"}, {"text": "Bariatric surgery", "relevance": 0.383524, "dbpedia_resource": "http://dbpedia.org/resource/Bariatric_surgery"}, {"text": "Childhood obesity", "relevance": 0.37048, "dbpedia_resource": "http://dbpedia.org/resource/Childhood_obesity"}, {"text": "Pharmaceutical drug", "relevance": 0.366021, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "World population", "relevance": 0.354896, "dbpedia_resource": "http://dbpedia.org/resource/World_population"}], "categories": [{"score": 0.763703, "label": "/health and fitness/weight loss"}, {"score": 0.43976, "label": "/health and fitness/disease/diabetes"}, {"score": 0.282731, "label": "/health and fitness/disease/heart disease"}], "relations": [{"type": "managerOf", "sentence": "Anti-Obesity Drugs Market Precise Analysis on Business Overview, Product Scope and Ongoing Market Development 2024  Global Anti-Obesity Drugs Market: Overview The World Health Organization reveals that global obesity has more than doubled since 1980, with over 1.9 billion adults overweight in 2014, of which, more than 600 million were obese.", "score": 0.350006, "arguments": [{"text": "Anti", "location": [0, 4], "entities": [{"type": "Person", "text": "Anti"}]}, {"text": "Obesity Drugs Market Precise Analysis", "location": [5, 42], "entities": [{"type": "Organization", "text": "Obesity Drugs Market Precise Analysis"}]}]}, {"type": "partOf", "sentence": "Advanced medical research by drug-manufacturing companies, medical universities and institutes, and government agencies has also substantially contributed toward the growth of the anti-obesity drugs market.", "score": 0.974634, "arguments": [{"text": "agencies", "location": [2362, 2370], "entities": [{"type": "Organization", "text": "agencies", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "government", "location": [2351, 2361], "entities": [{"type": "GeopoliticalEntity", "text": "US", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "The Asia Pacific market for anti-obesity drugs is anticipated to gain momentum in the coming years thanks to the rise in obese population, resulting from increased spending on processed and packaged foods and the growing consumption of sugar-sweetened beverages.", "score": 0.326428, "arguments": [{"text": "Asia", "location": [3032, 3036], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [3037, 3044], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "partOf", "sentence": "Global Anti-Obesity Drugs Market: Competitive Landscape Snapshot The leading companies operating in the global anti-obesity drugs market include Boehringer Ingelheim GmbH, Arena Pharmaceuticals Inc., Takeda Pharmaceuticals Company Limited, Zydus Cadila, Rhythm Pharmaceuticals, Merck & Co. Inc., Eisai Co. Ltd., Novo Nordisk A/S, Orexigen Therapeutics Inc., Zafgen, GlaxoSmithKline PLC, Norgine B.V., Pfizer Inc., and F. Hoffmann-La Roche AG.", "score": 0.442996, "arguments": [{"text": "companies", "location": [3509, 3518], "entities": [{"type": "Organization", "text": "Companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Snapshot", "location": [3488, 3496], "entities": [{"type": "Organization", "text": "Snapshot"}]}]}, {"type": "partOfMany", "sentence": "Global Anti-Obesity Drugs Market: Competitive Landscape Snapshot The leading companies operating in the global anti-obesity drugs market include Boehringer Ingelheim GmbH, Arena Pharmaceuticals Inc., Takeda Pharmaceuticals Company Limited, Zydus Cadila, Rhythm Pharmaceuticals, Merck & Co. Inc., Eisai Co. Ltd., Novo Nordisk A/S, Orexigen Therapeutics Inc., Zafgen, GlaxoSmithKline PLC, Norgine B.V., Pfizer Inc., and F. Hoffmann-La Roche AG.", "score": 0.532314, "arguments": [{"text": "Boehringer Ingelheim GmbH", "location": [3577, 3602], "entities": [{"type": "Organization", "text": "Boehringer Ingelheim GmbH", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3509, 3518], "entities": [{"type": "Organization", "text": "Companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Global Anti-Obesity Drugs Market: Competitive Landscape Snapshot The leading companies operating in the global anti-obesity drugs market include Boehringer Ingelheim GmbH, Arena Pharmaceuticals Inc., Takeda Pharmaceuticals Company Limited, Zydus Cadila, Rhythm Pharmaceuticals, Merck & Co. Inc., Eisai Co. Ltd., Novo Nordisk A/S, Orexigen Therapeutics Inc., Zafgen, GlaxoSmithKline PLC, Norgine B.V., Pfizer Inc., and F. Hoffmann-La Roche AG.", "score": 0.584216, "arguments": [{"text": "Arena Pharmaceuticals Inc.", "location": [3604, 3630], "entities": [{"type": "Organization", "text": "Arena Pharmaceuticals Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3509, 3518], "entities": [{"type": "Organization", "text": "Companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Global Anti-Obesity Drugs Market: Competitive Landscape Snapshot The leading companies operating in the global anti-obesity drugs market include Boehringer Ingelheim GmbH, Arena Pharmaceuticals Inc., Takeda Pharmaceuticals Company Limited, Zydus Cadila, Rhythm Pharmaceuticals, Merck & Co. Inc., Eisai Co. Ltd., Novo Nordisk A/S, Orexigen Therapeutics Inc., Zafgen, GlaxoSmithKline PLC, Norgine B.V., Pfizer Inc., and F. Hoffmann-La Roche AG.", "score": 0.668047, "arguments": [{"text": "Takeda Pharmaceuticals Company Limited", "location": [3632, 3670], "entities": [{"type": "Organization", "text": "Takeda Pharmaceuticals Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3509, 3518], "entities": [{"type": "Organization", "text": "Companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Global Anti-Obesity Drugs Market: Competitive Landscape Snapshot The leading companies operating in the global anti-obesity drugs market include Boehringer Ingelheim GmbH, Arena Pharmaceuticals Inc., Takeda Pharmaceuticals Company Limited, Zydus Cadila, Rhythm Pharmaceuticals, Merck & Co. Inc., Eisai Co. Ltd., Novo Nordisk A/S, Orexigen Therapeutics Inc., Zafgen, GlaxoSmithKline PLC, Norgine B.V., Pfizer Inc., and F. Hoffmann-La Roche AG.", "score": 0.621059, "arguments": [{"text": "Zydus Cadila", "location": [3672, 3684], "entities": [{"type": "Organization", "text": "Zydus Cadila", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3509, 3518], "entities": [{"type": "Organization", "text": "Companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Global Anti-Obesity Drugs Market: Competitive Landscape Snapshot The leading companies operating in the global anti-obesity drugs market include Boehringer Ingelheim GmbH, Arena Pharmaceuticals Inc., Takeda Pharmaceuticals Company Limited, Zydus Cadila, Rhythm Pharmaceuticals, Merck & Co. Inc., Eisai Co. Ltd., Novo Nordisk A/S, Orexigen Therapeutics Inc., Zafgen, GlaxoSmithKline PLC, Norgine B.V., Pfizer Inc., and F. Hoffmann-La Roche AG.", "score": 0.50426, "arguments": [{"text": "Rhythm Pharmaceuticals", "location": [3686, 3708], "entities": [{"type": "Organization", "text": "Rhythm Pharmaceuticals", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3509, 3518], "entities": [{"type": "Organization", "text": "Companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Global Anti-Obesity Drugs Market: Competitive Landscape Snapshot The leading companies operating in the global anti-obesity drugs market include Boehringer Ingelheim GmbH, Arena Pharmaceuticals Inc., Takeda Pharmaceuticals Company Limited, Zydus Cadila, Rhythm Pharmaceuticals, Merck & Co. Inc., Eisai Co. Ltd., Novo Nordisk A/S, Orexigen Therapeutics Inc., Zafgen, GlaxoSmithKline PLC, Norgine B.V., Pfizer Inc., and F. Hoffmann-La Roche AG.", "score": 0.543469, "arguments": [{"text": "Merck & Co. Inc.", "location": [3710, 3726], "entities": [{"type": "Organization", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3509, 3518], "entities": [{"type": "Organization", "text": "Companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Global Anti-Obesity Drugs Market: Competitive Landscape Snapshot The leading companies operating in the global anti-obesity drugs market include Boehringer Ingelheim GmbH, Arena Pharmaceuticals Inc., Takeda Pharmaceuticals Company Limited, Zydus Cadila, Rhythm Pharmaceuticals, Merck & Co. Inc., Eisai Co. Ltd., Novo Nordisk A/S, Orexigen Therapeutics Inc., Zafgen, GlaxoSmithKline PLC, Norgine B.V., Pfizer Inc., and F. Hoffmann-La Roche AG.", "score": 0.56181, "arguments": [{"text": "Eisai Co. Ltd.", "location": [3728, 3742], "entities": [{"type": "Organization", "text": "Eisai Co. Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3509, 3518], "entities": [{"type": "Organization", "text": "Companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Anti-Obesity Drugs Market Precise Analysis on Business Overview, Product Scope and Ongoing Market Development 2024  Global Anti-Obesity Drugs Market: Overview The World Health Organization reveals that global obesity has more than doubled since 1980, with over 1.9 billion adults overweight in 2014, of which, more than 600 million were obese.", "score": 0.570358, "arguments": [{"text": "Market Development", "location": [91, 109], "entities": [{"type": "Organization", "text": "Market Development"}]}, {"text": "Global Anti-Obesity Drugs Market", "location": [116, 148], "entities": [{"type": "Organization", "text": "Global Anti-Obesity Drugs Market", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "This gives players a greater chance of approval from regulatory bodies such as the US FDA.", "score": 0.789031, "arguments": [{"text": "bodies", "location": [4243, 4249], "entities": [{"type": "Person", "text": "players"}]}, {"text": "FDA", "location": [4265, 4268], "entities": [{"type": "Organization", "text": "FDA", "disambiguation": {"subtype": ["Government"]}}]}]}, {"type": "partOf", "sentence": "This gives players a greater chance of approval from regulatory bodies such as the US FDA.", "score": 0.978447, "arguments": [{"text": "FDA", "location": [4265, 4268], "entities": [{"type": "Organization", "text": "FDA", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "US", "location": [4262, 4264], "entities": [{"type": "GeopoliticalEntity", "text": "US", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "agentOf", "sentence": "Anti-Obesity Drugs Market Precise Analysis on Business Overview, Product Scope and Ongoing Market Development 2024  Global Anti-Obesity Drugs Market: Overview The World Health Organization reveals that global obesity has more than doubled since 1980, with over 1.9 billion adults overweight in 2014, of which, more than 600 million were obese.", "score": 0.978435, "arguments": [{"text": "Overview The World Health Organization", "location": [150, 188], "entities": [{"type": "Organization", "text": "Overview The World Health Organization", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "reveals", "location": [189, 196], "entities": [{"type": "EventCommunication", "text": "reveals"}]}]}, {"type": "hasAttribute", "sentence": "Anti-Obesity Drugs Market Precise Analysis on Business Overview, Product Scope and Ongoing Market Development 2024  Global Anti-Obesity Drugs Market: Overview The World Health Organization reveals that global obesity has more than doubled since 1980, with over 1.9 billion adults overweight in 2014, of which, more than 600 million were obese.", "score": 0.277766, "arguments": [{"text": "adults", "location": [273, 279], "entities": [{"type": "Person", "text": "adults"}]}, {"text": "1.9 billion", "location": [261, 272], "entities": [{"type": "Money", "text": "1.9 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "partOfMany", "sentence": "An additional 42 million children below the age of five were found to be overweight or obese in 2013.", "score": 0.790442, "arguments": [{"text": "children", "location": [457, 465], "entities": [{"type": "Person", "text": "children"}]}, {"text": "five", "location": [483, 487], "entities": [{"type": "Cardinal", "text": "five"}]}]}, {"type": "residesIn", "sentence": "Based on two surveys conducted by the Centers for Disease Control and Prevention, an astounding 68.8% of the U.S. adult population is considered to be overweight or obese.", "score": 0.854872, "arguments": [{"text": "population", "location": [654, 664], "entities": [{"type": "Person", "text": "population"}]}, {"text": "U.S.", "location": [643, 647], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "residesIn", "sentence": "It is no surprise, then, that today, most of the world's population lives in countries where obesity and overweight are claiming more lives than underweight and malnutrition.", "score": 0.663248, "arguments": [{"text": "population", "location": [763, 773], "entities": [{"type": "Person", "text": "population"}]}, {"text": "world", "location": [755, 760], "entities": [{"type": "GeopoliticalEntity", "text": "world", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "agentOf", "sentence": "It is no surprise, then, that today, most of the world's population lives in countries where obesity and overweight are claiming more lives than underweight and malnutrition.", "score": 0.666608, "arguments": [{"text": "countries", "location": [783, 792], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "claiming", "location": [826, 834], "entities": [{"type": "EventCommunication", "text": "claiming"}]}]}, {"type": "locatedAt", "sentence": "View Report: https://www.transparencymarketresearch.com/anti-obesity-drugs-market.html This alarming rise in the prevalence of obesity, particularly in the developed region of North America, has been single-handedly propelling the anti-obesity drugs market.", "score": 0.518882, "arguments": [{"text": "region", "location": [1047, 1053], "entities": [{"type": "GeopoliticalEntity", "text": "region"}]}, {"text": "North America", "location": [1057, 1070], "entities": [{"type": "GeopoliticalEntity", "text": "North America", "disambiguation": {"subtype": ["Area"]}}]}]}], "keywords": [{"text": "anti-obesity drugs", "sentiment": {"score": 0.552275, "label": "positive"}, "relevance": 0.997167}, {"text": "anti-obesity drugs market", "sentiment": {"score": -0.282969, "label": "negative"}, "relevance": 0.961324}, {"text": "global anti-obesity drugs", "sentiment": {"score": -0.216934, "label": "negative"}, "relevance": 0.651531}, {"text": "Drugs Market Precise", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.575731}, {"text": "prescription weight-loss drugs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.505849}, {"text": "Centrally-acting drugs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.474362}, {"text": "peripherally-acting drugs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.474285}, {"text": "Ongoing Market Development", "sentiment": {"score": -0.363752, "label": "negative"}, "relevance": 0.443104}, {"text": "Asia Pacific market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.417925}, {"text": "World Health Organization", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.411883}, {"text": "U.S. adult population", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.405734}, {"text": "North America", "sentiment": {"score": -0.206956, "label": "negative"}, "relevance": 0.403221}, {"text": "healthcare expenditure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.402848}, {"text": "comprehensive research publication", "sentiment": {"score": 0.832104, "label": "positive"}, "relevance": 0.401588}, {"text": "global obesity", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.399926}, {"text": "Advanced medical research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.399246}, {"text": "Boehringer Ingelheim GmbH", "sentiment": {"score": -0.217533, "label": "negative"}, "relevance": 0.397001}, {"text": "Takeda Pharmaceuticals Company", "sentiment": {"score": -0.484451, "label": "negative"}, "relevance": 0.395267}, {"text": "Arena Pharmaceuticals Inc.", "sentiment": {"score": -0.569302, "label": "negative"}, "relevance": 0.394278}, {"text": "obvious driving factor", "sentiment": {"score": -0.438812, "label": "negative"}, "relevance": 0.393324}, {"text": "favorable reimbursement policies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.39207}, {"text": "Orexigen Therapeutics Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.391803}, {"text": "global market", "sentiment": {"score": -0.37738, "label": "negative"}, "relevance": 0.391024}, {"text": "Novo Nordisk A/S", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.390767}, {"text": "Competitive Landscape Snapshot", "sentiment": {"score": -0.217533, "label": "negative"}, "relevance": 0.389707}, {"text": "Eisai Co. Ltd.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.38953}, {"text": "F. Hoffmann-La Roche", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.388638}, {"text": "high safety threshold", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.387987}, {"text": "obese population", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.381812}, {"text": "overall market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.377837}, {"text": "obesity levels", "sentiment": {"score": -0.438812, "label": "negative"}, "relevance": 0.37442}, {"text": "Business Overview", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.360402}, {"text": "alarming rise", "sentiment": {"score": -0.585197, "label": "negative"}, "relevance": 0.358531}, {"text": "Product Scope", "sentiment": {"score": -0.363752, "label": "negative"}, "relevance": 0.357563}, {"text": "overweight", "sentiment": {"score": -0.391791, "label": "negative"}, "relevance": 0.355651}, {"text": "Disease Control", "sentiment": {"score": -0.511131, "label": "negative"}, "relevance": 0.355645}, {"text": "weakest categories", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.355369}, {"text": "View Report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.354743}, {"text": "drug-manufacturing companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.35458}, {"text": "pharmacological agents", "sentiment": {"score": -0.466432, "label": "negative"}, "relevance": 0.35446}, {"text": "developed region", "sentiment": {"score": -0.209645, "label": "negative"}, "relevance": 0.354289}, {"text": "main types", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.353851}, {"text": "extensive research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.353734}, {"text": "development activities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.35371}, {"text": "recent information", "sentiment": {"score": -0.216335, "label": "negative"}, "relevance": 0.353309}, {"text": "flag=B&rep_id=12461 Companies", "sentiment": {"score": 0.850979, "label": "positive"}, "relevance": 0.353137}, {"text": "weight-loss efficacy", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.352886}, {"text": "Pfizer Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.352701}, {"text": "exhaustive database", "sentiment": {"score": 0.832104, "label": "positive"}, "relevance": 0.352613}, {"text": "Statistical data", "sentiment": {"score": 0.847137, "label": "positive"}, "relevance": 0.35259}]}, "extracted_metadata": {"sha1": "755ab76e5504a244a61c37f2c2469639f775e508", "filename": "1541624143880.zip-cc6b74a865e51da9616dc026bc827c78.xml", "file_type": "json"}, "external_links": ["https://www.transparencymarketresearch.com/anti-obesity-drugs-market.html", "https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=12461", "https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=12461"], "title": "Anti-Obesity Drugs Market Precise Analysis on Business Overview, Product Scope and Ongoing Market Development 2024", "forum_title": "ReleaseWire - Latest Press Releases"}, {"id": "UOP7ZHdoU7a9Iy5zCcMz6sTVL9Cs5OYnumBmb4yFFvvVDnIrT_ehX4FYStAC6ZSY", "result_metadata": {"score": 34.33766}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "USD", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceuticals International AG Pharmaceuticals Healthcare", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$250", "relevance": 0.33, "type": "Quantity"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Medicine", "relevance": 0.82944, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}], "categories": [{"score": 0.588018, "label": "/health and fitness/drugs"}, {"score": 0.541166, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.372661, "label": "/health and fitness/men's health"}], "relations": [], "keywords": [{"text": "Takeda Pharmaceuticals International", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.981319}, {"text": "Pharmaceuticals Healthcare Deals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.881221}, {"text": "Alliances Profile Report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.654539}, {"text": "USD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.356477}, {"text": "AG", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.299252}, {"text": "Updated", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.217865}, {"text": "Prices", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.217653}]}, "crawl_date": "2018-11-08T08:22:26Z", "url": "https://www.bioportfolio.com/news/article/3809390/Takeda-Pharmaceuticals-International-AG-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile-Report-Updated.html", "host": "bioportfolio.com", "text": "Printed From BioPortfolio.com Takeda Pharmaceuticals International AG Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 11102018] Prices from USD $250 03:21 EST 8 Nov 2018 | BioPortfolio Report Blog Summary Takeda Pharmaceuticals International AG Takeda , a subsidiary of Takeda Pharmaceutical Company Ltd is a developer, manufacturer and distributor of", "country": "GB", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-08T08:21:00Z", "enriched_text": {"entities": [{"count": 31, "sentiment": {"score": 0.223756, "label": "positive"}, "text": "Takeda Pharmaceutical Company Ltd", "relevance": 0.894277, "type": "Company"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceuticals International AG Takeda", "relevance": 0.400687, "type": "Company"}, {"count": 2, "sentiment": {"score": 0.425475, "label": "positive"}, "text": "Takeda Pharmaceuticals International AG Pharmaceuticals Healthcare", "relevance": 0.316439, "type": "Company"}, {"count": 2, "sentiment": {"score": 0.489186, "label": "positive"}, "text": "Venture Financing and Partnerships", "relevance": 0.15714, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.135684, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pharmaceutical and Healthcare News", "relevance": 0.134556, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "USD", "relevance": 0.126887, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Zurich", "relevance": 0.124503, "type": "Location", "disambiguation": {"subtype": ["City"], "name": "Zurich", "dbpedia_resource": "http://dbpedia.org/resource/Zurich"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.124483, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "developer", "relevance": 0.119726, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Central America", "relevance": 0.119462, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Central America", "dbpedia_resource": "http://dbpedia.org/resource/Central_America"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "product development", "relevance": 0.118176, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Switzerland", "relevance": 0.117769, "type": "Location", "disambiguation": {"subtype": ["Country"], "name": "Switzerland", "dbpedia_resource": "http://dbpedia.org/resource/Switzerland"}}, {"count": 1, "sentiment": {"score": 0.425475, "label": "positive"}, "text": "Alliances Profile", "relevance": 0.117158, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia", "relevance": 0.11329, "type": "Location", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "overthecounter", "relevance": 0.112375, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.110421, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.108382, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia Pacific", "relevance": 0.103844, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.102659, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "five year", "relevance": 0.102659, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$250 03", "relevance": 0.102659, "type": "Quantity"}], "sentiment": {"document": {"score": 0.428943, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Takeda Pharmaceuticals International AG Takeda , a subsidiary of Takeda Pharmaceutical Company Ltd", "keywords": [{"text": "Takeda Pharmaceuticals International"}, {"text": "AG Takeda"}, {"text": "Takeda Pharmaceutical Company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceuticals International AG Takeda"}, {"type": "Company", "text": "Takeda Pharmaceutical Company Ltd"}]}, "sentence": " Takeda Pharmaceuticals International AG Takeda , a subsidiary of Takeda Pharmaceutical Company Ltd is a developer, manufacturer and distributor of pharmaceutical products.", "object": {"text": "a developer, manufacturer and distributor of pharmaceutical products", "keywords": [{"text": "pharmaceutical products"}, {"text": "developer"}, {"text": "manufacturer"}, {"text": "distributor"}], "entities": [{"type": "JobTitle", "text": "developer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Ltd"}]}, "sentence": " The company offers treatments in respiratory and immunology, central nervous system, cardiovascular and metabolic, cancer, general medicine, and vaccines areas.", "object": {"text": "treatments in respiratory and immunology, central nervous system, cardiovascular and metabolic, cancer, general medicine, and vaccines areas", "keywords": [{"text": "general medicine"}, {"text": "immunology"}, {"text": "vaccines"}, {"text": "treatments"}], "entities": []}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "contract manufacturing and product development, product packaging and quality control services", "keywords": [{"text": "quality control services"}, {"text": "contract manufacturing"}, {"text": "product development"}, {"text": "product packaging"}], "entities": [{"type": "JobTitle", "text": "product development"}]}, "sentence": " Its services include contract manufacturing and product development, product packaging and quality control services.", "object": {"text": "Its services", "keywords": [{"text": "services"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceuticals International AG Takeda"}]}, "sentence": " Takeda offers portfolio of patented products, branded generics and overthecounter products.", "object": {"text": "portfolio of patented products, branded generics and overthecounter products", "keywords": [{"text": "branded generics"}, {"text": "overthecounter products"}, {"text": "portfolio"}], "entities": [{"type": "Company", "text": "overthecounter"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceuticals International AG Takeda"}]}, "sentence": " Takeda offers portfolio of patented products, branded generics and overthecounter products.", "object": {"text": "products", "keywords": [{"text": "products"}]}, "action": {"verb": {"text": "patent", "tense": "past"}, "text": "patented", "normalized": "patent"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Ltd"}]}, "sentence": " The company operates in Asia, North America, Europe, and Latin America, among others.", "action": {"verb": {"text": "operate", "tense": "present"}, "text": "operates", "normalized": "operate"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceuticals International AG Takeda"}]}, "sentence": " Takeda is headquartered in Zurich, Switzerland.", "object": {"text": "headquartered"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceuticals International AG Takeda"}]}, "sentence": " Takeda is headquartered in Zurich, Switzerland.", "action": {"verb": {"text": "headquarter", "tense": "past"}, "text": "is headquartered", "normalized": "be headquarter"}}, {"subject": {"text": "Takeda Pharmaceuticals International AG Pharmaceuticals Healthcare Deals and Alliances Profile", "keywords": [{"text": "Takeda Pharmaceuticals International"}, {"text": "AG Pharmaceuticals Healthcare"}, {"text": "Alliances Profile"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceuticals International AG Pharmaceuticals Healthcare"}, {"type": "Company", "text": "Alliances Profile"}]}, "sentence": " Takeda Pharmaceuticals International AG Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings.", "object": {"text": "comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings", "keywords": [{"text": "Acquisitions MAs"}, {"text": "trend analysis"}, {"text": "comprehensive data"}, {"text": "financings"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Ltd"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.", "object": {"text": "detailed information", "keywords": [{"text": "information"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "by the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Ltd"}]}, "sentence": " The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.", "object": {"text": "Partnership transactions", "keywords": [{"text": "Partnership transactions"}]}, "action": {"verb": {"text": "record", "tense": "past"}, "text": "recorded", "normalized": "record"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions.", "object": {"text": "detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions", "keywords": [{"text": "comparative data"}, {"text": "deal types"}, {"text": "subsector"}, {"text": "deals"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "GlobalData", "keywords": [{"text": "GlobalData"}]}, "sentence": " GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research.", "object": {"text": "the data presented in this report", "keywords": [{"text": "data"}, {"text": "report"}]}, "action": {"verb": {"text": "derive", "tense": "past"}, "text": "derived", "normalized": "derive"}}, {"subject": {"text": "the data", "keywords": [{"text": "data"}]}, "sentence": " GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research.", "action": {"verb": {"text": "present", "tense": "past"}, "text": "presented", "normalized": "present"}}, {"subject": {"text": "proprietary inhouse Pharma eTrack", "keywords": [{"text": "inhouse Pharma eTrack"}]}, "sentence": " GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research.", "object": {"text": "database", "keywords": [{"text": "database"}]}, "action": {"verb": {"text": "deal", "tense": "present"}, "text": "deals", "normalized": "deal"}}, {"subject": {"text": "Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships", "keywords": [{"text": "Equity/Debt Offerings"}, {"text": "Private Equity"}, {"text": "Venture Financing"}, {"text": "Mergers"}], "entities": [{"type": "JobTitle", "text": "Venture Financing and Partnerships"}]}, "sentence": " Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.", "object": {"text": "the company's financial deals", "keywords": [{"text": "financial deals"}, {"text": "company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Ltd"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Deals by Year Chart and table", "keywords": [{"text": "Deals"}, {"text": "Chart"}, {"text": "table"}]}, "sentence": " Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.", "object": {"text": "information encompassing the number of deals and value", "keywords": [{"text": "deals"}, {"text": "information"}, {"text": "number"}, {"text": "value"}]}, "action": {"verb": {"text": "display", "tense": "present"}, "text": "displaying", "normalized": "display"}}, {"subject": {"text": "by the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Ltd"}]}, "sentence": " Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.", "object": {"text": "value", "keywords": [{"text": "value"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "Deals by Type Chart and table", "keywords": [{"text": "Deals"}, {"text": "Type Chart"}, {"text": "table"}]}, "sentence": " Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.", "object": {"text": "information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc", "keywords": [{"text": "Equity/Debt Offering"}, {"text": "Mergers"}, {"text": "Acquisitions"}, {"text": "deals"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Ltd"}]}, "action": {"verb": {"text": "depict", "tense": "present"}, "text": "depicting", "normalized": "depict"}}, {"subject": {"text": "the number of deals and value", "keywords": [{"text": "deals"}, {"text": "number"}, {"text": "value"}]}, "sentence": " Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.", "object": {"text": "information", "keywords": [{"text": "information"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc", "keywords": [{"text": "Equity/Debt Offering"}, {"text": "Mergers"}, {"text": "Acquisitions"}, {"text": "company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Ltd"}]}, "sentence": " Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.", "object": {"text": "value", "keywords": [{"text": "value"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America", "keywords": [{"text": "Asia Pacific"}, {"text": "Middle East"}, {"text": "North America"}, {"text": "Central America"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Ltd"}, {"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Company", "text": "Asia Pacific"}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}, {"type": "Location", "text": "Central America", "disambiguation": {"subtype": ["Region"], "name": "Central America", "dbpedia_resource": "http://dbpedia.org/resource/Central_America"}}]}, "sentence": " Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.", "object": {"text": "deals and value", "keywords": [{"text": "deals"}, {"text": "value"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "Deals by Subsector Chart and table", "keywords": [{"text": "Subsector Chart"}, {"text": "Deals"}, {"text": "table"}]}, "sentence": " Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector.", "object": {"text": "information on the number of deals and value", "keywords": [{"text": "deals"}, {"text": "information"}, {"text": "number"}, {"text": "value"}]}, "action": {"verb": {"text": "show", "tense": "present"}, "text": "showing", "normalized": "show"}}, {"subject": {"text": "by the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Ltd"}]}, "sentence": " Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector.", "object": {"text": "deals and value", "keywords": [{"text": "deals"}, {"text": "value"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "Each such deal", "keywords": [{"text": "deal"}]}, "sentence": " Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios.", "object": {"text": "a brief summary, deal type, deal rationale", "keywords": [{"text": "brief summary"}, {"text": "rationale"}, {"text": "type"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Each such deal", "keywords": [{"text": "deal"}]}, "sentence": " Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios.", "object": {"text": "type, deal rationale", "keywords": [{"text": "rationale"}, {"text": "type"}]}, "action": {"verb": {"text": "deal", "tense": "present"}, "text": "deal", "normalized": "deal"}}, {"subject": {"text": "Each such deal", "keywords": [{"text": "deal"}]}, "sentence": " Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios.", "object": {"text": "financials", "keywords": [{"text": "financials"}]}, "action": {"verb": {"text": "deal", "tense": "present"}, "text": "deal", "normalized": "deal"}}, {"subject": {"text": "the company's financial deals", "keywords": [{"text": "financial deals"}, {"text": "company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Ltd"}]}, "sentence": " Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements", "object": {"text": "you to understand the company's expansion/divestiture and fund requirements", "keywords": [{"text": "company"}, {"text": "requirements"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Ltd"}]}, "action": {"verb": {"text": "enable", "tense": "present"}, "text": "enable", "normalized": "enable"}}, {"subject": {"text": "The profile", "keywords": [{"text": "profile"}]}, "sentence": " The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.", "object": {"text": "to analyze the company's financial deals by region", "keywords": [{"text": "financial deals"}, {"text": "company"}, {"text": "region"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Ltd"}]}, "action": {"verb": {"text": "enable", "tense": "present"}, "text": "enables", "normalized": "enable"}}, {"subject": {"text": "you"}, "sentence": " The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.", "object": {"text": "the company's financial deals by region", "keywords": [{"text": "financial deals"}, {"text": "company"}, {"text": "region"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Ltd"}]}, "action": {"verb": {"text": "analyze", "tense": "future"}, "text": "to analyze", "normalized": "to analyze"}}, {"subject": {"text": "The profile", "keywords": [{"text": "profile"}]}, "sentence": " The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.", "object": {"text": "deals", "keywords": [{"text": "deals"}]}, "action": {"verb": {"text": "present", "tense": "present"}, "text": "presents", "normalized": "present"}}, {"subject": {"text": "you"}, "sentence": " The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.", "object": {"text": "its corporate strategy", "keywords": [{"text": "corporate strategy"}]}, "action": {"verb": {"text": "understand", "tense": "present"}, "text": "understand", "normalized": "understand"}}, {"subject": {"text": "the company's recent financial deals", "keywords": [{"text": "recent financial deals"}, {"text": "company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Ltd"}]}, "sentence": " Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company", "object": {"text": "you to understand the key deals which have shaped the company", "keywords": [{"text": "key deals"}, {"text": "company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Ltd"}]}, "action": {"verb": {"text": "enable", "tense": "present"}, "text": "enable", "normalized": "enable"}}, {"subject": {"text": "the key deals", "keywords": [{"text": "key deals"}]}, "sentence": " Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company", "object": {"text": "shaped the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Ltd"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios", "keywords": [{"text": "deal"}, {"text": "Target Company"}, {"text": "rationale"}, {"text": "financials"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Ltd"}]}, "sentence": " Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.", "object": {"text": "Detailed information on major recent deals", "keywords": [{"text": "major recent deals"}, {"text": "information"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "a summary of each deal, deal type,", "keywords": [{"text": "deal"}, {"text": "summary"}, {"text": "type"}]}, "sentence": " Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.", "object": {"text": "rationale", "keywords": [{"text": "rationale"}]}, "action": {"verb": {"text": "deal", "tense": "present"}, "text": "deal", "normalized": "deal"}}, {"subject": {"text": "each deal, deal type, deal rationale,", "keywords": [{"text": "deal"}, {"text": "rationale"}, {"text": "type"}]}, "sentence": " Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.", "object": {"text": "financials and Target Company's key financial metrics and ratios", "keywords": [{"text": "Target Company"}, {"text": "financials"}, {"text": "ratios"}, {"text": "metrics"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Ltd"}]}, "action": {"verb": {"text": "deal", "tense": "present"}, "text": "deal", "normalized": "deal"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Ltd"}]}, "sentence": " Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.", "object": {"text": "potential customers and suppliers", "keywords": [{"text": "potential customers"}, {"text": "suppliers"}]}, "action": {"verb": {"text": "identify", "tense": "future"}, "text": "to identify", "normalized": "to identify"}}, {"subject": {"text": "The profile", "keywords": [{"text": "profile"}]}, "sentence": " The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.", "object": {"text": "the company's business structure, locations and subsidiaries, key executives and key competitors", "keywords": [{"text": "key competitors"}, {"text": "key executives"}, {"text": "business structure"}, {"text": "subsidiaries"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Ltd"}]}, "action": {"verb": {"text": "analyze", "tense": "present"}, "text": "analyzes", "normalized": "analyze"}}, {"subject": {"text": "the major developments", "keywords": [{"text": "major developments"}]}, "sentence": " Stay uptodate on the major developments affecting the company", "object": {"text": "the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Ltd"}]}, "action": {"verb": {"text": "affect", "tense": "present"}, "text": "affecting", "normalized": "affect"}}, {"subject": {"text": "Recent developments", "keywords": [{"text": "Recent developments"}]}, "sentence": " Recent developments concerning the company presented in the profile help you track important events.", "object": {"text": "the company presented", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Ltd"}]}, "action": {"verb": {"text": "concern", "tense": "present"}, "text": "concerning", "normalized": "concern"}}, {"subject": {"text": "you"}, "sentence": " Recent developments concerning the company presented in the profile help you track important events.", "object": {"text": "important events", "keywords": [{"text": "important events"}]}, "action": {"verb": {"text": "track", "tense": "present"}, "text": "track", "normalized": "track"}}, {"subject": {"text": "Key elements such as break up of deals into categories and information on detailed major deals", "keywords": [{"text": "detailed major deals"}, {"text": "Key elements"}, {"text": "categories"}, {"text": "information"}], "entities": []}, "sentence": " Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.", "object": {"text": "incorporated"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Key elements such as break up of deals into categories and information on detailed major deals", "keywords": [{"text": "detailed major deals"}, {"text": "Key elements"}, {"text": "categories"}, {"text": "information"}], "entities": []}, "sentence": " Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.", "object": {"text": "your academic or business research needs", "keywords": [{"text": "business research"}]}, "action": {"verb": {"text": "assist", "tense": "future"}, "text": "to assist", "normalized": "to assist"}}, {"subject": {"text": "Some sections", "keywords": [{"text": "sections"}]}, "sentence": " Note*: Some sections may be missing if data is unavailable for the company.", "object": {"text": "missing"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "data", "keywords": [{"text": "data"}]}, "sentence": " Note*: Some sections may be missing if data is unavailable for the company.", "object": {"text": "unavailable for the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Ltd"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "is", "normalized": "be"}}], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.94696, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.636964, "label": "/finance/financial news"}, {"score": 0.441641, "label": "/business and industrial"}, {"score": 0.418798, "label": "/business and industrial/company"}], "relations": [{"type": "agentOf", "sentence": "Printed From BioPortfolio.com Takeda Pharmaceuticals International AG Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 11102018] Prices from USD $250 03:21 EST 8 Nov 2018 | BioPortfolio Report Blog Summary Takeda Pharmaceuticals International AG Takeda , a subsidiary of Takeda Pharmaceutical Company Ltd is a developer, manufacturer and distributor of pharmaceutical products.", "score": 0.556029, "arguments": [{"text": "BioPortfolio.com Takeda Pharmaceuticals International AG Pharmaceuticals Healthcare Deals", "location": [13, 102], "entities": [{"type": "Organization", "text": "BioPortfolio.com Takeda Pharmaceuticals International AG Pharmaceuticals Healthcare Deals"}]}, {"text": "Report", "location": [126, 132], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "employedBy", "sentence": "Key Employees A list of the key executives of the company.", "score": 0.438716, "arguments": [{"text": "executives", "location": [2810, 2820], "entities": [{"type": "Person", "text": "executives"}]}, {"text": "company", "location": [2828, 2835], "entities": [{"type": "Organization", "text": "BioPortfolio Report Blog\nSummary\nTakeda Pharmaceuticals International AG Takeda"}]}]}, {"type": "partOf", "sentence": "Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company.", "score": 0.713979, "arguments": [{"text": "subsidiaries", "location": [2933, 2945], "entities": [{"type": "Organization", "text": "subsidiaries"}]}, {"text": "company", "location": [2953, 2960], "entities": [{"type": "Organization", "text": "BioPortfolio Report Blog\nSummary\nTakeda Pharmaceuticals International AG Takeda"}]}]}, {"type": "partOf", "sentence": "Key Competitors A list of the key competitors of the company.", "score": 0.689884, "arguments": [{"text": "competitors", "location": [2996, 3007], "entities": [{"type": "Organization", "text": "competitors", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "company", "location": [3015, 3022], "entities": [{"type": "Organization", "text": "BioPortfolio Report Blog\nSummary\nTakeda Pharmaceuticals International AG Takeda"}]}]}, {"type": "employedBy", "sentence": "Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.", "score": 0.374818, "arguments": [{"text": "you", "location": [3175, 3178], "entities": [{"type": "Person", "text": "yourself"}]}, {"text": "company", "location": [3197, 3204], "entities": [{"type": "Organization", "text": "BioPortfolio Report Blog\nSummary\nTakeda Pharmaceuticals International AG Takeda"}]}]}, {"type": "agentOf", "sentence": "Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.", "score": 0.799113, "arguments": [{"text": "you", "location": [3271, 3274], "entities": [{"type": "Person", "text": "yourself"}]}, {"text": "analyze", "location": [3278, 3285], "entities": [{"type": "EventCommunication", "text": "analyze"}]}]}, {"type": "employedBy", "sentence": "Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.", "score": 0.284605, "arguments": [{"text": "customers", "location": [4011, 4020], "entities": [{"type": "Person", "text": "customers"}]}, {"text": "company", "location": [3968, 3975], "entities": [{"type": "Organization", "text": "BioPortfolio Report Blog\nSummary\nTakeda Pharmaceuticals International AG Takeda"}]}]}, {"type": "locatedAt", "sentence": "The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.", "score": 0.337955, "arguments": [{"text": "company", "location": [4061, 4068], "entities": [{"type": "Organization", "text": "BioPortfolio Report Blog\nSummary\nTakeda Pharmaceuticals International AG Takeda"}]}, {"text": "locations", "location": [4091, 4100], "entities": [{"type": "Location", "text": "locations"}]}]}, {"type": "employedBy", "sentence": "Printed From BioPortfolio.com Takeda Pharmaceuticals International AG Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 11102018] Prices from USD $250 03:21 EST 8 Nov 2018 | BioPortfolio Report Blog Summary Takeda Pharmaceuticals International AG Takeda , a subsidiary of Takeda Pharmaceutical Company Ltd is a developer, manufacturer and distributor of pharmaceutical products.", "score": 0.627009, "arguments": [{"text": "Nov", "location": [185, 188], "entities": [{"type": "Person", "text": "Nov"}]}, {"text": "EST 8", "location": [179, 184], "entities": [{"type": "Organization", "text": "EST 8"}]}]}, {"type": "partOf", "sentence": "Printed From BioPortfolio.com Takeda Pharmaceuticals International AG Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 11102018] Prices from USD $250 03:21 EST 8 Nov 2018 | BioPortfolio Report Blog Summary Takeda Pharmaceuticals International AG Takeda , a subsidiary of Takeda Pharmaceutical Company Ltd is a developer, manufacturer and distributor of pharmaceutical products.", "score": 0.407629, "arguments": [{"text": "subsidiary", "location": [280, 290], "entities": [{"type": "Organization", "text": "BioPortfolio Report Blog\nSummary\nTakeda Pharmaceuticals International AG Takeda"}]}, {"text": "Takeda Pharmaceutical Company Ltd", "location": [294, 327], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "The company operates in Asia, North America, Europe, and Latin America, among others.", "score": 0.494037, "arguments": [{"text": "company", "location": [775, 782], "entities": [{"type": "Organization", "text": "BioPortfolio Report Blog\nSummary\nTakeda Pharmaceuticals International AG Takeda"}]}, {"text": "Asia", "location": [795, 799], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "basedIn", "sentence": "Takeda is headquartered in Zurich, Switzerland.", "score": 0.850059, "arguments": [{"text": "Takeda", "location": [857, 863], "entities": [{"type": "Organization", "text": "BioPortfolio Report Blog\nSummary\nTakeda Pharmaceuticals International AG Takeda"}]}, {"text": "Zurich", "location": [884, 890], "entities": [{"type": "GeopoliticalEntity", "text": "Zurich"}]}]}, {"type": "locatedAt", "sentence": "Takeda is headquartered in Zurich, Switzerland.", "score": 0.985058, "arguments": [{"text": "Zurich", "location": [884, 890], "entities": [{"type": "GeopoliticalEntity", "text": "Zurich"}]}, {"text": "Switzerland", "location": [892, 903], "entities": [{"type": "GeopoliticalEntity", "text": "Switzerland", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "productOf", "sentence": "Takeda Pharmaceuticals International AG Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings.", "score": 0.887293, "arguments": [{"text": "Mergers", "location": [1068, 1075], "entities": [{"type": "Product", "text": "Mergers"}]}, {"text": "company", "location": [1058, 1065], "entities": [{"type": "Organization", "text": "BioPortfolio Report Blog\nSummary\nTakeda Pharmaceuticals International AG Takeda"}]}]}, {"type": "productOf", "sentence": "Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.", "score": 0.535319, "arguments": [{"text": "Mergers", "location": [1685, 1692], "entities": [{"type": "Product", "text": "Mergers"}]}, {"text": "company", "location": [1649, 1656], "entities": [{"type": "Organization", "text": "BioPortfolio Report Blog\nSummary\nTakeda Pharmaceuticals International AG Takeda"}]}]}, {"type": "locatedAt", "sentence": "Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.", "score": 0.699349, "arguments": [{"text": "Asia", "location": [2284, 2288], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [2289, 2296], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "partOf", "sentence": "Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios.", "score": 0.910852, "arguments": [{"text": "companies", "location": [2664, 2673], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Company", "location": [2641, 2648], "entities": [{"type": "Organization", "text": "BioPortfolio.com Takeda Pharmaceuticals International AG Pharmaceuticals Healthcare Deals"}]}]}], "keywords": [{"text": "financial deals", "sentiment": {"score": 0.572001, "label": "positive"}, "relevance": 0.948671}, {"text": "company", "sentiment": {"score": -0.0250454, "label": "negative"}, "relevance": 0.898891}, {"text": "Takeda Pharmaceuticals International", "sentiment": {"score": 0.425475, "label": "positive"}, "relevance": 0.880574}, {"text": "Pharmaceuticals Healthcare Deals", "sentiment": {"score": 0.425475, "label": "positive"}, "relevance": 0.864969}, {"text": "Pharmaceuticals International AG", "sentiment": {"score": 0.425475, "label": "positive"}, "relevance": 0.792947}, {"text": "Major Deals Information", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.609002}, {"text": "Financial Deals Analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.605463}, {"text": "eTrack deals database", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.601644}, {"text": "major financial deals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.5985}, {"text": "International AG Pharmaceuticals", "sentiment": {"score": 0.425475, "label": "positive"}, "relevance": 0.587195}, {"text": "AG Pharmaceuticals Healthcare", "sentiment": {"score": 0.425475, "label": "positive"}, "relevance": 0.587127}, {"text": "detailed major deals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.568317}, {"text": "recent financial deals", "sentiment": {"score": 0.466963, "label": "positive"}, "relevance": 0.565929}, {"text": "major recent deals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.556976}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.551238}, {"text": "BioPortfolio.com Takeda Pharmaceuticals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.491816}, {"text": "key deals", "sentiment": {"score": 0.466963, "label": "positive"}, "relevance": 0.480221}, {"text": "International AG Takeda", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.458073}, {"text": "detailed information", "sentiment": {"score": 0.677039, "label": "positive"}, "relevance": 0.433567}, {"text": "business segments", "sentiment": {"score": -0.352689, "label": "negative"}, "relevance": 0.410326}, {"text": "key competitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.409518}, {"text": "key financial metrics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.36857}, {"text": "target company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.367699}, {"text": "Alliances Profile", "sentiment": {"score": 0.425475, "label": "positive"}, "relevance": 0.36545}, {"text": "Private Equity", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.344068}, {"text": "North America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.343497}, {"text": "Venture Financing", "sentiment": {"score": 0.489186, "label": "positive"}, "relevance": 0.343446}, {"text": "detailed comparative data", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.34089}, {"text": "Equity/Debt Offerings", "sentiment": {"score": 0.343645, "label": "positive"}, "relevance": 0.340087}, {"text": "quality control services", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.338666}, {"text": "Gain key insights", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.335147}, {"text": "Access elaborate information", "sentiment": {"score": 0.466963, "label": "positive"}, "relevance": 0.333557}, {"text": "key executives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.330786}, {"text": "major public companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.329658}, {"text": "core business segments", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.326959}, {"text": "business research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.2978}, {"text": "deal types", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.281744}, {"text": "Subsector Chart", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.261821}, {"text": "BioPortfolio Report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.256616}, {"text": "Key Employees", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.251188}, {"text": "key centers", "sentiment": {"score": 0.539694, "label": "positive"}, "relevance": 0.250297}, {"text": "Report Updated", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.247993}, {"text": "Key elements", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.246397}, {"text": "pharmaceutical products", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.23986}, {"text": "general medicine", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.238637}, {"text": "Acquisitions MAs", "sentiment": {"score": 0.425475, "label": "positive"}, "relevance": 0.237003}, {"text": "vaccines areas", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.236008}, {"text": "Latin America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.23294}, {"text": "Type Chart", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.232843}, {"text": "comprehensive data", "sentiment": {"score": 0.425475, "label": "positive"}, "relevance": 0.231779}]}, "extracted_metadata": {"sha1": "a2a085198e4cba5526105febd9e337f9d100664e", "filename": "1541665346896.zip-3475346d191e00e2f6efb52c15c66bd4.xml", "file_type": "json"}, "title": "Takeda Pharmaceuticals International AG Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 11102018 Prices from USD $250", "forum_title": "BioPortfolio Latest News"}, {"id": "5c2e5CCh9X2j6TbzYo7He3sdwBbWMCMaW2FFXFl3vxWSpFqEJWYTSnjuAZGOqYCo", "result_metadata": {"score": 34.252117}, "author": "Myovant Sciences, Ltd.", "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0.510542, "label": "positive"}}, "semantic_roles": [], "concepts": [{"text": "Corporate governance", "relevance": 0.84297, "dbpedia_resource": "http://dbpedia.org/resource/Corporate_governance"}, {"text": "Management", "relevance": 0.801, "dbpedia_resource": "http://dbpedia.org/resource/Management"}, {"text": "Board of directors", "relevance": 0.788543, "dbpedia_resource": "http://dbpedia.org/resource/Board_of_directors"}], "categories": [{"score": 0.577004, "label": "/art and entertainment/movies"}, {"score": 0.484518, "label": "/business and industrial/company"}, {"score": 0.438183, "label": "/finance/financial news"}], "relations": [], "keywords": [{"text": "Myovant Strengthens Management", "sentiment": {"score": 0.510542, "label": "positive"}, "relevance": 0.986289}, {"text": "New Directors", "sentiment": {"score": 0.510542, "label": "positive"}, "relevance": 0.463145}, {"text": "Team", "sentiment": {"score": 0.510542, "label": "positive"}, "relevance": 0.216376}, {"text": "Board", "sentiment": {"score": 0.510542, "label": "positive"}, "relevance": 0.215305}]}, "crawl_date": "2018-11-07T16:51:21Z", "url": "https://www.prnewswire.com:443/news-releases/myovant-strengthens-management-team-and-adds-new-directors-to-the-board-300745444.html", "host": "prnewswire.com", "text": "Myovant Sciences, Ltd.", "main_image_url": "https://mma.prnewswire.com/media/427661/Myovant_Sciences_Ltd___Logo.jpg?p=facebook", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-07T13:30:00Z", "enriched_text": {"entities": [{"count": 12, "sentiment": {"score": -0.540317, "label": "negative"}, "text": "Myovant", "relevance": 0.848543, "type": "Person"}, {"count": 4, "sentiment": {"score": -0.474197, "label": "negative"}, "text": "Vice President", "relevance": 0.689566, "type": "JobTitle"}, {"count": 5, "sentiment": {"score": -0.540317, "label": "negative"}, "text": "endocrine diseases", "relevance": 0.664526, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Endocrine disease", "dbpedia_resource": "http://dbpedia.org/resource/Endocrine_disease"}}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "Myovant Sciences", "relevance": 0.659774, "type": "Company"}, {"count": 2, "sentiment": {"score": -0.350266, "label": "negative"}, "text": "Senior Vice President of Technical Operations", "relevance": 0.651779, "type": "JobTitle"}, {"count": 8, "sentiment": {"score": 0.335111, "label": "positive"}, "text": "Myovant", "relevance": 0.624591, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 7, "sentiment": {"score": 0, "label": "neutral"}, "text": "Board", "relevance": 0.610607, "type": "Organization", "disambiguation": {"subtype": ["Industry"], "name": "Board game", "dbpedia_resource": "http://dbpedia.org/resource/Board_game"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Senior Vice President of Pharmaceutical Operations & Development", "relevance": 0.580982, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "President of Commercial Operations and Executive Vice President", "relevance": 0.559745, "type": "JobTitle"}, {"count": 6, "sentiment": {"score": 0.384414, "label": "positive"}, "text": "Frank Torti", "relevance": 0.543944, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Executive Vice President and Chief Financial Officer", "relevance": 0.541048, "type": "JobTitle"}, {"count": 6, "sentiment": {"score": 0.788622, "label": "positive"}, "text": "Myrtle Potter", "relevance": 0.536182, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Frank Karbe Chief Financial Officer Myovant Sciences", "relevance": 0.529434, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Vice President of Primary Care Marketing", "relevance": 0.520823, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Senior Vice President, Global Quality Affairs", "relevance": 0.510256, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Vice President, Global Medicines Commercialization", "relevance": 0.508504, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Vice President, U.S. Quality Operations", "relevance": 0.500735, "type": "JobTitle"}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "United States", "relevance": 0.497387, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "President and Chief Executive Officer of Myovant", "relevance": 0.492718, "type": "JobTitle"}, {"count": 4, "sentiment": {"score": 0.355856, "label": "positive"}, "text": "Kim Sablich", "relevance": 0.469279, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Myovant Sciences, Ltd.", "relevance": 0.461824, "type": "Company"}, {"count": 4, "sentiment": {"score": -0.412232, "label": "negative"}, "text": "Jeff Nornhold", "relevance": 0.458801, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "President", "relevance": 0.436611, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roivant Sciences", "relevance": 0.436377, "type": "Organization"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roivant", "relevance": 0.431556, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "President and CEO", "relevance": 0.416266, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": -0.350266, "label": "negative"}, "text": "Impax Laboratories", "relevance": 0.408608, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chief Commercial Officer", "relevance": 0.395127, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Urovant Sciences", "relevance": 0.394347, "type": "Company"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mark Guinan", "relevance": 0.379685, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Lynn Seely", "relevance": 0.36704, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chief Financial Officer", "relevance": 0.366402, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0.486571, "label": "positive"}, "text": "Management Team", "relevance": 0.36529, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chief Executive Officer", "relevance": 0.364401, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": -0.432699, "label": "negative"}, "text": "Amneal Pharmaceuticals, Inc.", "relevance": 0.359158, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BASEL", "relevance": 0.355065, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "City"], "name": "Basel", "dbpedia_resource": "http://dbpedia.org/resource/Basel"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roivant Pharma", "relevance": 0.346028, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Impax", "relevance": 0.343759, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Johnson & Johnson", "relevance": 0.342702, "type": "Company", "disambiguation": {"subtype": ["AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "NEA", "relevance": 0.340802, "type": "Organization", "disambiguation": {"subtype": ["Company"], "name": "New Enterprise Associates", "dbpedia_resource": "http://dbpedia.org/resource/New_Enterprise_Associates"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Switzerland", "relevance": 0.338728, "type": "Location", "disambiguation": {"subtype": ["Country"], "name": "Switzerland", "dbpedia_resource": "http://dbpedia.org/resource/Switzerland"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roivant Sciences", "relevance": 0.330903, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Impax", "relevance": 0.327791, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Denison University", "relevance": 0.326676, "type": "Organization", "disambiguation": {"subtype": ["Location", "CollegeUniversity", "University"], "name": "Denison University", "dbpedia_resource": "http://dbpedia.org/resource/Denison_University"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "University of Chicago", "relevance": 0.323917, "type": "Organization", "disambiguation": {"subtype": ["Location", "Company", "PeriodicalPublisher", "CollegeUniversity"], "name": "University of Chicago", "dbpedia_resource": "http://dbpedia.org/resource/University_of_Chicago"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chief Operating Officer of Genentech", "relevance": 0.319171, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "GSK", "relevance": 0.318331, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline", "relevance": 0.31702, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Genentech", "relevance": 0.316531, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Genentech", "dbpedia_resource": "http://dbpedia.org/resource/Genentech"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Impax", "relevance": 0.314481, "type": "Company"}], "sentiment": {"document": {"score": 0.127125, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "a clinical-stage biopharmaceutical company", "keywords": [{"text": "clinical-stage biopharmaceutical company"}], "entities": [{"type": "Company", "text": "Myovant Sciences"}]}, "sentence": " Myovant Sciences, Ltd. (NYSE: MYOV ), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, today announced that Kim Sablich , formerly Vice President of Primary Care Marketing in the United States for GlaxoSmithKline (GSK), will join Myovant Sciences as Chief Commercial Officer, and Jeff Nornhold , formerly Senior Vice President of Technical Operations for Impax Laboratories (now Amneal Pharmaceuticals, Inc.), has joined Myovant as Senior Vice President of Pharmaceutical Operations & Development.", "object": {"text": "innovative therapies", "keywords": [{"text": "innovative therapies"}]}, "action": {"verb": {"text": "develop", "tense": "future"}, "text": "developing", "normalized": "develop"}}, {"subject": {"text": "a clinical-stage biopharmaceutical company", "keywords": [{"text": "clinical-stage biopharmaceutical company"}], "entities": [{"type": "Company", "text": "Myovant Sciences"}]}, "sentence": " Myovant Sciences, Ltd. (NYSE: MYOV ), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, today announced that Kim Sablich , formerly Vice President of Primary Care Marketing in the United States for GlaxoSmithKline (GSK), will join Myovant Sciences as Chief Commercial Officer, and Jeff Nornhold , formerly Senior Vice President of Technical Operations for Impax Laboratories (now Amneal Pharmaceuticals, Inc.), has joined Myovant as Senior Vice President of Pharmaceutical Operations & Development.", "object": {"text": "innovative therapies", "keywords": [{"text": "innovative therapies"}]}, "action": {"verb": {"text": "commercialize", "tense": "present"}, "text": "commercializing", "normalized": "commercialize"}}, {"subject": {"text": "Myovant Sciences, Ltd. (NYSE: MYOV ), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases,", "keywords": [{"text": "clinical-stage biopharmaceutical company"}, {"text": "endocrine diseases"}, {"text": "innovative therapies"}, {"text": "Myovant Sciences"}], "entities": [{"type": "Company", "text": "Myovant Sciences, Ltd."}, {"type": "Company", "text": "NYSE"}, {"type": "Company", "text": "Myovant Sciences"}, {"type": "HealthCondition", "text": "endocrine diseases", "disambiguation": {"subtype": ["Disease"], "name": "Endocrine disease", "dbpedia_resource": "http://dbpedia.org/resource/Endocrine_disease"}}]}, "sentence": " Myovant Sciences, Ltd. (NYSE: MYOV ), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, today announced that Kim Sablich , formerly Vice President of Primary Care Marketing in the United States for GlaxoSmithKline (GSK), will join Myovant Sciences as Chief Commercial Officer, and Jeff Nornhold , formerly Senior Vice President of Technical Operations for Impax Laboratories (now Amneal Pharmaceuticals, Inc.), has joined Myovant as Senior Vice President of Pharmaceutical Operations & Development.", "object": {"text": "that Kim Sablich , formerly Vice President of Primary Care Marketing in the United States for GlaxoSmithKline (GSK), will join Myovant Sciences as Chief Commercial Officer, and Jeff Nornhold , formerly Senior Vice President of Technical Operations for Impax Laboratories (now Amneal Pharmaceuticals, Inc.), has joined Myovant as Senior Vice President of Pharmaceutical Operations & Development", "keywords": [{"text": "Senior Vice President"}, {"text": "Chief Commercial Officer"}, {"text": "Primary Care Marketing"}, {"text": "Impax Laboratories"}], "entities": [{"type": "Person", "text": "Kim Sablich"}, {"type": "JobTitle", "text": "Vice President of Primary Care Marketing"}, {"type": "Location", "text": "United States", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Company", "text": "GlaxoSmithKline", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"type": "Company", "text": "GSK"}, {"type": "Company", "text": "Myovant Sciences"}, {"type": "JobTitle", "text": "Chief Commercial Officer"}, {"type": "Person", "text": "Jeff Nornhold"}, {"type": "JobTitle", "text": "Senior Vice President of Technical Operations"}, {"type": "Company", "text": "Impax Laboratories"}, {"type": "Company", "text": "Amneal Pharmaceuticals, Inc."}, {"type": "Person", "text": "Myovant"}, {"type": "JobTitle", "text": "Senior Vice President of Pharmaceutical Operations & Development"}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "Myovant", "keywords": [{"text": "Myovant"}], "entities": [{"type": "Person", "text": "Myovant"}]}, "sentence": " In addition, Myovant has appointed industry veterans Myrtle Potter , Mark Guinan , and Frank Torti , M.D., to Myovant's Board of Directors, and Ms. Potter has been appointed Chairman of the Board.", "object": {"text": "appointed industry veterans Myrtle Potter , Mark Guinan , and Frank Torti , M.D.,", "keywords": [{"text": "veterans Myrtle Potter"}, {"text": "Mark Guinan"}, {"text": "Frank Torti"}, {"text": "M.D"}], "entities": [{"type": "Person", "text": "Myrtle Potter"}, {"type": "Person", "text": "Mark Guinan"}, {"type": "Person", "text": "Frank Torti"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Myovant", "keywords": [{"text": "Myovant"}], "entities": [{"type": "Person", "text": "Myovant"}]}, "sentence": " In addition, Myovant has appointed industry veterans Myrtle Potter , Mark Guinan , and Frank Torti , M.D., to Myovant's Board of Directors, and Ms. Potter has been appointed Chairman of the Board.", "object": {"text": "industry veterans Myrtle Potter , Mark Guinan , and Frank Torti , M.D.,", "keywords": [{"text": "veterans Myrtle Potter"}, {"text": "Mark Guinan"}, {"text": "Frank Torti"}, {"text": "M.D"}], "entities": [{"type": "Person", "text": "Myrtle Potter"}, {"type": "Person", "text": "Mark Guinan"}, {"type": "Person", "text": "Frank Torti"}]}, "action": {"verb": {"text": "appoint", "tense": "past"}, "text": "has appointed", "normalized": "have appoint"}}, {"subject": {"text": "Ms. Potter", "keywords": [{"text": "Ms. Potter"}], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, "sentence": " In addition, Myovant has appointed industry veterans Myrtle Potter , Mark Guinan , and Frank Torti , M.D., to Myovant's Board of Directors, and Ms. Potter has been appointed Chairman of the Board.", "object": {"text": "been appointed Chairman of the Board", "keywords": [{"text": "Chairman"}, {"text": "Board"}], "entities": [{"type": "JobTitle", "text": "Chairman"}, {"type": "Organization", "text": "Board", "disambiguation": {"subtype": ["Industry"], "name": "Board game", "dbpedia_resource": "http://dbpedia.org/resource/Board_game"}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Ms. Potter", "keywords": [{"text": "Ms. Potter"}], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, "sentence": " In addition, Myovant has appointed industry veterans Myrtle Potter , Mark Guinan , and Frank Torti , M.D., to Myovant's Board of Directors, and Ms. Potter has been appointed Chairman of the Board.", "object": {"text": "appointed Chairman of the Board", "keywords": [{"text": "Chairman"}, {"text": "Board"}], "entities": [{"type": "JobTitle", "text": "Chairman"}, {"type": "Organization", "text": "Board", "disambiguation": {"subtype": ["Industry"], "name": "Board game", "dbpedia_resource": "http://dbpedia.org/resource/Board_game"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "Ms. Potter", "keywords": [{"text": "Ms. Potter"}], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, "sentence": " In addition, Myovant has appointed industry veterans Myrtle Potter , Mark Guinan , and Frank Torti , M.D., to Myovant's Board of Directors, and Ms. Potter has been appointed Chairman of the Board.", "object": {"text": "Chairman of the Board", "keywords": [{"text": "Chairman"}, {"text": "Board"}], "entities": [{"type": "JobTitle", "text": "Chairman"}, {"type": "Organization", "text": "Board", "disambiguation": {"subtype": ["Industry"], "name": "Board game", "dbpedia_resource": "http://dbpedia.org/resource/Board_game"}}]}, "action": {"verb": {"text": "appoint", "tense": "past"}, "text": "has been appointed", "normalized": "have be appoint"}}, {"subject": {"text": "we"}, "sentence": " \"With top-line data from each of our five ongoing global Phase 3 clinical trials expected in 2019, we are pleased to announce the strengthening of our management team and Board as we look forward to the next stage of Myovant's growth,\" said Lynn Seely , M.D., President and CEO of Myovant.", "action": {"verb": {"text": "be", "tense": "present"}, "text": "are pleased to announce", "normalized": "be please to announce"}}, {"subject": {"text": "we"}, "sentence": " \"With top-line data from each of our five ongoing global Phase 3 clinical trials expected in 2019, we are pleased to announce the strengthening of our management team and Board as we look forward to the next stage of Myovant's growth,\" said Lynn Seely , M.D., President and CEO of Myovant.", "object": {"text": "to announce the strengthening of our management team and Board", "keywords": [{"text": "strengthening"}, {"text": "management team"}, {"text": "Board"}], "entities": [{"type": "JobTitle", "text": "Management Team"}]}, "action": {"verb": {"text": "please", "tense": "past"}, "text": "pleased", "normalized": "please"}}, {"subject": {"text": "we"}, "sentence": " \"With top-line data from each of our five ongoing global Phase 3 clinical trials expected in 2019, we are pleased to announce the strengthening of our management team and Board as we look forward to the next stage of Myovant's growth,\" said Lynn Seely , M.D., President and CEO of Myovant.", "object": {"text": "the strengthening of our management team and Board", "keywords": [{"text": "strengthening"}, {"text": "management team"}, {"text": "Board"}], "entities": [{"type": "JobTitle", "text": "Management Team"}]}, "action": {"verb": {"text": "announce", "tense": "future"}, "text": "are pleased to announce", "normalized": "be please to announce"}}, {"subject": {"text": "Lynn Seely , M.D., President and CEO of Myovant", "keywords": [{"text": "Lynn Seely"}, {"text": "CEO"}, {"text": "President"}, {"text": "M.D."}], "entities": [{"type": "Person", "text": "Lynn Seely"}, {"type": "JobTitle", "text": "President and CEO"}, {"type": "Company", "text": "Myovant"}]}, "sentence": " \"With top-line data from each of our five ongoing global Phase 3 clinical trials expected in 2019, we are pleased to announce the strengthening of our management team and Board as we look forward to the next stage of Myovant's growth,\" said Lynn Seely , M.D., President and CEO of Myovant.", "object": {"text": "With top-line data from each of our five ongoing global Phase 3 clinical trials expected in 2019, we are pleased to announce the strengthening of our management team and Board as we look forward to the next stage of Myovant's growth", "keywords": [{"text": "ongoing global Phase"}, {"text": "top-line data"}, {"text": "clinical trials"}, {"text": "management team"}], "entities": [{"type": "JobTitle", "text": "Management Team"}, {"type": "Location", "text": "Myovant", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "Ms. Potter's decades of commercial experience", "keywords": [{"text": "Ms. Potter"}, {"text": "decades"}, {"text": "commercial experience"}], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, "sentence": " \"Ms. Potter's decades of commercial experience perfectly position her to chair Myovant's Board of diverse industry and healthcare leaders.", "object": {"text": "her", "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, "action": {"verb": {"text": "position", "tense": "present"}, "text": "position", "normalized": "position"}}, {"subject": {"text": "Ms. Potter", "keywords": [{"text": "Ms. Potter"}], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, "sentence": " \"Ms. Potter's decades of commercial experience perfectly position her to chair Myovant's Board of diverse industry and healthcare leaders.", "object": {"text": "Myovant's Board of diverse industry and healthcare leaders", "keywords": [{"text": "diverse industry"}, {"text": "healthcare leaders"}, {"text": "Myovant"}], "entities": [{"type": "Person", "text": "Myovant"}]}, "action": {"verb": {"text": "chair", "tense": "future"}, "text": "to chair", "normalized": "to chair"}}, {"subject": {"text": "we"}, "sentence": " Together, we are committed to achieving our mission of becoming the leading company in women's health and endocrine diseases.\"", "object": {"text": "committed to achieving our mission of becoming the leading company in women's health and endocrine diseases", "keywords": [{"text": "endocrine diseases"}, {"text": "mission"}, {"text": "company"}, {"text": "women"}], "entities": [{"type": "HealthCondition", "text": "endocrine diseases", "disambiguation": {"subtype": ["Disease"], "name": "Endocrine disease", "dbpedia_resource": "http://dbpedia.org/resource/Endocrine_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "we"}, "sentence": " Together, we are committed to achieving our mission of becoming the leading company in women's health and endocrine diseases.\"", "object": {"text": "to achieving our mission of becoming the leading company in women's health and endocrine diseases", "keywords": [{"text": "endocrine diseases"}, {"text": "mission"}, {"text": "company"}, {"text": "women"}], "entities": [{"type": "HealthCondition", "text": "endocrine diseases", "disambiguation": {"subtype": ["Disease"], "name": "Endocrine disease", "dbpedia_resource": "http://dbpedia.org/resource/Endocrine_disease"}}]}, "action": {"verb": {"text": "commit", "tense": "past"}, "text": "are committed", "normalized": "be commit"}}, {"subject": {"text": "we"}, "sentence": " Together, we are committed to achieving our mission of becoming the leading company in women's health and endocrine diseases.\"", "object": {"text": "our mission of becoming the leading company in women's health and endocrine diseases", "keywords": [{"text": "endocrine diseases"}, {"text": "mission"}, {"text": "company"}, {"text": "women"}], "entities": [{"type": "HealthCondition", "text": "endocrine diseases", "disambiguation": {"subtype": ["Disease"], "name": "Endocrine disease", "dbpedia_resource": "http://dbpedia.org/resource/Endocrine_disease"}}]}, "action": {"verb": {"text": "achieve", "tense": "future"}, "text": "achieving", "normalized": "achieve"}}, {"subject": {"text": "Ms. Sablich", "keywords": [{"text": "Ms. Sablich"}], "entities": [{"type": "Person", "text": "Kim Sablich"}]}, "sentence": " Ms. Sablich previously served as Vice President, Primary Care Marketing in the United States for GSK, where she was responsible for revenue forecasts, product strategies and execution plans for a broad portfolio of products including Advair\u00ae, Breo, Anoro\u00ae, Incruse\u00ae, Tanzeum\u2122, Levitra\u00ae, and Trelegy.", "object": {"text": "as Vice President, Primary Care Marketing in the United States for GSK, where she was responsible for revenue forecasts, product strategies and execution plans for a broad portfolio of products including Advair\u00ae, Breo, Anoro\u00ae, Incruse\u00ae, Tanzeum\u2122, Levitra\u00ae, and Trelegy", "keywords": [{"text": "Primary Care Marketing"}, {"text": "Vice President"}, {"text": "revenue forecasts"}, {"text": "execution plans"}], "entities": [{"type": "JobTitle", "text": "Vice President"}, {"type": "JobTitle", "text": "Primary Care Marketing"}, {"type": "Location", "text": "United States", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Organization", "text": "GSK"}, {"type": "Person", "text": "Kim Sablich"}, {"type": "Location", "text": "Trelegy", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "Advair\u00ae, Breo, Anoro\u00ae, Incruse\u00ae, Tanzeum\u2122, Levitra\u00ae, and Trelegy", "keywords": [{"text": "Advair\u00ae"}, {"text": "Breo"}, {"text": "Anoro\u00ae"}, {"text": "Incruse\u00ae"}], "entities": [{"type": "Location", "text": "Trelegy", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " Ms. Sablich previously served as Vice President, Primary Care Marketing in the United States for GSK, where she was responsible for revenue forecasts, product strategies and execution plans for a broad portfolio of products including Advair\u00ae, Breo, Anoro\u00ae, Incruse\u00ae, Tanzeum\u2122, Levitra\u00ae, and Trelegy.", "object": {"text": "products", "keywords": [{"text": "products"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "she"}, "sentence": " Prior to that, she was Vice President, Global Medicines Commercialization in the United Kingdom , and before that, Vice President, Vaccines Commercial Strategies.", "object": {"text": "Vice President, Global Medicines Commercialization in the United Kingdom , and before that, Vice President, Vaccines Commercial Strategies", "keywords": [{"text": "Vice President"}, {"text": "Global Medicines Commercialization"}, {"text": "Vaccines Commercial Strategies"}, {"text": "United Kingdom"}], "entities": [{"type": "JobTitle", "text": "Vice President, Global Medicines Commercialization"}, {"type": "Location", "text": "United Kingdom", "disambiguation": {"subtype": ["AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"type": "JobTitle", "text": "Vice President"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "Ms. Sablich", "keywords": [{"text": "Ms. Sablich"}], "entities": [{"type": "Person", "text": "Kim Sablich"}]}, "sentence": " Before joining GSK, Ms. Sablich spent 15 years at Merck, where she held positions of increasing responsibility in the commercial organization across sales, product management, pricing/access, and customer insights, with a focus on the cardiovascular, respiratory and vaccines business areas.", "object": {"text": "GSK", "keywords": [{"text": "GSK"}], "entities": [{"type": "Organization", "text": "GSK"}]}, "action": {"verb": {"text": "join", "tense": "present"}, "text": "joining", "normalized": "join"}}, {"subject": {"text": "Ms. Sablich", "keywords": [{"text": "Ms. Sablich"}], "entities": [{"type": "Person", "text": "Kim Sablich"}]}, "sentence": " Before joining GSK, Ms. Sablich spent 15 years at Merck, where she held positions of increasing responsibility in the commercial organization across sales, product management, pricing/access, and customer insights, with a focus on the cardiovascular, respiratory and vaccines business areas.", "object": {"text": "15 years", "entities": [{"type": "Quantity", "text": "15 years"}]}, "action": {"verb": {"text": "spend", "tense": "past"}, "text": "spent", "normalized": "spend"}}, {"subject": {"text": "she", "entities": [{"type": "Person", "text": "Kim Sablich"}]}, "sentence": " Before joining GSK, Ms. Sablich spent 15 years at Merck, where she held positions of increasing responsibility in the commercial organization across sales, product management, pricing/access, and customer insights, with a focus on the cardiovascular, respiratory and vaccines business areas.", "object": {"text": "positions of increasing responsibility in the commercial organization across sales, product management, pricing/access, and customer insights, with a focus on the cardiovascular, respiratory and vaccines business areas", "keywords": [{"text": "vaccines business areas"}, {"text": "customer insights"}, {"text": "commercial organization"}, {"text": "product management"}]}, "action": {"verb": {"text": "hold", "tense": "past"}, "text": "held", "normalized": "hold"}}, {"subject": {"text": "she", "entities": [{"type": "Person", "text": "Kim Sablich"}]}, "sentence": " Before joining GSK, Ms. Sablich spent 15 years at Merck, where she held positions of increasing responsibility in the commercial organization across sales, product management, pricing/access, and customer insights, with a focus on the cardiovascular, respiratory and vaccines business areas.", "object": {"text": "responsibility", "keywords": [{"text": "responsibility"}]}, "action": {"verb": {"text": "increase", "tense": "future"}, "text": "increasing", "normalized": "increase"}}, {"subject": {"text": "Ms. Sablich", "keywords": [{"text": "Ms. Sablich"}], "entities": [{"type": "Person", "text": "Kim Sablich"}]}, "sentence": " Ms. Sablich has extensive experience in direct-to-consumer marketing, having led the development of consumer strategies and national multi-channel campaigns for multiple products.", "object": {"text": "extensive experience in direct-to-consumer marketing, having led the development of consumer strategies and national multi-channel campaigns for multiple products", "keywords": [{"text": "national multi-channel campaigns"}, {"text": "direct-to-consumer marketing"}, {"text": "extensive experience"}, {"text": "consumer strategies"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Ms. Sablich", "keywords": [{"text": "Ms. Sablich"}], "entities": [{"type": "Person", "text": "Kim Sablich"}]}, "sentence": " Ms. Sablich has extensive experience in direct-to-consumer marketing, having led the development of consumer strategies and national multi-channel campaigns for multiple products.", "object": {"text": "led the development of consumer strategies and national multi-channel campaigns for multiple products", "keywords": [{"text": "national multi-channel campaigns"}, {"text": "consumer strategies"}, {"text": "multiple products"}, {"text": "development"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "having", "normalized": "have"}}, {"subject": {"text": "Ms. Sablich", "keywords": [{"text": "Ms. Sablich"}], "entities": [{"type": "Person", "text": "Kim Sablich"}]}, "sentence": " Ms. Sablich has extensive experience in direct-to-consumer marketing, having led the development of consumer strategies and national multi-channel campaigns for multiple products.", "object": {"text": "the development of consumer strategies and national multi-channel campaigns", "keywords": [{"text": "national multi-channel campaigns"}, {"text": "consumer strategies"}, {"text": "development"}]}, "action": {"verb": {"text": "lead", "tense": "past"}, "text": "having led", "normalized": "have lead"}}, {"subject": {"text": "She", "entities": [{"type": "Person", "text": "Kim Sablich"}]}, "sentence": " She is currently a member of the Board of Directors of AllerGenis LLC.", "object": {"text": "a member of the Board of Directors of AllerGenis LLC", "keywords": [{"text": "AllerGenis LLC"}, {"text": "member"}, {"text": "Board"}, {"text": "Directors"}], "entities": [{"type": "Person", "text": "Kim Sablich"}, {"type": "Organization", "text": "Board", "disambiguation": {"subtype": ["Industry"], "name": "Board game", "dbpedia_resource": "http://dbpedia.org/resource/Board_game"}}, {"type": "Company", "text": "AllerGenis LLC"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "She", "entities": [{"type": "Person", "text": "Kim Sablich"}]}, "sentence": " She earned a B.A. from Denison University and an M.B.A. from The Wharton School of the University of Pennsylvania .", "object": {"text": "a B.A.", "keywords": [{"text": "B.A"}]}, "action": {"verb": {"text": "earn", "tense": "past"}, "text": "earned", "normalized": "earn"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Jeff Nornhold"}]}, "sentence": " Mr. Nornhold previously served as Senior Vice President of Technical Operations for Impax Laboratories (now Amneal Pharmaceuticals, Inc.), where he was responsible for Impax's manufacturing, supply chain, quality and technical operations.", "object": {"text": "responsible for Impax's manufacturing, supply chain, quality and technical operations", "keywords": [{"text": "Impax"}, {"text": "supply chain"}, {"text": "technical operations"}, {"text": "manufacturing"}], "entities": [{"type": "Company", "text": "Impax"}, {"type": "Person", "text": "Jeff Nornhold"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Jeff Nornhold"}]}, "sentence": " Prior to that, he served as Impax's Senior Vice President, Global Quality Affairs, and was responsible for establishing a sustainable quality and compliance program.", "object": {"text": "as Impax's Senior Vice President", "keywords": [{"text": "Senior Vice President"}, {"text": "Impax"}], "entities": [{"type": "Person", "text": "Impax"}, {"type": "JobTitle", "text": "Senior Vice President, Global Quality Affairs"}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Jeff Nornhold"}]}, "sentence": " Prior to that, he served as Impax's Senior Vice President, Global Quality Affairs, and was responsible for establishing a sustainable quality and compliance program.", "object": {"text": "a sustainable quality and compliance program", "keywords": [{"text": "sustainable quality"}, {"text": "compliance program"}]}, "action": {"verb": {"text": "establish", "tense": "past"}, "text": "establishing", "normalized": "establish"}}, {"subject": {"text": "Mr. Nornhold", "keywords": [{"text": "Mr. Nornhold"}], "entities": [{"type": "Person", "text": "Jeff Nornhold"}]}, "sentence": " Prior to Impax, Mr. Nornhold served as Vice President, Quality Operations \u2013 International for Watson Pharmaceuticals, Inc. (now Allergan PLC), and was responsible for ex-U.S. manufacturing sites for both dosage and active pharmaceutical ingredients.", "object": {"text": "as Vice President, Quality Operations \u2013 International for Watson Pharmaceuticals, Inc. (now Allergan PLC), and was responsible for ex-U.S. manufacturing sites for both dosage and active pharmaceutical ingredients", "keywords": [{"text": "active pharmaceutical ingredients"}, {"text": "Allergan PLC"}, {"text": "ex-U.S. manufacturing sites"}, {"text": "Watson Pharmaceuticals"}], "entities": [{"type": "JobTitle", "text": "Vice President"}, {"type": "Company", "text": "Watson Pharmaceuticals, Inc."}, {"type": "Company", "text": "Allergan PLC"}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Watson"}]}, "sentence": " While at Watson , he also served as Vice President, U.S. Quality Operations, where he led the development and execution of quality initiatives for all U.S. sites.", "object": {"text": "as Vice President, U.S. Quality Operations, where he led the development and execution of quality initiatives for all U.S. sites", "keywords": [{"text": "Vice President"}, {"text": "U.S. Quality Operations"}, {"text": "quality initiatives"}, {"text": "U.S. sites"}], "entities": [{"type": "JobTitle", "text": "Vice President, U.S. Quality Operations"}, {"type": "Person", "text": "Watson"}, {"type": "Location", "text": "United States", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Watson"}]}, "sentence": " Earlier in his career, he held numerous leadership positions in the pharmaceutical industry.", "object": {"text": "numerous leadership positions", "keywords": [{"text": "numerous leadership positions"}]}, "action": {"verb": {"text": "hold", "tense": "past"}, "text": "held", "normalized": "hold"}}, {"subject": {"text": "Mr. Nornhold", "keywords": [{"text": "Mr. Nornhold"}], "entities": [{"type": "Person", "text": "Jeff Nornhold"}]}, "sentence": " Mr. Nornhold earned a B.S. in chemistry from Bowling Green State University and an M.B.A. from the University of Southern California Marshall School of Business.", "object": {"text": "a B.S. in chemistry", "keywords": [{"text": "B.S."}, {"text": "chemistry"}]}, "action": {"verb": {"text": "earn", "tense": "past"}, "text": "earned", "normalized": "earn"}}, {"subject": {"text": "Ms. Potter", "keywords": [{"text": "Ms. Potter"}], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, "sentence": " Ms. Potter currently serves as Vant Operating Chair for Roivant Pharma, a division of Roivant Sciences.", "object": {"text": "for Roivant Pharma, a division of Roivant Sciences", "keywords": [{"text": "Roivant Pharma"}, {"text": "Roivant Sciences"}, {"text": "division"}], "entities": [{"type": "Company", "text": "Roivant Pharma"}, {"type": "Organization", "text": "Roivant Sciences"}]}, "action": {"verb": {"text": "serve", "tense": "present"}, "text": "serves", "normalized": "serve"}}, {"subject": {"text": "She"}, "sentence": " She previously served as Chief Executive Officer of Myrtle Potter & Company, LLC, and President of Commercial Operations and Executive Vice President, and Chief Operating Officer of Genentech.", "object": {"text": "of Myrtle Potter & Company, LLC, and President of Commercial Operations and Executive Vice President, and Chief Operating Officer of Genentech", "keywords": [{"text": "Executive Vice President"}, {"text": "Chief Operating Officer"}, {"text": "Myrtle Potter"}, {"text": "Commercial Operations"}], "entities": [{"type": "Company", "text": "Myrtle Potter & Company"}, {"type": "Company", "text": "AllerGenis LLC"}, {"type": "JobTitle", "text": "President of Commercial Operations and Executive Vice President"}, {"type": "JobTitle", "text": "Chief Operating Officer of Genentech"}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "she"}, "sentence": " Prior to Genentech, she held various positions, including President of Cardiovascular/Metabolics at Bristol- Myers Squibb .", "object": {"text": "various positions, including President of Cardiovascular/Metabolics at Bristol- Myers Squibb", "keywords": [{"text": "Bristol- Myers Squibb"}, {"text": "various positions"}, {"text": "President"}, {"text": "Cardiovascular/Metabolics"}], "entities": [{"type": "JobTitle", "text": "Vice President"}, {"type": "Company", "text": "Bristol- Myers Squibb"}]}, "action": {"verb": {"text": "hold", "tense": "past"}, "text": "held", "normalized": "hold"}}, {"subject": {"text": "President of Cardiovascular/Metabolics at Bristol- Myers Squibb", "keywords": [{"text": "Bristol- Myers Squibb"}, {"text": "President"}, {"text": "Cardiovascular/Metabolics"}], "entities": [{"type": "JobTitle", "text": "Vice President"}, {"type": "Company", "text": "Bristol- Myers Squibb"}]}, "sentence": " Prior to Genentech, she held various positions, including President of Cardiovascular/Metabolics at Bristol- Myers Squibb .", "object": {"text": "Genentech, she held various positions", "keywords": [{"text": "various positions"}, {"text": "Genentech"}], "entities": [{"type": "Company", "text": "Genentech", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Genentech", "dbpedia_resource": "http://dbpedia.org/resource/Genentech"}}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "She"}, "sentence": " She is a graduate of the University of Chicago .", "object": {"text": "a graduate of the University of Chicago", "keywords": [{"text": "graduate"}, {"text": "University"}, {"text": "Chicago"}], "entities": [{"type": "Organization", "text": "University of Chicago", "disambiguation": {"subtype": ["Location", "Company", "PeriodicalPublisher", "CollegeUniversity"], "name": "University of Chicago", "dbpedia_resource": "http://dbpedia.org/resource/University_of_Chicago"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Ms. Potter", "keywords": [{"text": "Ms. Potter"}], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, "sentence": " In addition to serving on our Board, Ms. Potter also serves on the boards of other companies in the Roivant family of companies, including Urovant Sciences, Axovant Sciences and Arbutus Biopharma.", "object": {"text": "on the boards of other companies in the Roivant family of companies, including Urovant Sciences, Axovant Sciences and Arbutus Biopharma", "keywords": [{"text": "Arbutus Biopharma"}, {"text": "Roivant family"}, {"text": "Urovant Sciences"}, {"text": "Axovant Sciences"}], "entities": [{"type": "Organization", "text": "Board", "disambiguation": {"subtype": ["Industry"], "name": "Board game", "dbpedia_resource": "http://dbpedia.org/resource/Board_game"}}, {"type": "Location", "text": "Roivant", "disambiguation": {"subtype": ["City"]}}, {"type": "Company", "text": "Urovant Sciences"}, {"type": "Company", "text": "Axovant Sciences"}, {"type": "Company", "text": "Arbutus Biopharma"}]}, "action": {"verb": {"text": "serve", "tense": "present"}, "text": "serves", "normalized": "serve"}}, {"subject": {"text": "Urovant Sciences, Axovant Sciences and Arbutus Biopharma", "keywords": [{"text": "Arbutus Biopharma"}, {"text": "Urovant Sciences"}, {"text": "Axovant Sciences"}], "entities": [{"type": "Company", "text": "Urovant Sciences"}, {"type": "Company", "text": "Axovant Sciences"}, {"type": "Company", "text": "Arbutus Biopharma"}]}, "sentence": " In addition to serving on our Board, Ms. Potter also serves on the boards of other companies in the Roivant family of companies, including Urovant Sciences, Axovant Sciences and Arbutus Biopharma.", "object": {"text": "companies", "keywords": [{"text": "companies"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Ms. Potter", "keywords": [{"text": "Ms. Potter"}], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, "sentence": " Ms. Potter has previously served on the boards of Amazon, Express Scripts Holding Co., and Medco Health Solutions Inc.", "object": {"text": "previously served on the boards of Amazon, Express Scripts Holding Co., and Medco Health Solutions Inc", "keywords": [{"text": "Medco Health Solutions"}, {"text": "Express Scripts Holding"}, {"text": "Amazon"}, {"text": "boards"}], "entities": [{"type": "Organization", "text": "Board", "disambiguation": {"subtype": ["Industry"], "name": "Board game", "dbpedia_resource": "http://dbpedia.org/resource/Board_game"}}, {"type": "Company", "text": "Amazon", "disambiguation": {"subtype": [], "name": "Amazon.com", "dbpedia_resource": "http://dbpedia.org/resource/Amazon.com"}}, {"type": "Company", "text": "Express Scripts Holding Co."}, {"type": "Company", "text": "Medco Health Solutions Inc"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Ms. Potter", "keywords": [{"text": "Ms. Potter"}], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, "sentence": " Ms. Potter has previously served on the boards of Amazon, Express Scripts Holding Co., and Medco Health Solutions Inc.", "object": {"text": "Medco Health Solutions Inc", "keywords": [{"text": "Medco Health Solutions"}], "entities": [{"type": "Company", "text": "Medco Health Solutions Inc"}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "Mr. Guinan", "keywords": [{"text": "Mr. Guinan"}], "entities": [{"type": "Person", "text": "Mark Guinan"}]}, "sentence": " Mr. Guinan serves as the Executive Vice President and Chief Financial Officer for Quest Diagnostics Inc.", "object": {"text": "for Quest Diagnostics Inc", "keywords": [{"text": "Quest Diagnostics"}], "entities": [{"type": "Company", "text": "Quest Diagnostics Inc"}]}, "action": {"verb": {"text": "serve", "tense": "present"}, "text": "serves", "normalized": "serve"}}, {"subject": {"text": "He", "entities": [{"type": "Person", "text": "Mark Guinan"}]}, "sentence": " He previously served as Chief Financial Officer for Hill-Rom Holdings Inc., a manufacturer and provider of medical technologies and related services for the healthcare industry.", "object": {"text": "for Hill-Rom Holdings Inc., a manufacturer and provider of medical technologies and related services for the healthcare industry", "keywords": [{"text": "Hill-Rom Holdings Inc."}, {"text": "medical technologies"}, {"text": "related services"}, {"text": "healthcare industry"}], "entities": [{"type": "Company", "text": "Hill-Rom Holdings Inc.", "disambiguation": {"subtype": ["Company"], "name": "Hill-Rom Holdings", "dbpedia_resource": "http://dbpedia.org/resource/Hill-Rom_Holdings"}}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Mark Guinan"}]}, "sentence": " Prior to that, he served in a number of finance and operations roles in a long career at Johnson & Johnson, including as Vice President, Chief Procurement Officer, and as CFO of the pharmaceutical business.", "object": {"text": "in a number of finance and operations roles in a long career at Johnson & Johnson, including as Vice President, Chief Procurement Officer, and as CFO of the pharmaceutical business", "keywords": [{"text": "Chief Procurement Officer"}, {"text": "Vice President"}, {"text": "operations roles"}, {"text": "long career"}], "entities": [{"type": "Company", "text": "Johnson & Johnson", "disambiguation": {"subtype": ["Organization", "AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"type": "JobTitle", "text": "Vice President"}, {"type": "JobTitle", "text": "Chief Procurement Officer"}, {"type": "JobTitle", "text": "Chief Financial Officer"}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "as Vice President, Chief Procurement Officer, and as CFO of the pharmaceutical business", "keywords": [{"text": "Chief Procurement Officer"}, {"text": "Vice President"}, {"text": "CFO"}, {"text": "pharmaceutical business"}], "entities": [{"type": "JobTitle", "text": "Vice President"}, {"type": "JobTitle", "text": "Chief Procurement Officer"}, {"type": "JobTitle", "text": "Chief Financial Officer"}]}, "sentence": " Prior to that, he served in a number of finance and operations roles in a long career at Johnson & Johnson, including as Vice President, Chief Procurement Officer, and as CFO of the pharmaceutical business.", "object": {"text": "Johnson & Johnson", "keywords": [{"text": "Johnson"}], "entities": [{"type": "Company", "text": "Johnson & Johnson", "disambiguation": {"subtype": ["Organization", "AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Mr. Guinan", "keywords": [{"text": "Mr. Guinan"}], "entities": [{"type": "Person", "text": "Mark Guinan"}]}, "sentence": " Before joining Johnson & Johnson, Mr. Guinan held a number of financial roles at Procter & Gamble.", "object": {"text": "Johnson & Johnson", "keywords": [{"text": "Johnson"}], "entities": [{"type": "Company", "text": "Johnson & Johnson", "disambiguation": {"subtype": ["Organization", "AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}]}, "action": {"verb": {"text": "join", "tense": "present"}, "text": "joining", "normalized": "join"}}], "concepts": [{"text": "Management occupations", "relevance": 0.963405, "dbpedia_resource": "http://dbpedia.org/resource/Management_occupations"}, {"text": "Vice president", "relevance": 0.6832, "dbpedia_resource": "http://dbpedia.org/resource/Vice_president"}, {"text": "Corporate governance", "relevance": 0.659944, "dbpedia_resource": "http://dbpedia.org/resource/Corporate_governance"}, {"text": "Vice President of the United States", "relevance": 0.641902, "dbpedia_resource": "http://dbpedia.org/resource/Vice_President_of_the_United_States"}, {"text": "Chief executive officer", "relevance": 0.605433, "dbpedia_resource": "http://dbpedia.org/resource/Chief_executive_officer"}, {"text": "Clinical trial", "relevance": 0.603039, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"}, {"text": "George W. Bush", "relevance": 0.507718, "dbpedia_resource": "http://dbpedia.org/resource/George_W._Bush"}, {"text": "Vice presidents", "relevance": 0.486808, "dbpedia_resource": "http://dbpedia.org/resource/Vice_presidents"}, {"text": "Chief executives", "relevance": 0.483825, "dbpedia_resource": "http://dbpedia.org/resource/Chief_executives"}, {"text": "Richard Nixon", "relevance": 0.480367, "dbpedia_resource": "http://dbpedia.org/resource/Richard_Nixon"}, {"text": "Executive officer", "relevance": 0.4801, "dbpedia_resource": "http://dbpedia.org/resource/Executive_officer"}, {"text": "Gerald Ford", "relevance": 0.478246, "dbpedia_resource": "http://dbpedia.org/resource/Gerald_Ford"}, {"text": "De facto", "relevance": 0.469373, "dbpedia_resource": "http://dbpedia.org/resource/De_facto"}, {"text": "Pharmacology", "relevance": 0.457303, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "President of the United States", "relevance": 0.454392, "dbpedia_resource": "http://dbpedia.org/resource/President_of_the_United_States"}, {"text": "President pro tempore of the United States Senate", "relevance": 0.453762, "dbpedia_resource": "http://dbpedia.org/resource/President_pro_tempore_of_the_United_States_Senate"}, {"text": "Electoral College", "relevance": 0.452798, "dbpedia_resource": "http://dbpedia.org/resource/Electoral_College_(United_States)"}], "categories": [{"score": 0.599624, "label": "/health and fitness"}, {"score": 0.473508, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.426088, "label": "/finance/financial news"}], "relations": [{"type": "locatedAt", "sentence": "BASEL, Switzerland , Nov. Myovant Sciences, Ltd. (NYSE: MYOV ), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, today announced that Kim Sablich , formerly Vice President of Primary Care Marketing in the United States for GlaxoSmithKline (GSK), will join Myovant Sciences as Chief Commercial Officer, and Jeff Nornhold , formerly Senior Vice President of Technical Operations for Impax Laboratories (now Amneal Pharmaceuticals, Inc.), has joined Myovant as Senior Vice President of Pharmaceutical Operations & Development.", "score": 0.956957, "arguments": [{"text": "BASEL", "location": [0, 5], "entities": [{"type": "GeopoliticalEntity", "text": "BASEL"}]}, {"text": "Switzerland", "location": [7, 18], "entities": [{"type": "GeopoliticalEntity", "text": "Switzerland", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOfMany", "sentence": "In addition, Myovant has appointed industry veterans Myrtle Potter , Mark Guinan , and Frank Torti , M.D., to Myovant's Board of Directors, and Ms. Potter has been appointed Chairman of the Board.", "score": 0.658574, "arguments": [{"text": "Frank Torti", "location": [711, 722], "entities": [{"type": "Person", "text": "Frank Torti"}]}, {"text": "veterans", "location": [668, 676], "entities": [{"type": "Person", "text": "veterans"}]}]}, {"type": "partOfMany", "sentence": "In addition, Myovant has appointed industry veterans Myrtle Potter , Mark Guinan , and Frank Torti , M.D., to Myovant's Board of Directors, and Ms. Potter has been appointed Chairman of the Board.", "score": 0.605923, "arguments": [{"text": "M.D.,", "location": [725, 730], "entities": [{"type": "Person", "text": "M.D.,"}]}, {"text": "veterans", "location": [668, 676], "entities": [{"type": "Person", "text": "veterans"}]}]}, {"type": "partOf", "sentence": "In addition, Myovant has appointed industry veterans Myrtle Potter , Mark Guinan , and Frank Torti , M.D., to Myovant's Board of Directors, and Ms. Potter has been appointed Chairman of the Board.", "score": 0.919569, "arguments": [{"text": "Board of Directors", "location": [744, 762], "entities": [{"type": "Organization", "text": "Board of Directors of AllerGenis LLC"}]}, {"text": "Myovant", "location": [734, 741], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc. investors@myovant.com\nMedia Contact"}]}]}, {"type": "partOf", "sentence": "\"Ms. Potter's decades of commercial experience perfectly position her to chair Myovant's Board of diverse industry and healthcare leaders.", "score": 0.824904, "arguments": [{"text": "Board of", "location": [1200, 1208], "entities": [{"type": "Organization", "text": "Board of Directors of AllerGenis LLC"}]}, {"text": "Myovant", "location": [1190, 1197], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc. investors@myovant.com\nMedia Contact"}]}]}, {"type": "affectedBy", "sentence": "In addition, Myovant has appointed industry veterans Myrtle Potter , Mark Guinan , and Frank Torti , M.D., to Myovant's Board of Directors, and Ms. Potter has been appointed Chairman of the Board.", "score": 0.423376, "arguments": [{"text": "Potter", "location": [772, 778], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, {"text": "appointed", "location": [788, 797], "entities": [{"type": "EventPersonnel", "text": "appointed"}]}]}, {"type": "affectedBy", "sentence": "In addition, Myovant has appointed industry veterans Myrtle Potter , Mark Guinan , and Frank Torti , M.D., to Myovant's Board of Directors, and Ms. Potter has been appointed Chairman of the Board.", "score": 0.499875, "arguments": [{"text": "Chairman", "location": [798, 806], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, {"text": "appointed", "location": [788, 797], "entities": [{"type": "EventPersonnel", "text": "appointed"}]}]}, {"type": "employedBy", "sentence": "In addition, Myovant has appointed industry veterans Myrtle Potter , Mark Guinan , and Frank Torti , M.D., to Myovant's Board of Directors, and Ms. Potter has been appointed Chairman of the Board.", "score": 0.599421, "arguments": [{"text": "Chairman", "location": [798, 806], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, {"text": "Board", "location": [814, 819], "entities": [{"type": "Organization", "text": "Board of Directors of AllerGenis LLC"}]}]}, {"type": "agentOf", "sentence": "\"With top-line data from each of our five ongoing global Phase 3 clinical trials expected in 2019, we are pleased to announce the strengthening of our management team and Board as we look forward to the next stage of Myovant's growth,\" said Lynn Seely , M.D., President and CEO of Myovant.", "score": 0.569544, "arguments": [{"text": "we", "location": [920, 922], "entities": [{"type": "Person", "text": "we"}]}, {"text": "announce", "location": [938, 946], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "employedBy", "sentence": "\"With top-line data from each of our five ongoing global Phase 3 clinical trials expected in 2019, we are pleased to announce the strengthening of our management team and Board as we look forward to the next stage of Myovant's growth,\" said Lynn Seely , M.D., President and CEO of Myovant.", "score": 0.891942, "arguments": [{"text": "management team", "location": [972, 987], "entities": [{"type": "Person", "text": "management team"}]}, {"text": "our", "location": [968, 971], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc. investors@myovant.com\nMedia Contact"}]}]}, {"type": "agentOf", "sentence": "\"With top-line data from each of our five ongoing global Phase 3 clinical trials expected in 2019, we are pleased to announce the strengthening of our management team and Board as we look forward to the next stage of Myovant's growth,\" said Lynn Seely , M.D., President and CEO of Myovant.", "score": 0.760998, "arguments": [{"text": "Lynn Seely", "location": [1062, 1072], "entities": [{"type": "Person", "text": "Lynn Seely"}]}, {"text": "said", "location": [1057, 1061], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "managerOf", "sentence": "\"With top-line data from each of our five ongoing global Phase 3 clinical trials expected in 2019, we are pleased to announce the strengthening of our management team and Board as we look forward to the next stage of Myovant's growth,\" said Lynn Seely , M.D., President and CEO of Myovant.", "score": 0.79961, "arguments": [{"text": "CEO", "location": [1095, 1098], "entities": [{"type": "Person", "text": "Lynn Seely"}]}, {"text": "Myovant", "location": [1102, 1109], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc. investors@myovant.com\nMedia Contact"}]}]}, {"type": "managerOf", "sentence": "Myovant's other directors include Kathleen Sebelius , former U.S. Secretary of Health and Human Services during the Obama administration; Vivek Ramaswamy , the founder and CEO of Roivant Sciences; Terrie Curran , President , Global Inflammation and Immunology Franchise of Celgene Corporation; and Lynn Seely , M.D., President and Chief Executive Officer of Myovant.", "score": 0.708248, "arguments": [{"text": "Chief Executive Officer", "location": [6421, 6444], "entities": [{"type": "Person", "text": "Lynn Seely"}]}, {"text": "Myovant", "location": [6448, 6455], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc. investors@myovant.com\nMedia Contact"}]}]}, {"type": "employedBy", "sentence": "Together, we are committed to achieving our mission of becoming the leading company in women's health and endocrine diseases.", "score": 0.291618, "arguments": [{"text": "women", "location": [1337, 1342], "entities": [{"type": "Person", "text": "women"}]}, {"text": "company", "location": [1326, 1333], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc. investors@myovant.com\nMedia Contact"}]}]}, {"type": "hasAttribute", "sentence": "BASEL, Switzerland , Nov. Myovant Sciences, Ltd. (NYSE: MYOV ), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, today announced that Kim Sablich , formerly Vice President of Primary Care Marketing in the United States for GlaxoSmithKline (GSK), will join Myovant Sciences as Chief Commercial Officer, and Jeff Nornhold , formerly Senior Vice President of Technical Operations for Impax Laboratories (now Amneal Pharmaceuticals, Inc.), has joined Myovant as Senior Vice President of Pharmaceutical Operations & Development.", "score": 0.607425, "arguments": [{"text": "Myovant Sciences, Ltd.", "location": [26, 48], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc. investors@myovant.com\nMedia Contact"}]}, {"text": "MYOV", "location": [56, 60], "entities": [{"type": "Ticker", "text": "MYOV"}]}]}, {"type": "hasAttribute", "sentence": "Together, we are committed to achieving our mission of becoming the leading company in women's health and endocrine diseases.", "score": 0.683725, "arguments": [{"text": "women", "location": [1337, 1342], "entities": [{"type": "Person", "text": "women"}]}, {"text": "diseases", "location": [1366, 1374], "entities": [{"type": "HealthCondition", "text": "prostate cancer"}]}]}, {"type": "employedBy", "sentence": "\" Additions to Myovant's Management Team Ms. Sablich previously served as Vice President, Primary Care Marketing in the United States for GSK, where she was responsible for revenue forecasts, product strategies and execution plans for a broad portfolio of products including Advair\u00ae, Breo, Anoro\u00ae, Incruse\u00ae, TanzeumM, Levitra\u00ae, and Trelegy.", "score": 0.413073, "arguments": [{"text": "Ms.", "location": [1416, 1419], "entities": [{"type": "Person", "text": "Kim Sablich"}]}, {"text": "Myovant's Management Team", "location": [1390, 1415], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc. investors@myovant.com\nMedia Contact"}]}]}, {"type": "locatedAt", "sentence": "\" Additions to Myovant's Management Team Ms. Sablich previously served as Vice President, Primary Care Marketing in the United States for GSK, where she was responsible for revenue forecasts, product strategies and execution plans for a broad portfolio of products including Advair\u00ae, Breo, Anoro\u00ae, Incruse\u00ae, TanzeumM, Levitra\u00ae, and Trelegy.", "score": 0.335323, "arguments": [{"text": "she", "location": [1524, 1527], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, {"text": "where", "location": [1518, 1523], "entities": [{"type": "Facility", "text": "where"}]}]}, {"type": "locatedAt", "sentence": "Before joining GSK, Ms. Sablich spent 15 years at Merck, where she held positions of increasing responsibility in the commercial organization across sales, product management, pricing/access, and customer insights, with a focus on the cardiovascular, respiratory and vaccines business areas.", "score": 0.244545, "arguments": [{"text": "she", "location": [1942, 1945], "entities": [{"type": "Person", "text": "Chief Procurement Officer"}]}, {"text": "where", "location": [1936, 1941], "entities": [{"type": "Facility", "text": "where"}]}]}, {"type": "memberOf", "sentence": "She is currently a member of the Board of Directors of AllerGenis LLC.", "score": 0.805736, "arguments": [{"text": "member", "location": [2370, 2376], "entities": [{"type": "Person", "text": "Chief Procurement Officer"}]}, {"text": "Board of Directors of AllerGenis LLC", "location": [2384, 2420], "entities": [{"type": "Organization", "text": "Board of Directors of AllerGenis LLC"}]}]}, {"type": "affectedBy", "sentence": "She earned a B.A. from Denison University and an M.B.A. from The Wharton School of the University of Pennsylvania .", "score": 0.515151, "arguments": [{"text": "She", "location": [2422, 2425], "entities": [{"type": "Person", "text": "Chief Procurement Officer"}]}, {"text": "earned", "location": [2426, 2432], "entities": [{"type": "EventEducation", "text": "earned"}]}]}, {"type": "educatedAt", "sentence": "She earned a B.A. from Denison University and an M.B.A. from The Wharton School of the University of Pennsylvania .", "score": 0.770997, "arguments": [{"text": "She", "location": [2422, 2425], "entities": [{"type": "Person", "text": "Chief Procurement Officer"}]}, {"text": "Denison University", "location": [2445, 2463], "entities": [{"type": "Organization", "text": "Denison University", "disambiguation": {"subtype": ["Educational"]}}]}]}, {"type": "agentOf", "sentence": "She earned a B.A. from Denison University and an M.B.A. from The Wharton School of the University of Pennsylvania .", "score": 0.803177, "arguments": [{"text": "M.B.A.", "location": [2471, 2477], "entities": [{"type": "Organization", "text": "M.B.A."}]}, {"text": "earned", "location": [2426, 2432], "entities": [{"type": "EventEducation", "text": "earned"}]}]}, {"type": "agentOf", "sentence": "She earned a B.A. from Denison University and an M.B.A. from The Wharton School of the University of Pennsylvania .", "score": 0.782197, "arguments": [{"text": "The Wharton School of the University of Pennsylvania", "location": [2483, 2535], "entities": [{"type": "Organization", "text": "The Wharton School of the University of Pennsylvania"}]}, {"text": "earned", "location": [2426, 2432], "entities": [{"type": "EventEducation", "text": "earned"}]}]}, {"type": "partOf", "sentence": "She earned a B.A. from Denison University and an M.B.A. from The Wharton School of the University of Pennsylvania .", "score": 0.656094, "arguments": [{"text": "M.B.A.", "location": [2471, 2477], "entities": [{"type": "Organization", "text": "M.B.A."}]}, {"text": "The Wharton School of the University of Pennsylvania", "location": [2483, 2535], "entities": [{"type": "Organization", "text": "The Wharton School of the University of Pennsylvania"}]}]}, {"type": "hasAttribute", "sentence": "BASEL, Switzerland , Nov. Myovant Sciences, Ltd. (NYSE: MYOV ), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, today announced that Kim Sablich , formerly Vice President of Primary Care Marketing in the United States for GlaxoSmithKline (GSK), will join Myovant Sciences as Chief Commercial Officer, and Jeff Nornhold , formerly Senior Vice President of Technical Operations for Impax Laboratories (now Amneal Pharmaceuticals, Inc.), has joined Myovant as Senior Vice President of Pharmaceutical Operations & Development.", "score": 0.77953, "arguments": [{"text": "women", "location": [174, 179], "entities": [{"type": "Person", "text": "women"}]}, {"text": "diseases", "location": [203, 211], "entities": [{"type": "HealthCondition", "text": "prostate cancer"}]}]}, {"type": "employedBy", "sentence": "Prior to that, he served as Impax's Senior Vice President, Global Quality Affairs, and was responsible for establishing a sustainable quality and compliance program.", "score": 0.464161, "arguments": [{"text": "Senior Vice President", "location": [2813, 2834], "entities": [{"type": "Person", "text": "Senior Vice President"}]}, {"text": "Impax", "location": [2805, 2810], "entities": [{"type": "Organization", "text": "Technical Operations for Impax Laboratories"}]}]}, {"type": "partOf", "sentence": "Prior to that, he served as Impax's Senior Vice President, Global Quality Affairs, and was responsible for establishing a sustainable quality and compliance program.", "score": 0.286576, "arguments": [{"text": "Impax", "location": [2805, 2810], "entities": [{"type": "Organization", "text": "Technical Operations for Impax Laboratories"}]}, {"text": "Global Quality Affairs", "location": [2836, 2858], "entities": [{"type": "Organization", "text": "Global Quality Affairs", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "While at Watson , he also served as Vice President, U.S. Quality Operations, where he led the development and execution of quality initiatives for all U.S. sites.", "score": 0.986659, "arguments": [{"text": "Quality Operations", "location": [3250, 3268], "entities": [{"type": "Organization", "text": "Quality Operations"}]}, {"text": "U.S.", "location": [3245, 3249], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "affectedBy", "sentence": "While at Watson , he also served as Vice President, U.S. Quality Operations, where he led the development and execution of quality initiatives for all U.S. sites.", "score": 0.472767, "arguments": [{"text": "he", "location": [3276, 3278], "entities": [{"type": "Person", "text": "Jeff Nornhold"}]}, {"text": "execution", "location": [3303, 3312], "entities": [{"type": "EventLegal", "text": "execution"}]}]}, {"type": "locatedAt", "sentence": "While at Watson , he also served as Vice President, U.S. Quality Operations, where he led the development and execution of quality initiatives for all U.S. sites.", "score": 0.153194, "arguments": [{"text": "sites", "location": [3349, 3354], "entities": [{"type": "Location", "text": "sites"}]}, {"text": "U.S.", "location": [3344, 3348], "entities": [{"type": "GeopoliticalEntity", "text": "Myovant Sciences, Inc. investors@myovant.com\nMedia Contact"}]}]}, {"type": "affectedBy", "sentence": "Mr. Nornhold earned a B.S. in chemistry from Bowling Green State University and an M.B.A. from the University of Southern California Marshall School of Business.", "score": 0.916672, "arguments": [{"text": "Nornhold", "location": [3453, 3461], "entities": [{"type": "Person", "text": "Jeff Nornhold"}]}, {"text": "earned", "location": [3462, 3468], "entities": [{"type": "EventEducation", "text": "earned"}]}]}, {"type": "awardedTo", "sentence": "Mr. Nornhold earned a B.S. in chemistry from Bowling Green State University and an M.B.A. from the University of Southern California Marshall School of Business.", "score": 0.677837, "arguments": [{"text": "B.S.", "location": [3471, 3475], "entities": [{"type": "Degree", "text": "B.S."}]}, {"text": "Nornhold", "location": [3453, 3461], "entities": [{"type": "Person", "text": "Jeff Nornhold"}]}]}, {"type": "educatedAt", "sentence": "Mr. Nornhold earned a B.S. in chemistry from Bowling Green State University and an M.B.A. from the University of Southern California Marshall School of Business.", "score": 0.522032, "arguments": [{"text": "Nornhold", "location": [3453, 3461], "entities": [{"type": "Person", "text": "Jeff Nornhold"}]}, {"text": "University of Southern California Marshall School of Business", "location": [3548, 3609], "entities": [{"type": "Organization", "text": "University of Southern California Marshall School of Business"}]}]}, {"type": "agentOf", "sentence": "Mr. Nornhold earned a B.S. in chemistry from Bowling Green State University and an M.B.A. from the University of Southern California Marshall School of Business.", "score": 0.967546, "arguments": [{"text": "Bowling Green State University", "location": [3494, 3524], "entities": [{"type": "Organization", "text": "Bowling Green State University"}]}, {"text": "earned", "location": [3462, 3468], "entities": [{"type": "EventEducation", "text": "earned"}]}]}, {"type": "agentOf", "sentence": "Mr. Nornhold earned a B.S. in chemistry from Bowling Green State University and an M.B.A. from the University of Southern California Marshall School of Business.", "score": 0.931533, "arguments": [{"text": "M.B.A.", "location": [3532, 3538], "entities": [{"type": "Organization", "text": "M.B.A."}]}, {"text": "earned", "location": [3462, 3468], "entities": [{"type": "EventEducation", "text": "earned"}]}]}, {"type": "timeOf", "sentence": "BASEL, Switzerland , Nov. Myovant Sciences, Ltd. (NYSE: MYOV ), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, today announced that Kim Sablich , formerly Vice President of Primary Care Marketing in the United States for GlaxoSmithKline (GSK), will join Myovant Sciences as Chief Commercial Officer, and Jeff Nornhold , formerly Senior Vice President of Technical Operations for Impax Laboratories (now Amneal Pharmaceuticals, Inc.), has joined Myovant as Senior Vice President of Pharmaceutical Operations & Development.", "score": 0.956741, "arguments": [{"text": "today", "location": [213, 218], "entities": [{"type": "Date", "text": "today"}]}, {"text": "announced", "location": [219, 228], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "agentOf", "sentence": "Mr. Nornhold earned a B.S. in chemistry from Bowling Green State University and an M.B.A. from the University of Southern California Marshall School of Business.", "score": 0.815323, "arguments": [{"text": "University of Southern California Marshall School of Business", "location": [3548, 3609], "entities": [{"type": "Organization", "text": "University of Southern California Marshall School of Business"}]}, {"text": "earned", "location": [3462, 3468], "entities": [{"type": "EventEducation", "text": "earned"}]}]}, {"type": "awardedBy", "sentence": "Mr. Nornhold earned a B.S. in chemistry from Bowling Green State University and an M.B.A. from the University of Southern California Marshall School of Business.", "score": 0.562099, "arguments": [{"text": "B.S.", "location": [3471, 3475], "entities": [{"type": "Degree", "text": "B.S."}]}, {"text": "Bowling Green State University", "location": [3494, 3524], "entities": [{"type": "Organization", "text": "Bowling Green State University"}]}]}, {"type": "partOf", "sentence": "Mr. Nornhold earned a B.S. in chemistry from Bowling Green State University and an M.B.A. from the University of Southern California Marshall School of Business.", "score": 0.516218, "arguments": [{"text": "M.B.A.", "location": [3532, 3538], "entities": [{"type": "Organization", "text": "M.B.A."}]}, {"text": "University of Southern California Marshall School of Business", "location": [3548, 3609], "entities": [{"type": "Organization", "text": "University of Southern California Marshall School of Business"}]}]}, {"type": "employedBy", "sentence": "New Myovant Directors Ms. Potter currently serves as Vant Operating Chair for Roivant Pharma, a division of Roivant Sciences.", "score": 0.60273, "arguments": [{"text": "Directors", "location": [3623, 3632], "entities": [{"type": "Person", "text": "directors"}]}, {"text": "Myovant", "location": [3615, 3622], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc. investors@myovant.com\nMedia Contact"}]}]}, {"type": "partOf", "sentence": "New Myovant Directors Ms. Potter currently serves as Vant Operating Chair for Roivant Pharma, a division of Roivant Sciences.", "score": 0.880253, "arguments": [{"text": "division", "location": [3707, 3715], "entities": [{"type": "Organization", "text": "Chair for Roivant Pharma"}]}, {"text": "Roivant Sciences", "location": [3719, 3735], "entities": [{"type": "Organization", "text": "Roivant Sciences"}]}]}, {"type": "partOf", "sentence": "Dr. Torti serves as Vant Investment Chair for Roivant Pharma, a division of Roivant Sciences.", "score": 0.882512, "arguments": [{"text": "division", "location": [5218, 5226], "entities": [{"type": "Organization", "text": "Chair for Roivant Pharma"}]}, {"text": "Roivant Sciences", "location": [5230, 5246], "entities": [{"type": "Organization", "text": "Roivant Sciences"}]}]}, {"type": "managerOf", "sentence": "She previously served as Chief Executive Officer of Myrtle Potter & Company, LLC, and President of Commercial Operations and Executive Vice President, and Chief Operating Officer of Genentech.", "score": 0.361243, "arguments": [{"text": "Myrtle Potter", "location": [3789, 3802], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, {"text": "Company", "location": [3805, 3812], "entities": [{"type": "Organization", "text": "Board of Directors of AllerGenis LLC"}]}]}, {"type": "managerOf", "sentence": "She previously served as Chief Executive Officer of Myrtle Potter & Company, LLC, and President of Commercial Operations and Executive Vice President, and Chief Operating Officer of Genentech.", "score": 0.543684, "arguments": [{"text": "President", "location": [3823, 3832], "entities": [{"type": "Person", "text": "Obama"}]}, {"text": "Commercial Operations", "location": [3836, 3857], "entities": [{"type": "Organization", "text": "Commercial Operations", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "managerOf", "sentence": "She previously served as Chief Executive Officer of Myrtle Potter & Company, LLC, and President of Commercial Operations and Executive Vice President, and Chief Operating Officer of Genentech.", "score": 0.417585, "arguments": [{"text": "Executive Vice President", "location": [3862, 3886], "entities": [{"type": "Person", "text": "Executive Vice President"}]}, {"text": "Genentech", "location": [3919, 3928], "entities": [{"type": "Organization", "text": "Genentech", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "managerOf", "sentence": "She previously served as Chief Executive Officer of Myrtle Potter & Company, LLC, and President of Commercial Operations and Executive Vice President, and Chief Operating Officer of Genentech.", "score": 0.582966, "arguments": [{"text": "Chief Operating Officer", "location": [3892, 3915], "entities": [{"type": "Person", "text": "Executive Vice President"}]}, {"text": "Genentech", "location": [3919, 3928], "entities": [{"type": "Organization", "text": "Genentech", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Prior to Genentech, she held various positions, including President of Cardiovascular/Metabolics at Bristol- Myers Squibb .", "score": 0.495487, "arguments": [{"text": "President", "location": [3988, 3997], "entities": [{"type": "Person", "text": "Obama"}]}, {"text": "Cardiovascular", "location": [4001, 4015], "entities": [{"type": "Organization", "text": "Cardiovascular"}]}]}, {"type": "partOf", "sentence": "Prior to Genentech, she held various positions, including President of Cardiovascular/Metabolics at Bristol- Myers Squibb .", "score": 0.440847, "arguments": [{"text": "Cardiovascular", "location": [4001, 4015], "entities": [{"type": "Organization", "text": "Cardiovascular"}]}, {"text": "Bristol- Myers Squibb", "location": [4030, 4051], "entities": [{"type": "Organization", "text": "Bristol- Myers Squibb", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "managerOf", "sentence": "BASEL, Switzerland , Nov. Myovant Sciences, Ltd. (NYSE: MYOV ), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, today announced that Kim Sablich , formerly Vice President of Primary Care Marketing in the United States for GlaxoSmithKline (GSK), will join Myovant Sciences as Chief Commercial Officer, and Jeff Nornhold , formerly Senior Vice President of Technical Operations for Impax Laboratories (now Amneal Pharmaceuticals, Inc.), has joined Myovant as Senior Vice President of Pharmaceutical Operations & Development.", "score": 0.634813, "arguments": [{"text": "Vice President", "location": [257, 271], "entities": [{"type": "Person", "text": "Chief Procurement Officer"}]}, {"text": "Primary Care Marketing", "location": [275, 297], "entities": [{"type": "Organization", "text": "Primary Care Marketing"}]}]}, {"type": "educatedAt", "sentence": "She is a graduate of the University of Chicago .", "score": 0.588971, "arguments": [{"text": "graduate", "location": [4063, 4071], "entities": [{"type": "Person", "text": "Executive Vice President"}]}, {"text": "University of Chicago", "location": [4079, 4100], "entities": [{"type": "Organization", "text": "University of Chicago"}]}]}, {"type": "partOf", "sentence": "In addition to serving on our Board, Ms. Potter also serves on the boards of other companies in the Roivant family of companies, including Urovant Sciences, Axovant Sciences and Arbutus Biopharma.", "score": 0.876053, "arguments": [{"text": "Board", "location": [4133, 4138], "entities": [{"type": "Organization", "text": "Board of Directors of AllerGenis LLC"}]}, {"text": "our", "location": [4129, 4132], "entities": [{"type": "Organization", "text": "companies"}]}]}, {"type": "employedBy", "sentence": "In addition to serving on our Board, Ms. Potter also serves on the boards of other companies in the Roivant family of companies, including Urovant Sciences, Axovant Sciences and Arbutus Biopharma.", "score": 0.630567, "arguments": [{"text": "family", "location": [4211, 4217], "entities": [{"type": "Person", "text": "family"}]}, {"text": "Roivant", "location": [4203, 4210], "entities": [{"type": "Organization", "text": "Roivant Sciences"}]}]}, {"type": "employedBy", "sentence": "In addition to serving on our Board, Dr. Torti also serves on the boards of several other companies in the Roivant family of companies, including Urovant Sciences, Axovant Sciences, Dermavant Sciences and Respivant Sciences.", "score": 0.630567, "arguments": [{"text": "family", "location": [5834, 5840], "entities": [{"type": "Person", "text": "family"}]}, {"text": "Roivant", "location": [5826, 5833], "entities": [{"type": "Organization", "text": "Roivant Sciences"}]}]}, {"type": "employedBy", "sentence": "In addition to serving on our Board, Ms. Potter also serves on the boards of other companies in the Roivant family of companies, including Urovant Sciences, Axovant Sciences and Arbutus Biopharma.", "score": 0.26758, "arguments": [{"text": "family", "location": [4211, 4217], "entities": [{"type": "Person", "text": "family"}]}, {"text": "companies", "location": [4221, 4230], "entities": [{"type": "Organization", "text": "companies"}]}]}, {"type": "partOf", "sentence": "Ms. Potter has previously served on the boards of Amazon, Express Scripts Holding Co., and Medco Health Solutions Inc. Mr. Guinan serves as the Executive Vice President and Chief Financial Officer for Quest Diagnostics Inc. He previously served as Chief Financial Officer for Hill-Rom Holdings Inc., a manufacturer and provider of medical technologies and related services for the healthcare industry.", "score": 0.371016, "arguments": [{"text": "Amazon", "location": [4350, 4356], "entities": [{"type": "Organization", "text": "Amazon"}]}, {"text": "Express Scripts Holding Co.", "location": [4358, 4385], "entities": [{"type": "Organization", "text": "Express Scripts Holding Co.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Ms. Potter has previously served on the boards of Amazon, Express Scripts Holding Co., and Medco Health Solutions Inc. Mr. Guinan serves as the Executive Vice President and Chief Financial Officer for Quest Diagnostics Inc. He previously served as Chief Financial Officer for Hill-Rom Holdings Inc., a manufacturer and provider of medical technologies and related services for the healthcare industry.", "score": 0.563959, "arguments": [{"text": "Mr.", "location": [4419, 4422], "entities": [{"type": "Person", "text": "Mark Guinan"}]}, {"text": "Medco Health Solutions Inc.", "location": [4391, 4418], "entities": [{"type": "Organization", "text": "Medco Health Solutions Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Ms. Potter has previously served on the boards of Amazon, Express Scripts Holding Co., and Medco Health Solutions Inc. Mr. Guinan serves as the Executive Vice President and Chief Financial Officer for Quest Diagnostics Inc. He previously served as Chief Financial Officer for Hill-Rom Holdings Inc., a manufacturer and provider of medical technologies and related services for the healthcare industry.", "score": 0.732579, "arguments": [{"text": "Chief Financial Officer", "location": [4473, 4496], "entities": [{"type": "Person", "text": "Chief Financial Officer"}]}, {"text": "Quest Diagnostics Inc.", "location": [4501, 4523], "entities": [{"type": "Organization", "text": "Quest Diagnostics Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "managerOf", "sentence": "Prior to that, he served in a number of finance and operations roles in a long career at Johnson & Johnson, including as Vice President, Chief Procurement Officer, and as CFO of the pharmaceutical business.", "score": 0.654973, "arguments": [{"text": "CFO", "location": [4873, 4876], "entities": [{"type": "Person", "text": "Chief Financial Officer"}]}, {"text": "pharmaceutical business", "location": [4884, 4907], "entities": [{"type": "Organization", "text": "pharmaceutical business", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Before joining Johnson & Johnson, Mr. Guinan held a number of financial roles at Procter & Gamble.", "score": 0.691061, "arguments": [{"text": "Guinan", "location": [4947, 4953], "entities": [{"type": "Person", "text": "Mark Guinan"}]}, {"text": "Procter & Gamble", "location": [4990, 5006], "entities": [{"type": "Organization", "text": "Procter & Gamble", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "awardedTo", "sentence": "He received a B.A. in economics from the University of Notre Dame and an M.B.A. from Olin Business School at Washington University in St. Louis .", "score": 0.759648, "arguments": [{"text": "B.A.", "location": [5022, 5026], "entities": [{"type": "Degree", "text": "B.A."}]}, {"text": "He", "location": [5008, 5010], "entities": [{"type": "Person", "text": "Mark Guinan"}]}]}, {"type": "locatedAt", "sentence": "BASEL, Switzerland , Nov. Myovant Sciences, Ltd. (NYSE: MYOV ), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, today announced that Kim Sablich , formerly Vice President of Primary Care Marketing in the United States for GlaxoSmithKline (GSK), will join Myovant Sciences as Chief Commercial Officer, and Jeff Nornhold , formerly Senior Vice President of Technical Operations for Impax Laboratories (now Amneal Pharmaceuticals, Inc.), has joined Myovant as Senior Vice President of Pharmaceutical Operations & Development.", "score": 0.502038, "arguments": [{"text": "Primary Care Marketing", "location": [275, 297], "entities": [{"type": "Organization", "text": "Primary Care Marketing"}]}, {"text": "United States", "location": [305, 318], "entities": [{"type": "GeopoliticalEntity", "text": "United States", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "\" Additions to Myovant's Management Team Ms. Sablich previously served as Vice President, Primary Care Marketing in the United States for GSK, where she was responsible for revenue forecasts, product strategies and execution plans for a broad portfolio of products including Advair\u00ae, Breo, Anoro\u00ae, Incruse\u00ae, TanzeumM, Levitra\u00ae, and Trelegy.", "score": 0.589281, "arguments": [{"text": "Primary Care Marketing", "location": [1465, 1487], "entities": [{"type": "Organization", "text": "Primary Care Marketing"}]}, {"text": "United States", "location": [1495, 1508], "entities": [{"type": "GeopoliticalEntity", "text": "United States", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "managerOf", "sentence": "He received a B.A. in economics from the University of Notre Dame and an M.B.A. from Olin Business School at Washington University in St. Louis .", "score": 0.490685, "arguments": [{"text": "Olin", "location": [5093, 5097], "entities": [{"type": "Person", "text": "Olin"}]}, {"text": "Business School", "location": [5098, 5113], "entities": [{"type": "Organization", "text": "Business School"}]}]}, {"type": "employedBy", "sentence": "He received a B.A. in economics from the University of Notre Dame and an M.B.A. from Olin Business School at Washington University in St. Louis .", "score": 0.589514, "arguments": [{"text": "Olin", "location": [5093, 5097], "entities": [{"type": "Person", "text": "Olin"}]}, {"text": "Washington University", "location": [5117, 5138], "entities": [{"type": "Organization", "text": "Washington University", "disambiguation": {"subtype": ["Educational"]}}]}]}, {"type": "partOf", "sentence": "He received a B.A. in economics from the University of Notre Dame and an M.B.A. from Olin Business School at Washington University in St. Louis .", "score": 0.722472, "arguments": [{"text": "Business School", "location": [5098, 5113], "entities": [{"type": "Organization", "text": "Business School"}]}, {"text": "Washington University", "location": [5117, 5138], "entities": [{"type": "Organization", "text": "Washington University", "disambiguation": {"subtype": ["Educational"]}}]}]}, {"type": "basedIn", "sentence": "He received a B.A. in economics from the University of Notre Dame and an M.B.A. from Olin Business School at Washington University in St. Louis .", "score": 0.75597, "arguments": [{"text": "Washington University", "location": [5117, 5138], "entities": [{"type": "Organization", "text": "Washington University", "disambiguation": {"subtype": ["Educational"]}}]}, {"text": "St. Louis", "location": [5142, 5151], "entities": [{"type": "GeopoliticalEntity", "text": "St. Louis"}]}]}, {"type": "employedBy", "sentence": "Prior to Roivant, he was a partner at New Enterprise Associates (NEA), a leading venture capital firm.", "score": 0.747172, "arguments": [{"text": "partner", "location": [5275, 5282], "entities": [{"type": "Person", "text": "partner"}]}, {"text": "New Enterprise Associates", "location": [5286, 5311], "entities": [{"type": "Organization", "text": "New Enterprise Associates", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Prior to Roivant, he was a partner at New Enterprise Associates (NEA), a leading venture capital firm.", "score": 0.500302, "arguments": [{"text": "partner", "location": [5275, 5282], "entities": [{"type": "Person", "text": "partner"}]}, {"text": "venture capital firm", "location": [5329, 5349], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc. investors@myovant.com\nMedia Contact"}]}]}, {"type": "employedBy", "sentence": "Prior to NEA, Dr. Torti was a researcher at the Duke University Center for Clinical & Genetic Economics where he was involved in clinical trial research and economic evaluations of multinational clinical trials.", "score": 0.623622, "arguments": [{"text": "researcher", "location": [5537, 5547], "entities": [{"type": "Person", "text": "Frank Torti"}]}, {"text": "Duke University Center for Clinical & Genetic Economics where", "location": [5555, 5616], "entities": [{"type": "Organization", "text": "Duke University Center for Clinical & Genetic Economics where"}]}]}, {"type": "employedBy", "sentence": "Prior to NEA, Dr. Torti was a researcher at the Duke University Center for Clinical & Genetic Economics where he was involved in clinical trial research and economic evaluations of multinational clinical trials.", "score": 0.25709, "arguments": [{"text": "he", "location": [5617, 5619], "entities": [{"type": "Person", "text": "Frank Torti"}]}, {"text": "Duke University Center for Clinical & Genetic Economics where", "location": [5555, 5616], "entities": [{"type": "Organization", "text": "Duke University Center for Clinical & Genetic Economics where"}]}]}, {"type": "partOf", "sentence": "In addition to serving on our Board, Dr. Torti also serves on the boards of several other companies in the Roivant family of companies, including Urovant Sciences, Axovant Sciences, Dermavant Sciences and Respivant Sciences.", "score": 0.876053, "arguments": [{"text": "Board", "location": [5749, 5754], "entities": [{"type": "Organization", "text": "Board of Directors of AllerGenis LLC"}]}, {"text": "our", "location": [5745, 5748], "entities": [{"type": "Organization", "text": "companies"}]}]}, {"type": "employedBy", "sentence": "In addition to serving on our Board, Dr. Torti also serves on the boards of several other companies in the Roivant family of companies, including Urovant Sciences, Axovant Sciences, Dermavant Sciences and Respivant Sciences.", "score": 0.26758, "arguments": [{"text": "family", "location": [5834, 5840], "entities": [{"type": "Person", "text": "family"}]}, {"text": "companies", "location": [5844, 5853], "entities": [{"type": "Organization", "text": "companies"}]}]}, {"type": "partOfMany", "sentence": "Myovant's other directors include Kathleen Sebelius , former U.S. Secretary of Health and Human Services during the Obama administration; Vivek Ramaswamy , the founder and CEO of Roivant Sciences; Terrie Curran , President , Global Inflammation and Immunology Franchise of Celgene Corporation; and Lynn Seely , M.D., President and Chief Executive Officer of Myovant.", "score": 0.775883, "arguments": [{"text": "Kathleen Sebelius", "location": [6124, 6141], "entities": [{"type": "Person", "text": "Kathleen Sebelius"}]}, {"text": "directors", "location": [6106, 6115], "entities": [{"type": "Person", "text": "directors"}]}]}, {"type": "employedBy", "sentence": "BASEL, Switzerland , Nov. Myovant Sciences, Ltd. (NYSE: MYOV ), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, today announced that Kim Sablich , formerly Vice President of Primary Care Marketing in the United States for GlaxoSmithKline (GSK), will join Myovant Sciences as Chief Commercial Officer, and Jeff Nornhold , formerly Senior Vice President of Technical Operations for Impax Laboratories (now Amneal Pharmaceuticals, Inc.), has joined Myovant as Senior Vice President of Pharmaceutical Operations & Development.", "score": 0.539525, "arguments": [{"text": "Senior Vice President of", "location": [558, 582], "entities": [{"type": "Person", "text": "Senior Vice President of"}]}, {"text": "Pharmaceutical Operations & Development", "location": [583, 622], "entities": [{"type": "Organization", "text": "Pharmaceutical Operations & Development"}]}]}, {"type": "partOfMany", "sentence": "Myovant's other directors include Kathleen Sebelius , former U.S. Secretary of Health and Human Services during the Obama administration; Vivek Ramaswamy , the founder and CEO of Roivant Sciences; Terrie Curran , President , Global Inflammation and Immunology Franchise of Celgene Corporation; and Lynn Seely , M.D., President and Chief Executive Officer of Myovant.", "score": 0.661912, "arguments": [{"text": "Secretary of Health and Human Services", "location": [6156, 6194], "entities": [{"type": "Person", "text": "Secretary of Health and Human Services"}]}, {"text": "directors", "location": [6106, 6115], "entities": [{"type": "Person", "text": "directors"}]}]}, {"type": "employedBy", "sentence": "Myovant's other directors include Kathleen Sebelius , former U.S. Secretary of Health and Human Services during the Obama administration; Vivek Ramaswamy , the founder and CEO of Roivant Sciences; Terrie Curran , President , Global Inflammation and Immunology Franchise of Celgene Corporation; and Lynn Seely , M.D., President and Chief Executive Officer of Myovant.", "score": 0.906055, "arguments": [{"text": "Secretary of Health and Human Services", "location": [6156, 6194], "entities": [{"type": "Person", "text": "Secretary of Health and Human Services"}]}, {"text": "U.S.", "location": [6151, 6155], "entities": [{"type": "GeopoliticalEntity", "text": "Myovant Sciences, Inc. investors@myovant.com\nMedia Contact"}]}]}, {"type": "managerOf", "sentence": "Myovant's other directors include Kathleen Sebelius , former U.S. Secretary of Health and Human Services during the Obama administration; Vivek Ramaswamy , the founder and CEO of Roivant Sciences; Terrie Curran , President , Global Inflammation and Immunology Franchise of Celgene Corporation; and Lynn Seely , M.D., President and Chief Executive Officer of Myovant.", "score": 0.964757, "arguments": [{"text": "Obama", "location": [6206, 6211], "entities": [{"type": "Person", "text": "Obama"}]}, {"text": "administration", "location": [6212, 6226], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "managerOf", "sentence": "Myovant's other directors include Kathleen Sebelius , former U.S. Secretary of Health and Human Services during the Obama administration; Vivek Ramaswamy , the founder and CEO of Roivant Sciences; Terrie Curran , President , Global Inflammation and Immunology Franchise of Celgene Corporation; and Lynn Seely , M.D., President and Chief Executive Officer of Myovant.", "score": 0.787492, "arguments": [{"text": "CEO", "location": [6262, 6265], "entities": [{"type": "Person", "text": "Vivek Ramaswamy"}]}, {"text": "Roivant Sciences", "location": [6269, 6285], "entities": [{"type": "Organization", "text": "Roivant Sciences"}]}]}, {"type": "hasAttribute", "sentence": "About Myovant Sciences Myovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of women's health and endocrine diseases.", "score": 0.748964, "arguments": [{"text": "women", "location": [6627, 6632], "entities": [{"type": "Person", "text": "women"}]}, {"text": "diseases", "location": [6656, 6664], "entities": [{"type": "HealthCondition", "text": "prostate cancer"}]}]}, {"type": "employedBy", "sentence": "Myovant's lead product candidate is relugolix, an oral, once-daily small molecule that acts as a GnRH receptor antagonist.", "score": 0.317786, "arguments": [{"text": "candidate", "location": [6689, 6698], "entities": [{"type": "Person", "text": "Kathleen Sebelius"}]}, {"text": "Myovant", "location": [6666, 6673], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc. investors@myovant.com\nMedia Contact"}]}]}, {"type": "hasAttribute", "sentence": "Myovant has initiated three clinical programs for relugolix consisting of five international Phase 3 clinical trials, two in women with heavy menstrual bleeding associated with uterine fibroids ( LIBERTY 1 and 2), two in women with pain associated with endometriosis (SPIRIT 1 and 2), and one in men with advanced prostate cancer (HERO).", "score": 0.926071, "arguments": [{"text": "men", "location": [7085, 7088], "entities": [{"type": "Person", "text": "women"}]}, {"text": "prostate cancer", "location": [7103, 7118], "entities": [{"type": "HealthCondition", "text": "prostate cancer"}]}]}, {"type": "hasAttribute", "sentence": "Myovant has initiated three clinical programs for relugolix consisting of five international Phase 3 clinical trials, two in women with heavy menstrual bleeding associated with uterine fibroids ( LIBERTY 1 and 2), two in women with pain associated with endometriosis (SPIRIT 1 and 2), and one in men with advanced prostate cancer (HERO).", "score": 0.833615, "arguments": [{"text": "HERO", "location": [7120, 7124], "entities": [{"type": "Person", "text": "HERO"}]}, {"text": "prostate cancer", "location": [7103, 7118], "entities": [{"type": "HealthCondition", "text": "prostate cancer"}]}]}, {"type": "managerOf", "sentence": "Takeda Pharmaceuticals International AG granted Myovant an exclusive, worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries where Takeda retains exclusive rights) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide.", "score": 0.679646, "arguments": [{"text": "Takeda", "location": [7316, 7322], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "Pharmaceuticals International AG", "location": [7323, 7355], "entities": [{"type": "Organization", "text": "Pharmaceuticals International AG"}]}]}, {"type": "affectedBy", "sentence": "Takeda Pharmaceuticals International AG granted Myovant an exclusive, worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries where Takeda retains exclusive rights) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide.", "score": 0.469702, "arguments": [{"text": "Takeda", "location": [7316, 7322], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "granted", "location": [7356, 7363], "entities": [{"type": "EntertainmentAward", "text": "granted"}]}]}, {"type": "partOfMany", "sentence": "In addition, Myovant has appointed industry veterans Myrtle Potter , Mark Guinan , and Frank Torti , M.D., to Myovant's Board of Directors, and Ms. Potter has been appointed Chairman of the Board.", "score": 0.842806, "arguments": [{"text": "Myrtle Potter", "location": [677, 690], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, {"text": "veterans", "location": [668, 676], "entities": [{"type": "Person", "text": "veterans"}]}]}, {"type": "agentOf", "sentence": "Takeda Pharmaceuticals International AG granted Myovant an exclusive, worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries where Takeda retains exclusive rights) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide.", "score": 0.923796, "arguments": [{"text": "Pharmaceuticals International AG", "location": [7323, 7355], "entities": [{"type": "Organization", "text": "Pharmaceuticals International AG"}]}, {"text": "granted", "location": [7356, 7363], "entities": [{"type": "EntertainmentAward", "text": "granted"}]}]}, {"type": "agentOf", "sentence": "Takeda Pharmaceuticals International AG granted Myovant an exclusive, worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries where Takeda retains exclusive rights) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide.", "score": 0.499432, "arguments": [{"text": "Myovant", "location": [7364, 7371], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc. investors@myovant.com\nMedia Contact"}]}, {"text": "granted", "location": [7356, 7363], "entities": [{"type": "EntertainmentAward", "text": "granted"}]}]}, {"type": "locatedAt", "sentence": "Takeda Pharmaceuticals International AG granted Myovant an exclusive, worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries where Takeda retains exclusive rights) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide.", "score": 0.793107, "arguments": [{"text": "countries", "location": [7484, 7493], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Asian", "location": [7478, 7483], "entities": [{"type": "GeopoliticalEntity", "text": "Asian"}]}]}, {"type": "locatedAt", "sentence": "Takeda Pharmaceuticals International AG granted Myovant an exclusive, worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries where Takeda retains exclusive rights) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide.", "score": 0.252388, "arguments": [{"text": "countries", "location": [7484, 7493], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "where", "location": [7494, 7499], "entities": [{"type": "Facility", "text": "where"}]}]}, {"type": "locatedAt", "sentence": "Takeda Pharmaceuticals International AG granted Myovant an exclusive, worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries where Takeda retains exclusive rights) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide.", "score": 0.322552, "arguments": [{"text": "Takeda", "location": [7500, 7506], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "where", "location": [7494, 7499], "entities": [{"type": "Facility", "text": "where"}]}]}, {"type": "employedBy", "sentence": "Over time, Myovant intends to expand its development pipeline to include other potential treatments for women's health and endocrine diseases.", "score": 0.307066, "arguments": [{"text": "women", "location": [7727, 7732], "entities": [{"type": "Person", "text": "women"}]}, {"text": "its", "location": [7660, 7663], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc. investors@myovant.com\nMedia Contact"}]}]}, {"type": "hasAttribute", "sentence": "Over time, Myovant intends to expand its development pipeline to include other potential treatments for women's health and endocrine diseases.", "score": 0.66745, "arguments": [{"text": "women", "location": [7727, 7732], "entities": [{"type": "Person", "text": "women"}]}, {"text": "diseases", "location": [7756, 7764], "entities": [{"type": "HealthCondition", "text": "prostate cancer"}]}]}, {"type": "hasAttribute", "sentence": "For more information, please visit Myovant's website at www.myovant.com .", "score": 0.698574, "arguments": [{"text": "Myovant", "location": [7801, 7808], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc. investors@myovant.com\nMedia Contact"}]}, {"text": "www.myovant.com", "location": [7822, 7837], "entities": [{"type": "Web", "text": "www.myovant.com"}]}]}, {"type": "hasAttribute", "sentence": "Forward-Looking Statements This press release contains forward-looking statements, including without limitation: Myovant's focus on developing and commercializing innovative therapies for the treatment of women's health and endocrine diseases; and the statements and quote related to the timing of reporting clinical trial results.", "score": 0.748964, "arguments": [{"text": "women", "location": [8045, 8050], "entities": [{"type": "Person", "text": "women"}]}, {"text": "diseases", "location": [8074, 8082], "entities": [{"type": "HealthCondition", "text": "prostate cancer"}]}]}, {"type": "agentOf", "sentence": "Factors that could cause or contribute to such differences include, but are not limited to, those identified herein, and those discussed in the section titled \"Risk Factors\" set forth in Myovant's Quarterly Report on Form 10-Q which was filed with the Securities and Exchange Commission on August 7, 2018 , and other filings that Myovant makes with the SEC from time to time.", "score": 0.890088, "arguments": [{"text": "Myovant", "location": [9321, 9328], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc. investors@myovant.com\nMedia Contact"}]}, {"text": "Report", "location": [9341, 9347], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "partOfMany", "sentence": "In addition, Myovant has appointed industry veterans Myrtle Potter , Mark Guinan , and Frank Torti , M.D., to Myovant's Board of Directors, and Ms. Potter has been appointed Chairman of the Board.", "score": 0.977454, "arguments": [{"text": "Mark Guinan", "location": [693, 704], "entities": [{"type": "Person", "text": "Mark Guinan"}]}, {"text": "veterans", "location": [668, 676], "entities": [{"type": "Person", "text": "veterans"}]}]}, {"type": "agentOf", "sentence": "These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.", "score": 0.811261, "arguments": [{"text": "investors", "location": [9930, 9939], "entities": [{"type": "Person", "text": "investors"}]}, {"text": "cautioned", "location": [9944, 9953], "entities": [{"type": "EventCommunication", "text": "cautioned"}]}]}, {"type": "managerOf", "sentence": "Investor Contact : Frank Karbe Chief Financial Officer Myovant Sciences, Inc. investors@myovant.com Media Contact : Julie Normart W2O pure jnormart@w2ogroup.com 415.946.1087 SOURCE Myovant Sciences, Ltd. Related Links http://www.myovant.com", "score": 0.454384, "arguments": [{"text": "Chief Financial Officer", "location": [10198, 10221], "entities": [{"type": "Person", "text": "Frank Karbe"}]}, {"text": "Myovant Sciences, Inc. investors@myovant.com\nMedia Contact", "location": [10222, 10280], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc. investors@myovant.com\nMedia Contact"}]}]}, {"type": "hasAttribute", "sentence": "Investor Contact : Frank Karbe Chief Financial Officer Myovant Sciences, Inc. investors@myovant.com Media Contact : Julie Normart W2O pure jnormart@w2ogroup.com 415.946.1087 SOURCE Myovant Sciences, Ltd. Related Links http://www.myovant.com", "score": 0.660514, "arguments": [{"text": "Ltd.\nRelated Links", "location": [10366, 10384], "entities": [{"type": "Organization", "text": "Ltd.\nRelated Links"}]}, {"text": "http://www.myovant.com", "location": [10385, 10407], "entities": [{"type": "Web", "text": "http://www.myovant.com"}]}]}], "keywords": [{"text": "Vice President", "sentiment": {"score": -0.412232, "label": "negative"}, "relevance": 0.98178}, {"text": "forward-looking statements", "sentiment": {"score": -0.340174, "label": "negative"}, "relevance": 0.784809}, {"text": "Senior Vice President", "sentiment": {"score": -0.350266, "label": "negative"}, "relevance": 0.775072}, {"text": "Executive Vice President", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.612708}, {"text": "Myovant Sciences", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.61174}, {"text": "Chief Financial Officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.586401}, {"text": "endocrine diseases", "sentiment": {"score": -0.540317, "label": "negative"}, "relevance": 0.583097}, {"text": "Ms. Potter", "sentiment": {"score": 0.788622, "label": "positive"}, "relevance": 0.576836}, {"text": "Dr. Torti", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.569746}, {"text": "Primary Care Marketing", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.535586}, {"text": "clinical-stage biopharmaceutical company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.532868}, {"text": "Chief Executive Officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518279}, {"text": "Officer Myovant Sciences", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.491871}, {"text": "Roivant Sciences", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.486843}, {"text": "New Myovant Directors", "sentiment": {"score": 0.724216, "label": "positive"}, "relevance": 0.482059}, {"text": "clinical trials", "sentiment": {"score": -0.302514, "label": "negative"}, "relevance": 0.481466}, {"text": "innovative therapies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.474322}, {"text": "technical operations", "sentiment": {"score": 0.021767, "label": "positive"}, "relevance": 0.472636}, {"text": "Mr. Nornhold", "sentiment": {"score": -0.412232, "label": "negative"}, "relevance": 0.465163}, {"text": "Chief Commercial Officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.460215}, {"text": "Ms. Sablich", "sentiment": {"score": 0.355856, "label": "positive"}, "relevance": 0.453888}, {"text": "Impax Laboratories", "sentiment": {"score": -0.350266, "label": "negative"}, "relevance": 0.453445}, {"text": "U.S. Quality Operations", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.437269}, {"text": "Chief Operating Officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.434861}, {"text": "Urovant Sciences", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.433904}, {"text": "Axovant Sciences", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.433877}, {"text": "management team", "sentiment": {"score": 0.486571, "label": "positive"}, "relevance": 0.42777}, {"text": "United States", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.427748}, {"text": "Chief Procurement Officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.427737}, {"text": "actual results", "sentiment": {"score": -0.340174, "label": "negative"}, "relevance": 0.4276}, {"text": "Green State University", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.426594}, {"text": "Global Quality Affairs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.425602}, {"text": "veterans Myrtle Potter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.425326}, {"text": "Amneal Pharmaceuticals", "sentiment": {"score": -0.432699, "label": "negative"}, "relevance": 0.425262}, {"text": "risk factors", "sentiment": {"score": -0.468341, "label": "negative"}, "relevance": 0.424945}, {"text": "Lynn Seely", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.42216}, {"text": "Roivant Pharma", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.421859}, {"text": "Vaccines Commercial Strategies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.421348}, {"text": "vaccines business areas", "sentiment": {"score": -0.323443, "label": "negative"}, "relevance": 0.420795}, {"text": "Olin Business School", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.4206}, {"text": "Roivant family", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.420314}, {"text": "Medco Health Solutions", "sentiment": {"score": 0.480265, "label": "positive"}, "relevance": 0.419569}, {"text": "ongoing global Phase", "sentiment": {"score": -0.302514, "label": "negative"}, "relevance": 0.418289}, {"text": "clinical trial results", "sentiment": {"score": -0.252545, "label": "negative"}, "relevance": 0.416759}, {"text": "Duke University Center", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.416406}, {"text": "clinical trial research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.415902}, {"text": "multinational clinical trials", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.415171}, {"text": "Harvard Business School", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.414847}, {"text": "numerous healthcare companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.413942}, {"text": "Global Medicines Commercialization", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.412814}]}, "extracted_metadata": {"sha1": "95ab148f2999f036bfd86b0358c54c074da12d83", "filename": "1541609481514.zip-f9b1fc333ab2b463e344dfc0e835e6cf.xml", "file_type": "json"}, "external_links": ["http://studio-5.financialcontent.com/prnews?Page=Quote&Ticker=MYOV", "http://www.myovant.com/"], "title": "Myovant Strengthens Management Team and Adds New Directors to the Board", "forum_title": "PR Newswire:"}, {"id": "bHf5dsOjnpe4YeB5YWhxdzdlPrcpcvCTKlk4DmQHy1DyYT0F1IZYcI2wSxNQXS7c", "result_metadata": {"score": 33.975357}, "author": "Myovant Sciences, Ltd.", "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0.510542, "label": "positive"}}, "semantic_roles": [], "concepts": [{"text": "Corporate governance", "relevance": 0.84297, "dbpedia_resource": "http://dbpedia.org/resource/Corporate_governance"}, {"text": "Management", "relevance": 0.801, "dbpedia_resource": "http://dbpedia.org/resource/Management"}, {"text": "Board of directors", "relevance": 0.788543, "dbpedia_resource": "http://dbpedia.org/resource/Board_of_directors"}], "categories": [{"score": 0.577004, "label": "/art and entertainment/movies"}, {"score": 0.484518, "label": "/business and industrial/company"}, {"score": 0.438183, "label": "/finance/financial news"}], "relations": [], "keywords": [{"text": "Myovant Strengthens Management", "sentiment": {"score": 0.510542, "label": "positive"}, "relevance": 0.986289}, {"text": "New Directors", "sentiment": {"score": 0.510542, "label": "positive"}, "relevance": 0.463145}, {"text": "Team", "sentiment": {"score": 0.510542, "label": "positive"}, "relevance": 0.216376}, {"text": "Board", "sentiment": {"score": 0.510542, "label": "positive"}, "relevance": 0.215305}]}, "crawl_date": "2018-11-07T15:34:46Z", "url": "https://www.prnewswire.com/news-releases/myovant-strengthens-management-team-and-adds-new-directors-to-the-board-300745444.html", "host": "prnewswire.com", "text": "Myovant Sciences, Ltd.", "main_image_url": "https://mma.prnewswire.com/media/427661/Myovant_Sciences_Ltd___Logo.jpg?p=facebook", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-07T13:30:00-06:00", "enriched_text": {"entities": [{"count": 12, "sentiment": {"score": -0.540317, "label": "negative"}, "text": "Myovant", "relevance": 0.848549, "type": "Person"}, {"count": 4, "sentiment": {"score": -0.474197, "label": "negative"}, "text": "Vice President", "relevance": 0.689573, "type": "JobTitle"}, {"count": 5, "sentiment": {"score": -0.540317, "label": "negative"}, "text": "endocrine diseases", "relevance": 0.664533, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Endocrine disease", "dbpedia_resource": "http://dbpedia.org/resource/Endocrine_disease"}}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "Myovant Sciences", "relevance": 0.659781, "type": "Company"}, {"count": 2, "sentiment": {"score": -0.350266, "label": "negative"}, "text": "Senior Vice President of Technical Operations", "relevance": 0.651782, "type": "JobTitle"}, {"count": 8, "sentiment": {"score": 0.335111, "label": "positive"}, "text": "Myovant", "relevance": 0.624594, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 7, "sentiment": {"score": 0, "label": "neutral"}, "text": "Board", "relevance": 0.610612, "type": "Organization", "disambiguation": {"subtype": ["Industry"], "name": "Board game", "dbpedia_resource": "http://dbpedia.org/resource/Board_game"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Senior Vice President of Pharmaceutical Operations & Development", "relevance": 0.580983, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "President of Commercial Operations and Executive Vice President", "relevance": 0.559757, "type": "JobTitle"}, {"count": 6, "sentiment": {"score": 0.384414, "label": "positive"}, "text": "Frank Torti", "relevance": 0.543952, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Executive Vice President and Chief Financial Officer", "relevance": 0.541061, "type": "JobTitle"}, {"count": 6, "sentiment": {"score": 0.788622, "label": "positive"}, "text": "Myrtle Potter", "relevance": 0.536186, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Frank Karbe Chief Financial Officer Myovant Sciences", "relevance": 0.529434, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Vice President of Primary Care Marketing", "relevance": 0.520824, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Senior Vice President, Global Quality Affairs", "relevance": 0.510264, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Vice President, Global Medicines Commercialization", "relevance": 0.508508, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Vice President, U.S. Quality Operations", "relevance": 0.500743, "type": "JobTitle"}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "United States", "relevance": 0.49739, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "President and Chief Executive Officer of Myovant", "relevance": 0.492736, "type": "JobTitle"}, {"count": 4, "sentiment": {"score": 0.355856, "label": "positive"}, "text": "Kim Sablich", "relevance": 0.469281, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Myovant Sciences, Ltd.", "relevance": 0.461824, "type": "Company"}, {"count": 4, "sentiment": {"score": -0.412232, "label": "negative"}, "text": "Jeff Nornhold", "relevance": 0.458804, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "President", "relevance": 0.43662, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roivant Sciences", "relevance": 0.436385, "type": "Organization"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roivant", "relevance": 0.431564, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "President and CEO", "relevance": 0.416268, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": -0.350266, "label": "negative"}, "text": "Impax Laboratories", "relevance": 0.40861, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chief Commercial Officer", "relevance": 0.395128, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Urovant Sciences", "relevance": 0.394356, "type": "Company"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mark Guinan", "relevance": 0.37969, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Lynn Seely", "relevance": 0.367046, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chief Financial Officer", "relevance": 0.36641, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0.486571, "label": "positive"}, "text": "Management Team", "relevance": 0.365292, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chief Executive Officer", "relevance": 0.364407, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": -0.432699, "label": "negative"}, "text": "Amneal Pharmaceuticals, Inc.", "relevance": 0.359161, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BASEL", "relevance": 0.355065, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "City"], "name": "Basel", "dbpedia_resource": "http://dbpedia.org/resource/Basel"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roivant Pharma", "relevance": 0.346035, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Impax", "relevance": 0.343763, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Johnson & Johnson", "relevance": 0.34271, "type": "Company", "disambiguation": {"subtype": ["AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "NEA", "relevance": 0.34081, "type": "Organization", "disambiguation": {"subtype": ["Company"], "name": "New Enterprise Associates", "dbpedia_resource": "http://dbpedia.org/resource/New_Enterprise_Associates"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Switzerland", "relevance": 0.338728, "type": "Location", "disambiguation": {"subtype": ["Country"], "name": "Switzerland", "dbpedia_resource": "http://dbpedia.org/resource/Switzerland"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roivant Sciences", "relevance": 0.330914, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Impax", "relevance": 0.327795, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Denison University", "relevance": 0.326679, "type": "Organization", "disambiguation": {"subtype": ["Location", "CollegeUniversity", "University"], "name": "Denison University", "dbpedia_resource": "http://dbpedia.org/resource/Denison_University"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "University of Chicago", "relevance": 0.323923, "type": "Organization", "disambiguation": {"subtype": ["Location", "Company", "PeriodicalPublisher", "CollegeUniversity"], "name": "University of Chicago", "dbpedia_resource": "http://dbpedia.org/resource/University_of_Chicago"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chief Operating Officer of Genentech", "relevance": 0.319179, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "GSK", "relevance": 0.318334, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline", "relevance": 0.317021, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Genentech", "relevance": 0.316537, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Genentech", "dbpedia_resource": "http://dbpedia.org/resource/Genentech"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Impax", "relevance": 0.314486, "type": "Company"}], "sentiment": {"document": {"score": 0.128026, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "a clinical-stage biopharmaceutical company", "keywords": [{"text": "clinical-stage biopharmaceutical company"}], "entities": [{"type": "Company", "text": "Myovant Sciences"}]}, "sentence": " Myovant Sciences, Ltd. (NYSE: MYOV ), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, today announced that Kim Sablich , formerly Vice President of Primary Care Marketing in the United States for GlaxoSmithKline (GSK), will join Myovant Sciences as Chief Commercial Officer, and Jeff Nornhold , formerly Senior Vice President of Technical Operations for Impax Laboratories (now Amneal Pharmaceuticals, Inc.), has joined Myovant as Senior Vice President of Pharmaceutical Operations & Development.", "object": {"text": "innovative therapies", "keywords": [{"text": "innovative therapies"}]}, "action": {"verb": {"text": "develop", "tense": "future"}, "text": "developing", "normalized": "develop"}}, {"subject": {"text": "a clinical-stage biopharmaceutical company", "keywords": [{"text": "clinical-stage biopharmaceutical company"}], "entities": [{"type": "Company", "text": "Myovant Sciences"}]}, "sentence": " Myovant Sciences, Ltd. (NYSE: MYOV ), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, today announced that Kim Sablich , formerly Vice President of Primary Care Marketing in the United States for GlaxoSmithKline (GSK), will join Myovant Sciences as Chief Commercial Officer, and Jeff Nornhold , formerly Senior Vice President of Technical Operations for Impax Laboratories (now Amneal Pharmaceuticals, Inc.), has joined Myovant as Senior Vice President of Pharmaceutical Operations & Development.", "object": {"text": "innovative therapies", "keywords": [{"text": "innovative therapies"}]}, "action": {"verb": {"text": "commercialize", "tense": "present"}, "text": "commercializing", "normalized": "commercialize"}}, {"subject": {"text": "Myovant Sciences, Ltd. (NYSE: MYOV ), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases,", "keywords": [{"text": "clinical-stage biopharmaceutical company"}, {"text": "endocrine diseases"}, {"text": "innovative therapies"}, {"text": "Myovant Sciences"}], "entities": [{"type": "Company", "text": "Myovant Sciences, Ltd."}, {"type": "Company", "text": "NYSE"}, {"type": "Company", "text": "Myovant Sciences"}, {"type": "HealthCondition", "text": "endocrine diseases", "disambiguation": {"subtype": ["Disease"], "name": "Endocrine disease", "dbpedia_resource": "http://dbpedia.org/resource/Endocrine_disease"}}]}, "sentence": " Myovant Sciences, Ltd. (NYSE: MYOV ), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, today announced that Kim Sablich , formerly Vice President of Primary Care Marketing in the United States for GlaxoSmithKline (GSK), will join Myovant Sciences as Chief Commercial Officer, and Jeff Nornhold , formerly Senior Vice President of Technical Operations for Impax Laboratories (now Amneal Pharmaceuticals, Inc.), has joined Myovant as Senior Vice President of Pharmaceutical Operations & Development.", "object": {"text": "that Kim Sablich , formerly Vice President of Primary Care Marketing in the United States for GlaxoSmithKline (GSK), will join Myovant Sciences as Chief Commercial Officer, and Jeff Nornhold , formerly Senior Vice President of Technical Operations for Impax Laboratories (now Amneal Pharmaceuticals, Inc.), has joined Myovant as Senior Vice President of Pharmaceutical Operations & Development", "keywords": [{"text": "Senior Vice President"}, {"text": "Chief Commercial Officer"}, {"text": "Primary Care Marketing"}, {"text": "Impax Laboratories"}], "entities": [{"type": "Person", "text": "Kim Sablich"}, {"type": "JobTitle", "text": "Vice President of Primary Care Marketing"}, {"type": "Location", "text": "United States", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Company", "text": "GlaxoSmithKline", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"type": "Company", "text": "GSK"}, {"type": "Company", "text": "Myovant Sciences"}, {"type": "JobTitle", "text": "Chief Commercial Officer"}, {"type": "Person", "text": "Jeff Nornhold"}, {"type": "JobTitle", "text": "Senior Vice President of Technical Operations"}, {"type": "Company", "text": "Impax Laboratories"}, {"type": "Company", "text": "Amneal Pharmaceuticals, Inc."}, {"type": "Person", "text": "Myovant"}, {"type": "JobTitle", "text": "Senior Vice President of Pharmaceutical Operations & Development"}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "Myovant", "keywords": [{"text": "Myovant"}], "entities": [{"type": "Person", "text": "Myovant"}]}, "sentence": " In addition, Myovant has appointed industry veterans Myrtle Potter , Mark Guinan , and Frank Torti , M.D., to Myovant's Board of Directors, and Ms. Potter has been appointed Chairman of the Board.", "object": {"text": "appointed industry veterans Myrtle Potter , Mark Guinan , and Frank Torti , M.D.,", "keywords": [{"text": "veterans Myrtle Potter"}, {"text": "Mark Guinan"}, {"text": "Frank Torti"}, {"text": "M.D"}], "entities": [{"type": "Person", "text": "Myrtle Potter"}, {"type": "Person", "text": "Mark Guinan"}, {"type": "Person", "text": "Frank Torti"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Myovant", "keywords": [{"text": "Myovant"}], "entities": [{"type": "Person", "text": "Myovant"}]}, "sentence": " In addition, Myovant has appointed industry veterans Myrtle Potter , Mark Guinan , and Frank Torti , M.D., to Myovant's Board of Directors, and Ms. Potter has been appointed Chairman of the Board.", "object": {"text": "industry veterans Myrtle Potter , Mark Guinan , and Frank Torti , M.D.,", "keywords": [{"text": "veterans Myrtle Potter"}, {"text": "Mark Guinan"}, {"text": "Frank Torti"}, {"text": "M.D"}], "entities": [{"type": "Person", "text": "Myrtle Potter"}, {"type": "Person", "text": "Mark Guinan"}, {"type": "Person", "text": "Frank Torti"}]}, "action": {"verb": {"text": "appoint", "tense": "past"}, "text": "has appointed", "normalized": "have appoint"}}, {"subject": {"text": "Ms. Potter", "keywords": [{"text": "Ms. Potter"}], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, "sentence": " In addition, Myovant has appointed industry veterans Myrtle Potter , Mark Guinan , and Frank Torti , M.D., to Myovant's Board of Directors, and Ms. Potter has been appointed Chairman of the Board.", "object": {"text": "been appointed Chairman of the Board", "keywords": [{"text": "Chairman"}, {"text": "Board"}], "entities": [{"type": "JobTitle", "text": "Chairman"}, {"type": "Organization", "text": "Board", "disambiguation": {"subtype": ["Industry"], "name": "Board game", "dbpedia_resource": "http://dbpedia.org/resource/Board_game"}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Ms. Potter", "keywords": [{"text": "Ms. Potter"}], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, "sentence": " In addition, Myovant has appointed industry veterans Myrtle Potter , Mark Guinan , and Frank Torti , M.D., to Myovant's Board of Directors, and Ms. Potter has been appointed Chairman of the Board.", "object": {"text": "appointed Chairman of the Board", "keywords": [{"text": "Chairman"}, {"text": "Board"}], "entities": [{"type": "JobTitle", "text": "Chairman"}, {"type": "Organization", "text": "Board", "disambiguation": {"subtype": ["Industry"], "name": "Board game", "dbpedia_resource": "http://dbpedia.org/resource/Board_game"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "Ms. Potter", "keywords": [{"text": "Ms. Potter"}], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, "sentence": " In addition, Myovant has appointed industry veterans Myrtle Potter , Mark Guinan , and Frank Torti , M.D., to Myovant's Board of Directors, and Ms. Potter has been appointed Chairman of the Board.", "object": {"text": "Chairman of the Board", "keywords": [{"text": "Chairman"}, {"text": "Board"}], "entities": [{"type": "JobTitle", "text": "Chairman"}, {"type": "Organization", "text": "Board", "disambiguation": {"subtype": ["Industry"], "name": "Board game", "dbpedia_resource": "http://dbpedia.org/resource/Board_game"}}]}, "action": {"verb": {"text": "appoint", "tense": "past"}, "text": "has been appointed", "normalized": "have be appoint"}}, {"subject": {"text": "we"}, "sentence": " \"With top-line data from each of our five ongoing global Phase 3 clinical trials expected in 2019, we are pleased to announce the strengthening of our management team and Board as we look forward to the next stage of Myovant's growth,\" said Lynn Seely , M.D., President and CEO of Myovant.", "action": {"verb": {"text": "be", "tense": "present"}, "text": "are pleased to announce", "normalized": "be please to announce"}}, {"subject": {"text": "we"}, "sentence": " \"With top-line data from each of our five ongoing global Phase 3 clinical trials expected in 2019, we are pleased to announce the strengthening of our management team and Board as we look forward to the next stage of Myovant's growth,\" said Lynn Seely , M.D., President and CEO of Myovant.", "object": {"text": "to announce the strengthening of our management team and Board", "keywords": [{"text": "strengthening"}, {"text": "management team"}, {"text": "Board"}], "entities": [{"type": "JobTitle", "text": "Management Team"}]}, "action": {"verb": {"text": "please", "tense": "past"}, "text": "pleased", "normalized": "please"}}, {"subject": {"text": "we"}, "sentence": " \"With top-line data from each of our five ongoing global Phase 3 clinical trials expected in 2019, we are pleased to announce the strengthening of our management team and Board as we look forward to the next stage of Myovant's growth,\" said Lynn Seely , M.D., President and CEO of Myovant.", "object": {"text": "the strengthening of our management team and Board", "keywords": [{"text": "strengthening"}, {"text": "management team"}, {"text": "Board"}], "entities": [{"type": "JobTitle", "text": "Management Team"}]}, "action": {"verb": {"text": "announce", "tense": "future"}, "text": "are pleased to announce", "normalized": "be please to announce"}}, {"subject": {"text": "Lynn Seely , M.D., President and CEO of Myovant", "keywords": [{"text": "Lynn Seely"}, {"text": "CEO"}, {"text": "President"}, {"text": "M.D."}], "entities": [{"type": "Person", "text": "Lynn Seely"}, {"type": "JobTitle", "text": "President and CEO"}, {"type": "Company", "text": "Myovant"}]}, "sentence": " \"With top-line data from each of our five ongoing global Phase 3 clinical trials expected in 2019, we are pleased to announce the strengthening of our management team and Board as we look forward to the next stage of Myovant's growth,\" said Lynn Seely , M.D., President and CEO of Myovant.", "object": {"text": "With top-line data from each of our five ongoing global Phase 3 clinical trials expected in 2019, we are pleased to announce the strengthening of our management team and Board as we look forward to the next stage of Myovant's growth", "keywords": [{"text": "ongoing global Phase"}, {"text": "top-line data"}, {"text": "clinical trials"}, {"text": "management team"}], "entities": [{"type": "JobTitle", "text": "Management Team"}, {"type": "Location", "text": "Myovant", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "Ms. Potter's decades of commercial experience", "keywords": [{"text": "Ms. Potter"}, {"text": "decades"}, {"text": "commercial experience"}], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, "sentence": " \"Ms. Potter's decades of commercial experience perfectly position her to chair Myovant's Board of diverse industry and healthcare leaders.", "object": {"text": "her", "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, "action": {"verb": {"text": "position", "tense": "present"}, "text": "position", "normalized": "position"}}, {"subject": {"text": "Ms. Potter", "keywords": [{"text": "Ms. Potter"}], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, "sentence": " \"Ms. Potter's decades of commercial experience perfectly position her to chair Myovant's Board of diverse industry and healthcare leaders.", "object": {"text": "Myovant's Board of diverse industry and healthcare leaders", "keywords": [{"text": "diverse industry"}, {"text": "healthcare leaders"}, {"text": "Myovant"}], "entities": [{"type": "Person", "text": "Myovant"}]}, "action": {"verb": {"text": "chair", "tense": "future"}, "text": "to chair", "normalized": "to chair"}}, {"subject": {"text": "we"}, "sentence": " Together, we are committed to achieving our mission of becoming the leading company in women's health and endocrine diseases.\"", "object": {"text": "committed to achieving our mission of becoming the leading company in women's health and endocrine diseases", "keywords": [{"text": "endocrine diseases"}, {"text": "mission"}, {"text": "company"}, {"text": "women"}], "entities": [{"type": "HealthCondition", "text": "endocrine diseases", "disambiguation": {"subtype": ["Disease"], "name": "Endocrine disease", "dbpedia_resource": "http://dbpedia.org/resource/Endocrine_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "we"}, "sentence": " Together, we are committed to achieving our mission of becoming the leading company in women's health and endocrine diseases.\"", "object": {"text": "to achieving our mission of becoming the leading company in women's health and endocrine diseases", "keywords": [{"text": "endocrine diseases"}, {"text": "mission"}, {"text": "company"}, {"text": "women"}], "entities": [{"type": "HealthCondition", "text": "endocrine diseases", "disambiguation": {"subtype": ["Disease"], "name": "Endocrine disease", "dbpedia_resource": "http://dbpedia.org/resource/Endocrine_disease"}}]}, "action": {"verb": {"text": "commit", "tense": "past"}, "text": "are committed", "normalized": "be commit"}}, {"subject": {"text": "we"}, "sentence": " Together, we are committed to achieving our mission of becoming the leading company in women's health and endocrine diseases.\"", "object": {"text": "our mission of becoming the leading company in women's health and endocrine diseases", "keywords": [{"text": "endocrine diseases"}, {"text": "mission"}, {"text": "company"}, {"text": "women"}], "entities": [{"type": "HealthCondition", "text": "endocrine diseases", "disambiguation": {"subtype": ["Disease"], "name": "Endocrine disease", "dbpedia_resource": "http://dbpedia.org/resource/Endocrine_disease"}}]}, "action": {"verb": {"text": "achieve", "tense": "future"}, "text": "achieving", "normalized": "achieve"}}, {"subject": {"text": "Ms. Sablich", "keywords": [{"text": "Ms. Sablich"}], "entities": [{"type": "Person", "text": "Kim Sablich"}]}, "sentence": " Ms. Sablich previously served as Vice President, Primary Care Marketing in the United States for GSK, where she was responsible for revenue forecasts, product strategies and execution plans for a broad portfolio of products including Advair\u00ae, Breo, Anoro\u00ae, Incruse\u00ae, Tanzeum\u2122, Levitra\u00ae, and Trelegy.", "object": {"text": "as Vice President, Primary Care Marketing in the United States for GSK, where she was responsible for revenue forecasts, product strategies and execution plans for a broad portfolio of products including Advair\u00ae, Breo, Anoro\u00ae, Incruse\u00ae, Tanzeum\u2122, Levitra\u00ae, and Trelegy", "keywords": [{"text": "Primary Care Marketing"}, {"text": "Vice President"}, {"text": "revenue forecasts"}, {"text": "execution plans"}], "entities": [{"type": "JobTitle", "text": "Vice President"}, {"type": "JobTitle", "text": "Primary Care Marketing"}, {"type": "Location", "text": "United States", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Organization", "text": "GSK"}, {"type": "Person", "text": "Kim Sablich"}, {"type": "Location", "text": "Trelegy", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "Advair\u00ae, Breo, Anoro\u00ae, Incruse\u00ae, Tanzeum\u2122, Levitra\u00ae, and Trelegy", "keywords": [{"text": "Advair\u00ae"}, {"text": "Breo"}, {"text": "Anoro\u00ae"}, {"text": "Incruse\u00ae"}], "entities": [{"type": "Location", "text": "Trelegy", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " Ms. Sablich previously served as Vice President, Primary Care Marketing in the United States for GSK, where she was responsible for revenue forecasts, product strategies and execution plans for a broad portfolio of products including Advair\u00ae, Breo, Anoro\u00ae, Incruse\u00ae, Tanzeum\u2122, Levitra\u00ae, and Trelegy.", "object": {"text": "products", "keywords": [{"text": "products"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "she"}, "sentence": " Prior to that, she was Vice President, Global Medicines Commercialization in the United Kingdom , and before that, Vice President, Vaccines Commercial Strategies.", "object": {"text": "Vice President, Global Medicines Commercialization in the United Kingdom , and before that, Vice President, Vaccines Commercial Strategies", "keywords": [{"text": "Vice President"}, {"text": "Global Medicines Commercialization"}, {"text": "Vaccines Commercial Strategies"}, {"text": "United Kingdom"}], "entities": [{"type": "JobTitle", "text": "Vice President, Global Medicines Commercialization"}, {"type": "Location", "text": "United Kingdom", "disambiguation": {"subtype": ["AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"type": "JobTitle", "text": "Vice President"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "Ms. Sablich", "keywords": [{"text": "Ms. Sablich"}], "entities": [{"type": "Person", "text": "Kim Sablich"}]}, "sentence": " Before joining GSK, Ms. Sablich spent 15 years at Merck, where she held positions of increasing responsibility in the commercial organization across sales, product management, pricing/access, and customer insights, with a focus on the cardiovascular, respiratory and vaccines business areas.", "object": {"text": "GSK", "keywords": [{"text": "GSK"}], "entities": [{"type": "Organization", "text": "GSK"}]}, "action": {"verb": {"text": "join", "tense": "present"}, "text": "joining", "normalized": "join"}}, {"subject": {"text": "Ms. Sablich", "keywords": [{"text": "Ms. Sablich"}], "entities": [{"type": "Person", "text": "Kim Sablich"}]}, "sentence": " Before joining GSK, Ms. Sablich spent 15 years at Merck, where she held positions of increasing responsibility in the commercial organization across sales, product management, pricing/access, and customer insights, with a focus on the cardiovascular, respiratory and vaccines business areas.", "object": {"text": "15 years", "entities": [{"type": "Quantity", "text": "15 years"}]}, "action": {"verb": {"text": "spend", "tense": "past"}, "text": "spent", "normalized": "spend"}}, {"subject": {"text": "she", "entities": [{"type": "Person", "text": "Kim Sablich"}]}, "sentence": " Before joining GSK, Ms. Sablich spent 15 years at Merck, where she held positions of increasing responsibility in the commercial organization across sales, product management, pricing/access, and customer insights, with a focus on the cardiovascular, respiratory and vaccines business areas.", "object": {"text": "positions of increasing responsibility in the commercial organization across sales, product management, pricing/access, and customer insights, with a focus on the cardiovascular, respiratory and vaccines business areas", "keywords": [{"text": "vaccines business areas"}, {"text": "customer insights"}, {"text": "commercial organization"}, {"text": "product management"}]}, "action": {"verb": {"text": "hold", "tense": "past"}, "text": "held", "normalized": "hold"}}, {"subject": {"text": "she", "entities": [{"type": "Person", "text": "Kim Sablich"}]}, "sentence": " Before joining GSK, Ms. Sablich spent 15 years at Merck, where she held positions of increasing responsibility in the commercial organization across sales, product management, pricing/access, and customer insights, with a focus on the cardiovascular, respiratory and vaccines business areas.", "object": {"text": "responsibility", "keywords": [{"text": "responsibility"}]}, "action": {"verb": {"text": "increase", "tense": "future"}, "text": "increasing", "normalized": "increase"}}, {"subject": {"text": "Ms. Sablich", "keywords": [{"text": "Ms. Sablich"}], "entities": [{"type": "Person", "text": "Kim Sablich"}]}, "sentence": " Ms. Sablich has extensive experience in direct-to-consumer marketing, having led the development of consumer strategies and national multi-channel campaigns for multiple products.", "object": {"text": "extensive experience in direct-to-consumer marketing, having led the development of consumer strategies and national multi-channel campaigns for multiple products", "keywords": [{"text": "national multi-channel campaigns"}, {"text": "direct-to-consumer marketing"}, {"text": "extensive experience"}, {"text": "consumer strategies"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Ms. Sablich", "keywords": [{"text": "Ms. Sablich"}], "entities": [{"type": "Person", "text": "Kim Sablich"}]}, "sentence": " Ms. Sablich has extensive experience in direct-to-consumer marketing, having led the development of consumer strategies and national multi-channel campaigns for multiple products.", "object": {"text": "led the development of consumer strategies and national multi-channel campaigns for multiple products", "keywords": [{"text": "national multi-channel campaigns"}, {"text": "consumer strategies"}, {"text": "multiple products"}, {"text": "development"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "having", "normalized": "have"}}, {"subject": {"text": "Ms. Sablich", "keywords": [{"text": "Ms. Sablich"}], "entities": [{"type": "Person", "text": "Kim Sablich"}]}, "sentence": " Ms. Sablich has extensive experience in direct-to-consumer marketing, having led the development of consumer strategies and national multi-channel campaigns for multiple products.", "object": {"text": "the development of consumer strategies and national multi-channel campaigns", "keywords": [{"text": "national multi-channel campaigns"}, {"text": "consumer strategies"}, {"text": "development"}]}, "action": {"verb": {"text": "lead", "tense": "past"}, "text": "having led", "normalized": "have lead"}}, {"subject": {"text": "She", "entities": [{"type": "Person", "text": "Kim Sablich"}]}, "sentence": " She is currently a member of the Board of Directors of AllerGenis LLC.", "object": {"text": "a member of the Board of Directors of AllerGenis LLC", "keywords": [{"text": "AllerGenis LLC"}, {"text": "member"}, {"text": "Board"}, {"text": "Directors"}], "entities": [{"type": "Person", "text": "Kim Sablich"}, {"type": "Organization", "text": "Board", "disambiguation": {"subtype": ["Industry"], "name": "Board game", "dbpedia_resource": "http://dbpedia.org/resource/Board_game"}}, {"type": "Company", "text": "AllerGenis LLC"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "She", "entities": [{"type": "Person", "text": "Kim Sablich"}]}, "sentence": " She earned a B.A. from Denison University and an M.B.A. from The Wharton School of the University of Pennsylvania .", "object": {"text": "a B.A.", "keywords": [{"text": "B.A"}]}, "action": {"verb": {"text": "earn", "tense": "past"}, "text": "earned", "normalized": "earn"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Jeff Nornhold"}]}, "sentence": " Mr. Nornhold previously served as Senior Vice President of Technical Operations for Impax Laboratories (now Amneal Pharmaceuticals, Inc.), where he was responsible for Impax's manufacturing, supply chain, quality and technical operations.", "object": {"text": "responsible for Impax's manufacturing, supply chain, quality and technical operations", "keywords": [{"text": "Impax"}, {"text": "supply chain"}, {"text": "technical operations"}, {"text": "manufacturing"}], "entities": [{"type": "Company", "text": "Impax"}, {"type": "Person", "text": "Jeff Nornhold"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Jeff Nornhold"}]}, "sentence": " Prior to that, he served as Impax's Senior Vice President, Global Quality Affairs, and was responsible for establishing a sustainable quality and compliance program.", "object": {"text": "as Impax's Senior Vice President", "keywords": [{"text": "Senior Vice President"}, {"text": "Impax"}], "entities": [{"type": "Person", "text": "Impax"}, {"type": "JobTitle", "text": "Senior Vice President, Global Quality Affairs"}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Jeff Nornhold"}]}, "sentence": " Prior to that, he served as Impax's Senior Vice President, Global Quality Affairs, and was responsible for establishing a sustainable quality and compliance program.", "object": {"text": "a sustainable quality and compliance program", "keywords": [{"text": "sustainable quality"}, {"text": "compliance program"}]}, "action": {"verb": {"text": "establish", "tense": "past"}, "text": "establishing", "normalized": "establish"}}, {"subject": {"text": "Mr. Nornhold", "keywords": [{"text": "Mr. Nornhold"}], "entities": [{"type": "Person", "text": "Jeff Nornhold"}]}, "sentence": " Prior to Impax, Mr. Nornhold served as Vice President, Quality Operations \u2013 International for Watson Pharmaceuticals, Inc. (now Allergan PLC), and was responsible for ex-U.S. manufacturing sites for both dosage and active pharmaceutical ingredients.", "object": {"text": "as Vice President, Quality Operations \u2013 International for Watson Pharmaceuticals, Inc. (now Allergan PLC), and was responsible for ex-U.S. manufacturing sites for both dosage and active pharmaceutical ingredients", "keywords": [{"text": "active pharmaceutical ingredients"}, {"text": "Allergan PLC"}, {"text": "ex-U.S. manufacturing sites"}, {"text": "Watson Pharmaceuticals"}], "entities": [{"type": "JobTitle", "text": "Vice President"}, {"type": "Company", "text": "Watson Pharmaceuticals, Inc."}, {"type": "Company", "text": "Allergan PLC"}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Watson"}]}, "sentence": " While at Watson , he also served as Vice President, U.S. Quality Operations, where he led the development and execution of quality initiatives for all U.S. sites.", "object": {"text": "as Vice President, U.S. Quality Operations, where he led the development and execution of quality initiatives for all U.S. sites", "keywords": [{"text": "Vice President"}, {"text": "U.S. Quality Operations"}, {"text": "quality initiatives"}, {"text": "U.S. sites"}], "entities": [{"type": "JobTitle", "text": "Vice President, U.S. Quality Operations"}, {"type": "Person", "text": "Watson"}, {"type": "Location", "text": "United States", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Watson"}]}, "sentence": " Earlier in his career, he held numerous leadership positions in the pharmaceutical industry.", "object": {"text": "numerous leadership positions", "keywords": [{"text": "numerous leadership positions"}]}, "action": {"verb": {"text": "hold", "tense": "past"}, "text": "held", "normalized": "hold"}}, {"subject": {"text": "Mr. Nornhold", "keywords": [{"text": "Mr. Nornhold"}], "entities": [{"type": "Person", "text": "Jeff Nornhold"}]}, "sentence": " Mr. Nornhold earned a B.S. in chemistry from Bowling Green State University and an M.B.A. from the University of Southern California Marshall School of Business.", "object": {"text": "a B.S. in chemistry", "keywords": [{"text": "B.S."}, {"text": "chemistry"}]}, "action": {"verb": {"text": "earn", "tense": "past"}, "text": "earned", "normalized": "earn"}}, {"subject": {"text": "Ms. Potter", "keywords": [{"text": "Ms. Potter"}], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, "sentence": " Ms. Potter currently serves as Vant Operating Chair for Roivant Pharma, a division of Roivant Sciences.", "object": {"text": "for Roivant Pharma, a division of Roivant Sciences", "keywords": [{"text": "Roivant Pharma"}, {"text": "Roivant Sciences"}, {"text": "division"}], "entities": [{"type": "Company", "text": "Roivant Pharma"}, {"type": "Organization", "text": "Roivant Sciences"}]}, "action": {"verb": {"text": "serve", "tense": "present"}, "text": "serves", "normalized": "serve"}}, {"subject": {"text": "She"}, "sentence": " She previously served as Chief Executive Officer of Myrtle Potter & Company, LLC, and President of Commercial Operations and Executive Vice President, and Chief Operating Officer of Genentech.", "object": {"text": "of Myrtle Potter & Company, LLC, and President of Commercial Operations and Executive Vice President, and Chief Operating Officer of Genentech", "keywords": [{"text": "Executive Vice President"}, {"text": "Chief Operating Officer"}, {"text": "Myrtle Potter"}, {"text": "Commercial Operations"}], "entities": [{"type": "Company", "text": "Myrtle Potter & Company"}, {"type": "Company", "text": "AllerGenis LLC"}, {"type": "JobTitle", "text": "President of Commercial Operations and Executive Vice President"}, {"type": "JobTitle", "text": "Chief Operating Officer of Genentech"}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "she"}, "sentence": " Prior to Genentech, she held various positions, including President of Cardiovascular/Metabolics at Bristol- Myers Squibb .", "object": {"text": "various positions, including President of Cardiovascular/Metabolics at Bristol- Myers Squibb", "keywords": [{"text": "Bristol- Myers Squibb"}, {"text": "various positions"}, {"text": "President"}, {"text": "Cardiovascular/Metabolics"}], "entities": [{"type": "JobTitle", "text": "Vice President"}, {"type": "Company", "text": "Bristol- Myers Squibb"}]}, "action": {"verb": {"text": "hold", "tense": "past"}, "text": "held", "normalized": "hold"}}, {"subject": {"text": "President of Cardiovascular/Metabolics at Bristol- Myers Squibb", "keywords": [{"text": "Bristol- Myers Squibb"}, {"text": "President"}, {"text": "Cardiovascular/Metabolics"}], "entities": [{"type": "JobTitle", "text": "Vice President"}, {"type": "Company", "text": "Bristol- Myers Squibb"}]}, "sentence": " Prior to Genentech, she held various positions, including President of Cardiovascular/Metabolics at Bristol- Myers Squibb .", "object": {"text": "Genentech, she held various positions", "keywords": [{"text": "various positions"}, {"text": "Genentech"}], "entities": [{"type": "Company", "text": "Genentech", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Genentech", "dbpedia_resource": "http://dbpedia.org/resource/Genentech"}}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "She"}, "sentence": " She is a graduate of the University of Chicago .", "object": {"text": "a graduate of the University of Chicago", "keywords": [{"text": "graduate"}, {"text": "University"}, {"text": "Chicago"}], "entities": [{"type": "Organization", "text": "University of Chicago", "disambiguation": {"subtype": ["Location", "Company", "PeriodicalPublisher", "CollegeUniversity"], "name": "University of Chicago", "dbpedia_resource": "http://dbpedia.org/resource/University_of_Chicago"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Ms. Potter", "keywords": [{"text": "Ms. Potter"}], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, "sentence": " In addition to serving on our Board, Ms. Potter also serves on the boards of other companies in the Roivant family of companies, including Urovant Sciences, Axovant Sciences and Arbutus Biopharma.", "object": {"text": "on the boards of other companies in the Roivant family of companies, including Urovant Sciences, Axovant Sciences and Arbutus Biopharma", "keywords": [{"text": "Arbutus Biopharma"}, {"text": "Roivant family"}, {"text": "Urovant Sciences"}, {"text": "Axovant Sciences"}], "entities": [{"type": "Organization", "text": "Board", "disambiguation": {"subtype": ["Industry"], "name": "Board game", "dbpedia_resource": "http://dbpedia.org/resource/Board_game"}}, {"type": "Location", "text": "Roivant", "disambiguation": {"subtype": ["City"]}}, {"type": "Company", "text": "Urovant Sciences"}, {"type": "Company", "text": "Axovant Sciences"}, {"type": "Company", "text": "Arbutus Biopharma"}]}, "action": {"verb": {"text": "serve", "tense": "present"}, "text": "serves", "normalized": "serve"}}, {"subject": {"text": "Urovant Sciences, Axovant Sciences and Arbutus Biopharma", "keywords": [{"text": "Arbutus Biopharma"}, {"text": "Urovant Sciences"}, {"text": "Axovant Sciences"}], "entities": [{"type": "Company", "text": "Urovant Sciences"}, {"type": "Company", "text": "Axovant Sciences"}, {"type": "Company", "text": "Arbutus Biopharma"}]}, "sentence": " In addition to serving on our Board, Ms. Potter also serves on the boards of other companies in the Roivant family of companies, including Urovant Sciences, Axovant Sciences and Arbutus Biopharma.", "object": {"text": "companies", "keywords": [{"text": "companies"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Ms. Potter", "keywords": [{"text": "Ms. Potter"}], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, "sentence": " Ms. Potter has previously served on the boards of Amazon, Express Scripts Holding Co., and Medco Health Solutions Inc.", "object": {"text": "previously served on the boards of Amazon, Express Scripts Holding Co., and Medco Health Solutions Inc", "keywords": [{"text": "Medco Health Solutions"}, {"text": "Express Scripts Holding"}, {"text": "Amazon"}, {"text": "boards"}], "entities": [{"type": "Organization", "text": "Board", "disambiguation": {"subtype": ["Industry"], "name": "Board game", "dbpedia_resource": "http://dbpedia.org/resource/Board_game"}}, {"type": "Company", "text": "Amazon", "disambiguation": {"subtype": [], "name": "Amazon.com", "dbpedia_resource": "http://dbpedia.org/resource/Amazon.com"}}, {"type": "Company", "text": "Express Scripts Holding Co."}, {"type": "Company", "text": "Medco Health Solutions Inc"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Ms. Potter", "keywords": [{"text": "Ms. Potter"}], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, "sentence": " Ms. Potter has previously served on the boards of Amazon, Express Scripts Holding Co., and Medco Health Solutions Inc.", "object": {"text": "Medco Health Solutions Inc", "keywords": [{"text": "Medco Health Solutions"}], "entities": [{"type": "Company", "text": "Medco Health Solutions Inc"}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "Mr. Guinan", "keywords": [{"text": "Mr. Guinan"}], "entities": [{"type": "Person", "text": "Mark Guinan"}]}, "sentence": " Mr. Guinan serves as the Executive Vice President and Chief Financial Officer for Quest Diagnostics Inc.", "object": {"text": "for Quest Diagnostics Inc", "keywords": [{"text": "Quest Diagnostics"}], "entities": [{"type": "Company", "text": "Quest Diagnostics Inc"}]}, "action": {"verb": {"text": "serve", "tense": "present"}, "text": "serves", "normalized": "serve"}}, {"subject": {"text": "He", "entities": [{"type": "Person", "text": "Mark Guinan"}]}, "sentence": " He previously served as Chief Financial Officer for Hill-Rom Holdings Inc., a manufacturer and provider of medical technologies and related services for the healthcare industry.", "object": {"text": "for Hill-Rom Holdings Inc., a manufacturer and provider of medical technologies and related services for the healthcare industry", "keywords": [{"text": "Hill-Rom Holdings Inc."}, {"text": "medical technologies"}, {"text": "related services"}, {"text": "healthcare industry"}], "entities": [{"type": "Company", "text": "Hill-Rom Holdings Inc.", "disambiguation": {"subtype": ["Company"], "name": "Hill-Rom Holdings", "dbpedia_resource": "http://dbpedia.org/resource/Hill-Rom_Holdings"}}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Mark Guinan"}]}, "sentence": " Prior to that, he served in a number of finance and operations roles in a long career at Johnson & Johnson, including as Vice President, Chief Procurement Officer, and as CFO of the pharmaceutical business.", "object": {"text": "in a number of finance and operations roles in a long career at Johnson & Johnson, including as Vice President, Chief Procurement Officer, and as CFO of the pharmaceutical business", "keywords": [{"text": "Chief Procurement Officer"}, {"text": "Vice President"}, {"text": "operations roles"}, {"text": "long career"}], "entities": [{"type": "Company", "text": "Johnson & Johnson", "disambiguation": {"subtype": ["Organization", "AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"type": "JobTitle", "text": "Vice President"}, {"type": "JobTitle", "text": "Chief Procurement Officer"}, {"type": "JobTitle", "text": "Chief Financial Officer"}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "as Vice President, Chief Procurement Officer, and as CFO of the pharmaceutical business", "keywords": [{"text": "Chief Procurement Officer"}, {"text": "Vice President"}, {"text": "CFO"}, {"text": "pharmaceutical business"}], "entities": [{"type": "JobTitle", "text": "Vice President"}, {"type": "JobTitle", "text": "Chief Procurement Officer"}, {"type": "JobTitle", "text": "Chief Financial Officer"}]}, "sentence": " Prior to that, he served in a number of finance and operations roles in a long career at Johnson & Johnson, including as Vice President, Chief Procurement Officer, and as CFO of the pharmaceutical business.", "object": {"text": "Johnson & Johnson", "keywords": [{"text": "Johnson"}], "entities": [{"type": "Company", "text": "Johnson & Johnson", "disambiguation": {"subtype": ["Organization", "AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Mr. Guinan", "keywords": [{"text": "Mr. Guinan"}], "entities": [{"type": "Person", "text": "Mark Guinan"}]}, "sentence": " Before joining Johnson & Johnson, Mr. Guinan held a number of financial roles at Procter & Gamble.", "object": {"text": "Johnson & Johnson", "keywords": [{"text": "Johnson"}], "entities": [{"type": "Company", "text": "Johnson & Johnson", "disambiguation": {"subtype": ["Organization", "AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}]}, "action": {"verb": {"text": "join", "tense": "present"}, "text": "joining", "normalized": "join"}}], "concepts": [{"text": "Management occupations", "relevance": 0.963405, "dbpedia_resource": "http://dbpedia.org/resource/Management_occupations"}, {"text": "Vice president", "relevance": 0.6832, "dbpedia_resource": "http://dbpedia.org/resource/Vice_president"}, {"text": "Corporate governance", "relevance": 0.659944, "dbpedia_resource": "http://dbpedia.org/resource/Corporate_governance"}, {"text": "Vice President of the United States", "relevance": 0.641902, "dbpedia_resource": "http://dbpedia.org/resource/Vice_President_of_the_United_States"}, {"text": "Chief executive officer", "relevance": 0.605433, "dbpedia_resource": "http://dbpedia.org/resource/Chief_executive_officer"}, {"text": "Clinical trial", "relevance": 0.603039, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"}, {"text": "George W. Bush", "relevance": 0.507718, "dbpedia_resource": "http://dbpedia.org/resource/George_W._Bush"}, {"text": "Vice presidents", "relevance": 0.486808, "dbpedia_resource": "http://dbpedia.org/resource/Vice_presidents"}, {"text": "Chief executives", "relevance": 0.483825, "dbpedia_resource": "http://dbpedia.org/resource/Chief_executives"}, {"text": "Richard Nixon", "relevance": 0.480367, "dbpedia_resource": "http://dbpedia.org/resource/Richard_Nixon"}, {"text": "Executive officer", "relevance": 0.4801, "dbpedia_resource": "http://dbpedia.org/resource/Executive_officer"}, {"text": "Gerald Ford", "relevance": 0.478246, "dbpedia_resource": "http://dbpedia.org/resource/Gerald_Ford"}, {"text": "De facto", "relevance": 0.469373, "dbpedia_resource": "http://dbpedia.org/resource/De_facto"}, {"text": "Pharmacology", "relevance": 0.457303, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "President of the United States", "relevance": 0.454392, "dbpedia_resource": "http://dbpedia.org/resource/President_of_the_United_States"}, {"text": "President pro tempore of the United States Senate", "relevance": 0.453762, "dbpedia_resource": "http://dbpedia.org/resource/President_pro_tempore_of_the_United_States_Senate"}, {"text": "Electoral College", "relevance": 0.452798, "dbpedia_resource": "http://dbpedia.org/resource/Electoral_College_(United_States)"}], "categories": [{"score": 0.599624, "label": "/health and fitness"}, {"score": 0.473508, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.426088, "label": "/finance/financial news"}], "relations": [{"type": "locatedAt", "sentence": "BASEL, Switzerland , Nov. Myovant Sciences, Ltd. (NYSE: MYOV ), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, today announced that Kim Sablich , formerly Vice President of Primary Care Marketing in the United States for GlaxoSmithKline (GSK), will join Myovant Sciences as Chief Commercial Officer, and Jeff Nornhold , formerly Senior Vice President of Technical Operations for Impax Laboratories (now Amneal Pharmaceuticals, Inc.), has joined Myovant as Senior Vice President of Pharmaceutical Operations & Development.", "score": 0.956957, "arguments": [{"text": "BASEL", "location": [0, 5], "entities": [{"type": "GeopoliticalEntity", "text": "BASEL"}]}, {"text": "Switzerland", "location": [7, 18], "entities": [{"type": "GeopoliticalEntity", "text": "Switzerland", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOfMany", "sentence": "In addition, Myovant has appointed industry veterans Myrtle Potter , Mark Guinan , and Frank Torti , M.D., to Myovant's Board of Directors, and Ms. Potter has been appointed Chairman of the Board.", "score": 0.658574, "arguments": [{"text": "Frank Torti", "location": [711, 722], "entities": [{"type": "Person", "text": "Frank Torti"}]}, {"text": "veterans", "location": [668, 676], "entities": [{"type": "Person", "text": "veterans"}]}]}, {"type": "partOfMany", "sentence": "In addition, Myovant has appointed industry veterans Myrtle Potter , Mark Guinan , and Frank Torti , M.D., to Myovant's Board of Directors, and Ms. Potter has been appointed Chairman of the Board.", "score": 0.605923, "arguments": [{"text": "M.D.,", "location": [725, 730], "entities": [{"type": "Person", "text": "M.D.,"}]}, {"text": "veterans", "location": [668, 676], "entities": [{"type": "Person", "text": "veterans"}]}]}, {"type": "partOf", "sentence": "In addition, Myovant has appointed industry veterans Myrtle Potter , Mark Guinan , and Frank Torti , M.D., to Myovant's Board of Directors, and Ms. Potter has been appointed Chairman of the Board.", "score": 0.919569, "arguments": [{"text": "Board of Directors", "location": [744, 762], "entities": [{"type": "Organization", "text": "Board of Directors of AllerGenis LLC"}]}, {"text": "Myovant", "location": [734, 741], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc. investors@myovant.com\nMedia Contact"}]}]}, {"type": "partOf", "sentence": "\"Ms. Potter's decades of commercial experience perfectly position her to chair Myovant's Board of diverse industry and healthcare leaders.", "score": 0.824904, "arguments": [{"text": "Board of", "location": [1200, 1208], "entities": [{"type": "Organization", "text": "Board of Directors of AllerGenis LLC"}]}, {"text": "Myovant", "location": [1190, 1197], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc. investors@myovant.com\nMedia Contact"}]}]}, {"type": "affectedBy", "sentence": "In addition, Myovant has appointed industry veterans Myrtle Potter , Mark Guinan , and Frank Torti , M.D., to Myovant's Board of Directors, and Ms. Potter has been appointed Chairman of the Board.", "score": 0.423376, "arguments": [{"text": "Potter", "location": [772, 778], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, {"text": "appointed", "location": [788, 797], "entities": [{"type": "EventPersonnel", "text": "appointed"}]}]}, {"type": "affectedBy", "sentence": "In addition, Myovant has appointed industry veterans Myrtle Potter , Mark Guinan , and Frank Torti , M.D., to Myovant's Board of Directors, and Ms. Potter has been appointed Chairman of the Board.", "score": 0.499875, "arguments": [{"text": "Chairman", "location": [798, 806], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, {"text": "appointed", "location": [788, 797], "entities": [{"type": "EventPersonnel", "text": "appointed"}]}]}, {"type": "employedBy", "sentence": "In addition, Myovant has appointed industry veterans Myrtle Potter , Mark Guinan , and Frank Torti , M.D., to Myovant's Board of Directors, and Ms. Potter has been appointed Chairman of the Board.", "score": 0.599421, "arguments": [{"text": "Chairman", "location": [798, 806], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, {"text": "Board", "location": [814, 819], "entities": [{"type": "Organization", "text": "Board of Directors of AllerGenis LLC"}]}]}, {"type": "agentOf", "sentence": "\"With top-line data from each of our five ongoing global Phase 3 clinical trials expected in 2019, we are pleased to announce the strengthening of our management team and Board as we look forward to the next stage of Myovant's growth,\" said Lynn Seely , M.D., President and CEO of Myovant.", "score": 0.569544, "arguments": [{"text": "we", "location": [920, 922], "entities": [{"type": "Person", "text": "we"}]}, {"text": "announce", "location": [938, 946], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "employedBy", "sentence": "\"With top-line data from each of our five ongoing global Phase 3 clinical trials expected in 2019, we are pleased to announce the strengthening of our management team and Board as we look forward to the next stage of Myovant's growth,\" said Lynn Seely , M.D., President and CEO of Myovant.", "score": 0.891942, "arguments": [{"text": "management team", "location": [972, 987], "entities": [{"type": "Person", "text": "management team"}]}, {"text": "our", "location": [968, 971], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc. investors@myovant.com\nMedia Contact"}]}]}, {"type": "agentOf", "sentence": "\"With top-line data from each of our five ongoing global Phase 3 clinical trials expected in 2019, we are pleased to announce the strengthening of our management team and Board as we look forward to the next stage of Myovant's growth,\" said Lynn Seely , M.D., President and CEO of Myovant.", "score": 0.760998, "arguments": [{"text": "Lynn Seely", "location": [1062, 1072], "entities": [{"type": "Person", "text": "Lynn Seely"}]}, {"text": "said", "location": [1057, 1061], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "managerOf", "sentence": "\"With top-line data from each of our five ongoing global Phase 3 clinical trials expected in 2019, we are pleased to announce the strengthening of our management team and Board as we look forward to the next stage of Myovant's growth,\" said Lynn Seely , M.D., President and CEO of Myovant.", "score": 0.79961, "arguments": [{"text": "CEO", "location": [1095, 1098], "entities": [{"type": "Person", "text": "Lynn Seely"}]}, {"text": "Myovant", "location": [1102, 1109], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc. investors@myovant.com\nMedia Contact"}]}]}, {"type": "managerOf", "sentence": "Myovant's other directors include Kathleen Sebelius , former U.S. Secretary of Health and Human Services during the Obama administration; Vivek Ramaswamy , the founder and CEO of Roivant Sciences; Terrie Curran , President , Global Inflammation and Immunology Franchise of Celgene Corporation; and Lynn Seely , M.D., President and Chief Executive Officer of Myovant.", "score": 0.708248, "arguments": [{"text": "Chief Executive Officer", "location": [6421, 6444], "entities": [{"type": "Person", "text": "Lynn Seely"}]}, {"text": "Myovant", "location": [6448, 6455], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc. investors@myovant.com\nMedia Contact"}]}]}, {"type": "employedBy", "sentence": "Together, we are committed to achieving our mission of becoming the leading company in women's health and endocrine diseases.", "score": 0.291618, "arguments": [{"text": "women", "location": [1337, 1342], "entities": [{"type": "Person", "text": "women"}]}, {"text": "company", "location": [1326, 1333], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc. investors@myovant.com\nMedia Contact"}]}]}, {"type": "hasAttribute", "sentence": "BASEL, Switzerland , Nov. Myovant Sciences, Ltd. (NYSE: MYOV ), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, today announced that Kim Sablich , formerly Vice President of Primary Care Marketing in the United States for GlaxoSmithKline (GSK), will join Myovant Sciences as Chief Commercial Officer, and Jeff Nornhold , formerly Senior Vice President of Technical Operations for Impax Laboratories (now Amneal Pharmaceuticals, Inc.), has joined Myovant as Senior Vice President of Pharmaceutical Operations & Development.", "score": 0.607425, "arguments": [{"text": "Myovant Sciences, Ltd.", "location": [26, 48], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc. investors@myovant.com\nMedia Contact"}]}, {"text": "MYOV", "location": [56, 60], "entities": [{"type": "Ticker", "text": "MYOV"}]}]}, {"type": "hasAttribute", "sentence": "Together, we are committed to achieving our mission of becoming the leading company in women's health and endocrine diseases.", "score": 0.683725, "arguments": [{"text": "women", "location": [1337, 1342], "entities": [{"type": "Person", "text": "women"}]}, {"text": "diseases", "location": [1366, 1374], "entities": [{"type": "HealthCondition", "text": "prostate cancer"}]}]}, {"type": "employedBy", "sentence": "\" Additions to Myovant's Management Team Ms. Sablich previously served as Vice President, Primary Care Marketing in the United States for GSK, where she was responsible for revenue forecasts, product strategies and execution plans for a broad portfolio of products including Advair\u00ae, Breo, Anoro\u00ae, Incruse\u00ae, TanzeumM, Levitra\u00ae, and Trelegy.", "score": 0.413073, "arguments": [{"text": "Ms.", "location": [1416, 1419], "entities": [{"type": "Person", "text": "Kim Sablich"}]}, {"text": "Myovant's Management Team", "location": [1390, 1415], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc. investors@myovant.com\nMedia Contact"}]}]}, {"type": "locatedAt", "sentence": "\" Additions to Myovant's Management Team Ms. Sablich previously served as Vice President, Primary Care Marketing in the United States for GSK, where she was responsible for revenue forecasts, product strategies and execution plans for a broad portfolio of products including Advair\u00ae, Breo, Anoro\u00ae, Incruse\u00ae, TanzeumM, Levitra\u00ae, and Trelegy.", "score": 0.335323, "arguments": [{"text": "she", "location": [1524, 1527], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, {"text": "where", "location": [1518, 1523], "entities": [{"type": "Facility", "text": "where"}]}]}, {"type": "locatedAt", "sentence": "Before joining GSK, Ms. Sablich spent 15 years at Merck, where she held positions of increasing responsibility in the commercial organization across sales, product management, pricing/access, and customer insights, with a focus on the cardiovascular, respiratory and vaccines business areas.", "score": 0.244545, "arguments": [{"text": "she", "location": [1942, 1945], "entities": [{"type": "Person", "text": "Chief Procurement Officer"}]}, {"text": "where", "location": [1936, 1941], "entities": [{"type": "Facility", "text": "where"}]}]}, {"type": "memberOf", "sentence": "She is currently a member of the Board of Directors of AllerGenis LLC.", "score": 0.805736, "arguments": [{"text": "member", "location": [2370, 2376], "entities": [{"type": "Person", "text": "Chief Procurement Officer"}]}, {"text": "Board of Directors of AllerGenis LLC", "location": [2384, 2420], "entities": [{"type": "Organization", "text": "Board of Directors of AllerGenis LLC"}]}]}, {"type": "affectedBy", "sentence": "She earned a B.A. from Denison University and an M.B.A. from The Wharton School of the University of Pennsylvania .", "score": 0.515151, "arguments": [{"text": "She", "location": [2422, 2425], "entities": [{"type": "Person", "text": "Chief Procurement Officer"}]}, {"text": "earned", "location": [2426, 2432], "entities": [{"type": "EventEducation", "text": "earned"}]}]}, {"type": "educatedAt", "sentence": "She earned a B.A. from Denison University and an M.B.A. from The Wharton School of the University of Pennsylvania .", "score": 0.770997, "arguments": [{"text": "She", "location": [2422, 2425], "entities": [{"type": "Person", "text": "Chief Procurement Officer"}]}, {"text": "Denison University", "location": [2445, 2463], "entities": [{"type": "Organization", "text": "Denison University", "disambiguation": {"subtype": ["Educational"]}}]}]}, {"type": "agentOf", "sentence": "She earned a B.A. from Denison University and an M.B.A. from The Wharton School of the University of Pennsylvania .", "score": 0.803177, "arguments": [{"text": "M.B.A.", "location": [2471, 2477], "entities": [{"type": "Organization", "text": "M.B.A."}]}, {"text": "earned", "location": [2426, 2432], "entities": [{"type": "EventEducation", "text": "earned"}]}]}, {"type": "agentOf", "sentence": "She earned a B.A. from Denison University and an M.B.A. from The Wharton School of the University of Pennsylvania .", "score": 0.782197, "arguments": [{"text": "The Wharton School of the University of Pennsylvania", "location": [2483, 2535], "entities": [{"type": "Organization", "text": "The Wharton School of the University of Pennsylvania"}]}, {"text": "earned", "location": [2426, 2432], "entities": [{"type": "EventEducation", "text": "earned"}]}]}, {"type": "partOf", "sentence": "She earned a B.A. from Denison University and an M.B.A. from The Wharton School of the University of Pennsylvania .", "score": 0.656094, "arguments": [{"text": "M.B.A.", "location": [2471, 2477], "entities": [{"type": "Organization", "text": "M.B.A."}]}, {"text": "The Wharton School of the University of Pennsylvania", "location": [2483, 2535], "entities": [{"type": "Organization", "text": "The Wharton School of the University of Pennsylvania"}]}]}, {"type": "hasAttribute", "sentence": "BASEL, Switzerland , Nov. Myovant Sciences, Ltd. (NYSE: MYOV ), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, today announced that Kim Sablich , formerly Vice President of Primary Care Marketing in the United States for GlaxoSmithKline (GSK), will join Myovant Sciences as Chief Commercial Officer, and Jeff Nornhold , formerly Senior Vice President of Technical Operations for Impax Laboratories (now Amneal Pharmaceuticals, Inc.), has joined Myovant as Senior Vice President of Pharmaceutical Operations & Development.", "score": 0.77953, "arguments": [{"text": "women", "location": [174, 179], "entities": [{"type": "Person", "text": "women"}]}, {"text": "diseases", "location": [203, 211], "entities": [{"type": "HealthCondition", "text": "prostate cancer"}]}]}, {"type": "employedBy", "sentence": "Prior to that, he served as Impax's Senior Vice President, Global Quality Affairs, and was responsible for establishing a sustainable quality and compliance program.", "score": 0.464161, "arguments": [{"text": "Senior Vice President", "location": [2813, 2834], "entities": [{"type": "Person", "text": "Senior Vice President"}]}, {"text": "Impax", "location": [2805, 2810], "entities": [{"type": "Organization", "text": "Technical Operations for Impax Laboratories"}]}]}, {"type": "partOf", "sentence": "Prior to that, he served as Impax's Senior Vice President, Global Quality Affairs, and was responsible for establishing a sustainable quality and compliance program.", "score": 0.286576, "arguments": [{"text": "Impax", "location": [2805, 2810], "entities": [{"type": "Organization", "text": "Technical Operations for Impax Laboratories"}]}, {"text": "Global Quality Affairs", "location": [2836, 2858], "entities": [{"type": "Organization", "text": "Global Quality Affairs", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "While at Watson , he also served as Vice President, U.S. Quality Operations, where he led the development and execution of quality initiatives for all U.S. sites.", "score": 0.986659, "arguments": [{"text": "Quality Operations", "location": [3250, 3268], "entities": [{"type": "Organization", "text": "Quality Operations"}]}, {"text": "U.S.", "location": [3245, 3249], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "affectedBy", "sentence": "While at Watson , he also served as Vice President, U.S. Quality Operations, where he led the development and execution of quality initiatives for all U.S. sites.", "score": 0.472767, "arguments": [{"text": "he", "location": [3276, 3278], "entities": [{"type": "Person", "text": "Jeff Nornhold"}]}, {"text": "execution", "location": [3303, 3312], "entities": [{"type": "EventLegal", "text": "execution"}]}]}, {"type": "locatedAt", "sentence": "While at Watson , he also served as Vice President, U.S. Quality Operations, where he led the development and execution of quality initiatives for all U.S. sites.", "score": 0.153194, "arguments": [{"text": "sites", "location": [3349, 3354], "entities": [{"type": "Location", "text": "sites"}]}, {"text": "U.S.", "location": [3344, 3348], "entities": [{"type": "GeopoliticalEntity", "text": "Myovant Sciences, Inc. investors@myovant.com\nMedia Contact"}]}]}, {"type": "affectedBy", "sentence": "Mr. Nornhold earned a B.S. in chemistry from Bowling Green State University and an M.B.A. from the University of Southern California Marshall School of Business.", "score": 0.916672, "arguments": [{"text": "Nornhold", "location": [3453, 3461], "entities": [{"type": "Person", "text": "Jeff Nornhold"}]}, {"text": "earned", "location": [3462, 3468], "entities": [{"type": "EventEducation", "text": "earned"}]}]}, {"type": "awardedTo", "sentence": "Mr. Nornhold earned a B.S. in chemistry from Bowling Green State University and an M.B.A. from the University of Southern California Marshall School of Business.", "score": 0.677837, "arguments": [{"text": "B.S.", "location": [3471, 3475], "entities": [{"type": "Degree", "text": "B.S."}]}, {"text": "Nornhold", "location": [3453, 3461], "entities": [{"type": "Person", "text": "Jeff Nornhold"}]}]}, {"type": "educatedAt", "sentence": "Mr. Nornhold earned a B.S. in chemistry from Bowling Green State University and an M.B.A. from the University of Southern California Marshall School of Business.", "score": 0.522032, "arguments": [{"text": "Nornhold", "location": [3453, 3461], "entities": [{"type": "Person", "text": "Jeff Nornhold"}]}, {"text": "University of Southern California Marshall School of Business", "location": [3548, 3609], "entities": [{"type": "Organization", "text": "University of Southern California Marshall School of Business"}]}]}, {"type": "agentOf", "sentence": "Mr. Nornhold earned a B.S. in chemistry from Bowling Green State University and an M.B.A. from the University of Southern California Marshall School of Business.", "score": 0.967546, "arguments": [{"text": "Bowling Green State University", "location": [3494, 3524], "entities": [{"type": "Organization", "text": "Bowling Green State University"}]}, {"text": "earned", "location": [3462, 3468], "entities": [{"type": "EventEducation", "text": "earned"}]}]}, {"type": "agentOf", "sentence": "Mr. Nornhold earned a B.S. in chemistry from Bowling Green State University and an M.B.A. from the University of Southern California Marshall School of Business.", "score": 0.931533, "arguments": [{"text": "M.B.A.", "location": [3532, 3538], "entities": [{"type": "Organization", "text": "M.B.A."}]}, {"text": "earned", "location": [3462, 3468], "entities": [{"type": "EventEducation", "text": "earned"}]}]}, {"type": "timeOf", "sentence": "BASEL, Switzerland , Nov. Myovant Sciences, Ltd. (NYSE: MYOV ), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, today announced that Kim Sablich , formerly Vice President of Primary Care Marketing in the United States for GlaxoSmithKline (GSK), will join Myovant Sciences as Chief Commercial Officer, and Jeff Nornhold , formerly Senior Vice President of Technical Operations for Impax Laboratories (now Amneal Pharmaceuticals, Inc.), has joined Myovant as Senior Vice President of Pharmaceutical Operations & Development.", "score": 0.956741, "arguments": [{"text": "today", "location": [213, 218], "entities": [{"type": "Date", "text": "today"}]}, {"text": "announced", "location": [219, 228], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "agentOf", "sentence": "Mr. Nornhold earned a B.S. in chemistry from Bowling Green State University and an M.B.A. from the University of Southern California Marshall School of Business.", "score": 0.815323, "arguments": [{"text": "University of Southern California Marshall School of Business", "location": [3548, 3609], "entities": [{"type": "Organization", "text": "University of Southern California Marshall School of Business"}]}, {"text": "earned", "location": [3462, 3468], "entities": [{"type": "EventEducation", "text": "earned"}]}]}, {"type": "awardedBy", "sentence": "Mr. Nornhold earned a B.S. in chemistry from Bowling Green State University and an M.B.A. from the University of Southern California Marshall School of Business.", "score": 0.562099, "arguments": [{"text": "B.S.", "location": [3471, 3475], "entities": [{"type": "Degree", "text": "B.S."}]}, {"text": "Bowling Green State University", "location": [3494, 3524], "entities": [{"type": "Organization", "text": "Bowling Green State University"}]}]}, {"type": "partOf", "sentence": "Mr. Nornhold earned a B.S. in chemistry from Bowling Green State University and an M.B.A. from the University of Southern California Marshall School of Business.", "score": 0.516218, "arguments": [{"text": "M.B.A.", "location": [3532, 3538], "entities": [{"type": "Organization", "text": "M.B.A."}]}, {"text": "University of Southern California Marshall School of Business", "location": [3548, 3609], "entities": [{"type": "Organization", "text": "University of Southern California Marshall School of Business"}]}]}, {"type": "employedBy", "sentence": "New Myovant Directors Ms. Potter currently serves as Vant Operating Chair for Roivant Pharma, a division of Roivant Sciences.", "score": 0.60273, "arguments": [{"text": "Directors", "location": [3623, 3632], "entities": [{"type": "Person", "text": "directors"}]}, {"text": "Myovant", "location": [3615, 3622], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc. investors@myovant.com\nMedia Contact"}]}]}, {"type": "partOf", "sentence": "New Myovant Directors Ms. Potter currently serves as Vant Operating Chair for Roivant Pharma, a division of Roivant Sciences.", "score": 0.880253, "arguments": [{"text": "division", "location": [3707, 3715], "entities": [{"type": "Organization", "text": "Chair for Roivant Pharma"}]}, {"text": "Roivant Sciences", "location": [3719, 3735], "entities": [{"type": "Organization", "text": "Roivant Sciences"}]}]}, {"type": "partOf", "sentence": "Dr. Torti serves as Vant Investment Chair for Roivant Pharma, a division of Roivant Sciences.", "score": 0.882512, "arguments": [{"text": "division", "location": [5218, 5226], "entities": [{"type": "Organization", "text": "Chair for Roivant Pharma"}]}, {"text": "Roivant Sciences", "location": [5230, 5246], "entities": [{"type": "Organization", "text": "Roivant Sciences"}]}]}, {"type": "managerOf", "sentence": "She previously served as Chief Executive Officer of Myrtle Potter & Company, LLC, and President of Commercial Operations and Executive Vice President, and Chief Operating Officer of Genentech.", "score": 0.361243, "arguments": [{"text": "Myrtle Potter", "location": [3789, 3802], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, {"text": "Company", "location": [3805, 3812], "entities": [{"type": "Organization", "text": "Board of Directors of AllerGenis LLC"}]}]}, {"type": "managerOf", "sentence": "She previously served as Chief Executive Officer of Myrtle Potter & Company, LLC, and President of Commercial Operations and Executive Vice President, and Chief Operating Officer of Genentech.", "score": 0.543684, "arguments": [{"text": "President", "location": [3823, 3832], "entities": [{"type": "Person", "text": "Obama"}]}, {"text": "Commercial Operations", "location": [3836, 3857], "entities": [{"type": "Organization", "text": "Commercial Operations", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "managerOf", "sentence": "She previously served as Chief Executive Officer of Myrtle Potter & Company, LLC, and President of Commercial Operations and Executive Vice President, and Chief Operating Officer of Genentech.", "score": 0.417585, "arguments": [{"text": "Executive Vice President", "location": [3862, 3886], "entities": [{"type": "Person", "text": "Executive Vice President"}]}, {"text": "Genentech", "location": [3919, 3928], "entities": [{"type": "Organization", "text": "Genentech", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "managerOf", "sentence": "She previously served as Chief Executive Officer of Myrtle Potter & Company, LLC, and President of Commercial Operations and Executive Vice President, and Chief Operating Officer of Genentech.", "score": 0.582966, "arguments": [{"text": "Chief Operating Officer", "location": [3892, 3915], "entities": [{"type": "Person", "text": "Executive Vice President"}]}, {"text": "Genentech", "location": [3919, 3928], "entities": [{"type": "Organization", "text": "Genentech", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Prior to Genentech, she held various positions, including President of Cardiovascular/Metabolics at Bristol- Myers Squibb .", "score": 0.495487, "arguments": [{"text": "President", "location": [3988, 3997], "entities": [{"type": "Person", "text": "Obama"}]}, {"text": "Cardiovascular", "location": [4001, 4015], "entities": [{"type": "Organization", "text": "Cardiovascular"}]}]}, {"type": "partOf", "sentence": "Prior to Genentech, she held various positions, including President of Cardiovascular/Metabolics at Bristol- Myers Squibb .", "score": 0.440847, "arguments": [{"text": "Cardiovascular", "location": [4001, 4015], "entities": [{"type": "Organization", "text": "Cardiovascular"}]}, {"text": "Bristol- Myers Squibb", "location": [4030, 4051], "entities": [{"type": "Organization", "text": "Bristol- Myers Squibb", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "managerOf", "sentence": "BASEL, Switzerland , Nov. Myovant Sciences, Ltd. (NYSE: MYOV ), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, today announced that Kim Sablich , formerly Vice President of Primary Care Marketing in the United States for GlaxoSmithKline (GSK), will join Myovant Sciences as Chief Commercial Officer, and Jeff Nornhold , formerly Senior Vice President of Technical Operations for Impax Laboratories (now Amneal Pharmaceuticals, Inc.), has joined Myovant as Senior Vice President of Pharmaceutical Operations & Development.", "score": 0.634813, "arguments": [{"text": "Vice President", "location": [257, 271], "entities": [{"type": "Person", "text": "Chief Procurement Officer"}]}, {"text": "Primary Care Marketing", "location": [275, 297], "entities": [{"type": "Organization", "text": "Primary Care Marketing"}]}]}, {"type": "educatedAt", "sentence": "She is a graduate of the University of Chicago .", "score": 0.588971, "arguments": [{"text": "graduate", "location": [4063, 4071], "entities": [{"type": "Person", "text": "Executive Vice President"}]}, {"text": "University of Chicago", "location": [4079, 4100], "entities": [{"type": "Organization", "text": "University of Chicago"}]}]}, {"type": "partOf", "sentence": "In addition to serving on our Board, Ms. Potter also serves on the boards of other companies in the Roivant family of companies, including Urovant Sciences, Axovant Sciences and Arbutus Biopharma.", "score": 0.876053, "arguments": [{"text": "Board", "location": [4133, 4138], "entities": [{"type": "Organization", "text": "Board of Directors of AllerGenis LLC"}]}, {"text": "our", "location": [4129, 4132], "entities": [{"type": "Organization", "text": "companies"}]}]}, {"type": "employedBy", "sentence": "In addition to serving on our Board, Ms. Potter also serves on the boards of other companies in the Roivant family of companies, including Urovant Sciences, Axovant Sciences and Arbutus Biopharma.", "score": 0.630567, "arguments": [{"text": "family", "location": [4211, 4217], "entities": [{"type": "Person", "text": "family"}]}, {"text": "Roivant", "location": [4203, 4210], "entities": [{"type": "Organization", "text": "Roivant Sciences"}]}]}, {"type": "employedBy", "sentence": "In addition to serving on our Board, Dr. Torti also serves on the boards of several other companies in the Roivant family of companies, including Urovant Sciences, Axovant Sciences, Dermavant Sciences and Respivant Sciences.", "score": 0.630567, "arguments": [{"text": "family", "location": [5834, 5840], "entities": [{"type": "Person", "text": "family"}]}, {"text": "Roivant", "location": [5826, 5833], "entities": [{"type": "Organization", "text": "Roivant Sciences"}]}]}, {"type": "employedBy", "sentence": "In addition to serving on our Board, Ms. Potter also serves on the boards of other companies in the Roivant family of companies, including Urovant Sciences, Axovant Sciences and Arbutus Biopharma.", "score": 0.26758, "arguments": [{"text": "family", "location": [4211, 4217], "entities": [{"type": "Person", "text": "family"}]}, {"text": "companies", "location": [4221, 4230], "entities": [{"type": "Organization", "text": "companies"}]}]}, {"type": "partOf", "sentence": "Ms. Potter has previously served on the boards of Amazon, Express Scripts Holding Co., and Medco Health Solutions Inc. Mr. Guinan serves as the Executive Vice President and Chief Financial Officer for Quest Diagnostics Inc. He previously served as Chief Financial Officer for Hill-Rom Holdings Inc., a manufacturer and provider of medical technologies and related services for the healthcare industry.", "score": 0.371016, "arguments": [{"text": "Amazon", "location": [4350, 4356], "entities": [{"type": "Organization", "text": "Amazon"}]}, {"text": "Express Scripts Holding Co.", "location": [4358, 4385], "entities": [{"type": "Organization", "text": "Express Scripts Holding Co.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Ms. Potter has previously served on the boards of Amazon, Express Scripts Holding Co., and Medco Health Solutions Inc. Mr. Guinan serves as the Executive Vice President and Chief Financial Officer for Quest Diagnostics Inc. He previously served as Chief Financial Officer for Hill-Rom Holdings Inc., a manufacturer and provider of medical technologies and related services for the healthcare industry.", "score": 0.563959, "arguments": [{"text": "Mr.", "location": [4419, 4422], "entities": [{"type": "Person", "text": "Mark Guinan"}]}, {"text": "Medco Health Solutions Inc.", "location": [4391, 4418], "entities": [{"type": "Organization", "text": "Medco Health Solutions Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Ms. Potter has previously served on the boards of Amazon, Express Scripts Holding Co., and Medco Health Solutions Inc. Mr. Guinan serves as the Executive Vice President and Chief Financial Officer for Quest Diagnostics Inc. He previously served as Chief Financial Officer for Hill-Rom Holdings Inc., a manufacturer and provider of medical technologies and related services for the healthcare industry.", "score": 0.732579, "arguments": [{"text": "Chief Financial Officer", "location": [4473, 4496], "entities": [{"type": "Person", "text": "Chief Financial Officer"}]}, {"text": "Quest Diagnostics Inc.", "location": [4501, 4523], "entities": [{"type": "Organization", "text": "Quest Diagnostics Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "managerOf", "sentence": "Prior to that, he served in a number of finance and operations roles in a long career at Johnson & Johnson, including as Vice President, Chief Procurement Officer, and as CFO of the pharmaceutical business.", "score": 0.654973, "arguments": [{"text": "CFO", "location": [4873, 4876], "entities": [{"type": "Person", "text": "Chief Financial Officer"}]}, {"text": "pharmaceutical business", "location": [4884, 4907], "entities": [{"type": "Organization", "text": "pharmaceutical business", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Before joining Johnson & Johnson, Mr. Guinan held a number of financial roles at Procter & Gamble.", "score": 0.691061, "arguments": [{"text": "Guinan", "location": [4947, 4953], "entities": [{"type": "Person", "text": "Mark Guinan"}]}, {"text": "Procter & Gamble", "location": [4990, 5006], "entities": [{"type": "Organization", "text": "Procter & Gamble", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "awardedTo", "sentence": "He received a B.A. in economics from the University of Notre Dame and an M.B.A. from Olin Business School at Washington University in St. Louis .", "score": 0.759648, "arguments": [{"text": "B.A.", "location": [5022, 5026], "entities": [{"type": "Degree", "text": "B.A."}]}, {"text": "He", "location": [5008, 5010], "entities": [{"type": "Person", "text": "Mark Guinan"}]}]}, {"type": "locatedAt", "sentence": "BASEL, Switzerland , Nov. Myovant Sciences, Ltd. (NYSE: MYOV ), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, today announced that Kim Sablich , formerly Vice President of Primary Care Marketing in the United States for GlaxoSmithKline (GSK), will join Myovant Sciences as Chief Commercial Officer, and Jeff Nornhold , formerly Senior Vice President of Technical Operations for Impax Laboratories (now Amneal Pharmaceuticals, Inc.), has joined Myovant as Senior Vice President of Pharmaceutical Operations & Development.", "score": 0.502038, "arguments": [{"text": "Primary Care Marketing", "location": [275, 297], "entities": [{"type": "Organization", "text": "Primary Care Marketing"}]}, {"text": "United States", "location": [305, 318], "entities": [{"type": "GeopoliticalEntity", "text": "United States", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "\" Additions to Myovant's Management Team Ms. Sablich previously served as Vice President, Primary Care Marketing in the United States for GSK, where she was responsible for revenue forecasts, product strategies and execution plans for a broad portfolio of products including Advair\u00ae, Breo, Anoro\u00ae, Incruse\u00ae, TanzeumM, Levitra\u00ae, and Trelegy.", "score": 0.589281, "arguments": [{"text": "Primary Care Marketing", "location": [1465, 1487], "entities": [{"type": "Organization", "text": "Primary Care Marketing"}]}, {"text": "United States", "location": [1495, 1508], "entities": [{"type": "GeopoliticalEntity", "text": "United States", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "managerOf", "sentence": "He received a B.A. in economics from the University of Notre Dame and an M.B.A. from Olin Business School at Washington University in St. Louis .", "score": 0.490685, "arguments": [{"text": "Olin", "location": [5093, 5097], "entities": [{"type": "Person", "text": "Olin"}]}, {"text": "Business School", "location": [5098, 5113], "entities": [{"type": "Organization", "text": "Business School"}]}]}, {"type": "employedBy", "sentence": "He received a B.A. in economics from the University of Notre Dame and an M.B.A. from Olin Business School at Washington University in St. Louis .", "score": 0.589514, "arguments": [{"text": "Olin", "location": [5093, 5097], "entities": [{"type": "Person", "text": "Olin"}]}, {"text": "Washington University", "location": [5117, 5138], "entities": [{"type": "Organization", "text": "Washington University", "disambiguation": {"subtype": ["Educational"]}}]}]}, {"type": "partOf", "sentence": "He received a B.A. in economics from the University of Notre Dame and an M.B.A. from Olin Business School at Washington University in St. Louis .", "score": 0.722472, "arguments": [{"text": "Business School", "location": [5098, 5113], "entities": [{"type": "Organization", "text": "Business School"}]}, {"text": "Washington University", "location": [5117, 5138], "entities": [{"type": "Organization", "text": "Washington University", "disambiguation": {"subtype": ["Educational"]}}]}]}, {"type": "basedIn", "sentence": "He received a B.A. in economics from the University of Notre Dame and an M.B.A. from Olin Business School at Washington University in St. Louis .", "score": 0.75597, "arguments": [{"text": "Washington University", "location": [5117, 5138], "entities": [{"type": "Organization", "text": "Washington University", "disambiguation": {"subtype": ["Educational"]}}]}, {"text": "St. Louis", "location": [5142, 5151], "entities": [{"type": "GeopoliticalEntity", "text": "St. Louis"}]}]}, {"type": "employedBy", "sentence": "Prior to Roivant, he was a partner at New Enterprise Associates (NEA), a leading venture capital firm.", "score": 0.747172, "arguments": [{"text": "partner", "location": [5275, 5282], "entities": [{"type": "Person", "text": "partner"}]}, {"text": "New Enterprise Associates", "location": [5286, 5311], "entities": [{"type": "Organization", "text": "New Enterprise Associates", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Prior to Roivant, he was a partner at New Enterprise Associates (NEA), a leading venture capital firm.", "score": 0.500302, "arguments": [{"text": "partner", "location": [5275, 5282], "entities": [{"type": "Person", "text": "partner"}]}, {"text": "venture capital firm", "location": [5329, 5349], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc. investors@myovant.com\nMedia Contact"}]}]}, {"type": "employedBy", "sentence": "Prior to NEA, Dr. Torti was a researcher at the Duke University Center for Clinical & Genetic Economics where he was involved in clinical trial research and economic evaluations of multinational clinical trials.", "score": 0.623622, "arguments": [{"text": "researcher", "location": [5537, 5547], "entities": [{"type": "Person", "text": "Frank Torti"}]}, {"text": "Duke University Center for Clinical & Genetic Economics where", "location": [5555, 5616], "entities": [{"type": "Organization", "text": "Duke University Center for Clinical & Genetic Economics where"}]}]}, {"type": "employedBy", "sentence": "Prior to NEA, Dr. Torti was a researcher at the Duke University Center for Clinical & Genetic Economics where he was involved in clinical trial research and economic evaluations of multinational clinical trials.", "score": 0.25709, "arguments": [{"text": "he", "location": [5617, 5619], "entities": [{"type": "Person", "text": "Frank Torti"}]}, {"text": "Duke University Center for Clinical & Genetic Economics where", "location": [5555, 5616], "entities": [{"type": "Organization", "text": "Duke University Center for Clinical & Genetic Economics where"}]}]}, {"type": "partOf", "sentence": "In addition to serving on our Board, Dr. Torti also serves on the boards of several other companies in the Roivant family of companies, including Urovant Sciences, Axovant Sciences, Dermavant Sciences and Respivant Sciences.", "score": 0.876053, "arguments": [{"text": "Board", "location": [5749, 5754], "entities": [{"type": "Organization", "text": "Board of Directors of AllerGenis LLC"}]}, {"text": "our", "location": [5745, 5748], "entities": [{"type": "Organization", "text": "companies"}]}]}, {"type": "employedBy", "sentence": "In addition to serving on our Board, Dr. Torti also serves on the boards of several other companies in the Roivant family of companies, including Urovant Sciences, Axovant Sciences, Dermavant Sciences and Respivant Sciences.", "score": 0.26758, "arguments": [{"text": "family", "location": [5834, 5840], "entities": [{"type": "Person", "text": "family"}]}, {"text": "companies", "location": [5844, 5853], "entities": [{"type": "Organization", "text": "companies"}]}]}, {"type": "partOfMany", "sentence": "Myovant's other directors include Kathleen Sebelius , former U.S. Secretary of Health and Human Services during the Obama administration; Vivek Ramaswamy , the founder and CEO of Roivant Sciences; Terrie Curran , President , Global Inflammation and Immunology Franchise of Celgene Corporation; and Lynn Seely , M.D., President and Chief Executive Officer of Myovant.", "score": 0.775883, "arguments": [{"text": "Kathleen Sebelius", "location": [6124, 6141], "entities": [{"type": "Person", "text": "Kathleen Sebelius"}]}, {"text": "directors", "location": [6106, 6115], "entities": [{"type": "Person", "text": "directors"}]}]}, {"type": "employedBy", "sentence": "BASEL, Switzerland , Nov. Myovant Sciences, Ltd. (NYSE: MYOV ), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, today announced that Kim Sablich , formerly Vice President of Primary Care Marketing in the United States for GlaxoSmithKline (GSK), will join Myovant Sciences as Chief Commercial Officer, and Jeff Nornhold , formerly Senior Vice President of Technical Operations for Impax Laboratories (now Amneal Pharmaceuticals, Inc.), has joined Myovant as Senior Vice President of Pharmaceutical Operations & Development.", "score": 0.539525, "arguments": [{"text": "Senior Vice President of", "location": [558, 582], "entities": [{"type": "Person", "text": "Senior Vice President of"}]}, {"text": "Pharmaceutical Operations & Development", "location": [583, 622], "entities": [{"type": "Organization", "text": "Pharmaceutical Operations & Development"}]}]}, {"type": "partOfMany", "sentence": "Myovant's other directors include Kathleen Sebelius , former U.S. Secretary of Health and Human Services during the Obama administration; Vivek Ramaswamy , the founder and CEO of Roivant Sciences; Terrie Curran , President , Global Inflammation and Immunology Franchise of Celgene Corporation; and Lynn Seely , M.D., President and Chief Executive Officer of Myovant.", "score": 0.661912, "arguments": [{"text": "Secretary of Health and Human Services", "location": [6156, 6194], "entities": [{"type": "Person", "text": "Secretary of Health and Human Services"}]}, {"text": "directors", "location": [6106, 6115], "entities": [{"type": "Person", "text": "directors"}]}]}, {"type": "employedBy", "sentence": "Myovant's other directors include Kathleen Sebelius , former U.S. Secretary of Health and Human Services during the Obama administration; Vivek Ramaswamy , the founder and CEO of Roivant Sciences; Terrie Curran , President , Global Inflammation and Immunology Franchise of Celgene Corporation; and Lynn Seely , M.D., President and Chief Executive Officer of Myovant.", "score": 0.906055, "arguments": [{"text": "Secretary of Health and Human Services", "location": [6156, 6194], "entities": [{"type": "Person", "text": "Secretary of Health and Human Services"}]}, {"text": "U.S.", "location": [6151, 6155], "entities": [{"type": "GeopoliticalEntity", "text": "Myovant Sciences, Inc. investors@myovant.com\nMedia Contact"}]}]}, {"type": "managerOf", "sentence": "Myovant's other directors include Kathleen Sebelius , former U.S. Secretary of Health and Human Services during the Obama administration; Vivek Ramaswamy , the founder and CEO of Roivant Sciences; Terrie Curran , President , Global Inflammation and Immunology Franchise of Celgene Corporation; and Lynn Seely , M.D., President and Chief Executive Officer of Myovant.", "score": 0.964757, "arguments": [{"text": "Obama", "location": [6206, 6211], "entities": [{"type": "Person", "text": "Obama"}]}, {"text": "administration", "location": [6212, 6226], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "managerOf", "sentence": "Myovant's other directors include Kathleen Sebelius , former U.S. Secretary of Health and Human Services during the Obama administration; Vivek Ramaswamy , the founder and CEO of Roivant Sciences; Terrie Curran , President , Global Inflammation and Immunology Franchise of Celgene Corporation; and Lynn Seely , M.D., President and Chief Executive Officer of Myovant.", "score": 0.787492, "arguments": [{"text": "CEO", "location": [6262, 6265], "entities": [{"type": "Person", "text": "Vivek Ramaswamy"}]}, {"text": "Roivant Sciences", "location": [6269, 6285], "entities": [{"type": "Organization", "text": "Roivant Sciences"}]}]}, {"type": "hasAttribute", "sentence": "About Myovant Sciences Myovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of women's health and endocrine diseases.", "score": 0.748964, "arguments": [{"text": "women", "location": [6627, 6632], "entities": [{"type": "Person", "text": "women"}]}, {"text": "diseases", "location": [6656, 6664], "entities": [{"type": "HealthCondition", "text": "prostate cancer"}]}]}, {"type": "employedBy", "sentence": "Myovant's lead product candidate is relugolix, an oral, once-daily small molecule that acts as a GnRH receptor antagonist.", "score": 0.317786, "arguments": [{"text": "candidate", "location": [6689, 6698], "entities": [{"type": "Person", "text": "Kathleen Sebelius"}]}, {"text": "Myovant", "location": [6666, 6673], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc. investors@myovant.com\nMedia Contact"}]}]}, {"type": "hasAttribute", "sentence": "Myovant has initiated three clinical programs for relugolix consisting of five international Phase 3 clinical trials, two in women with heavy menstrual bleeding associated with uterine fibroids ( LIBERTY 1 and 2), two in women with pain associated with endometriosis (SPIRIT 1 and 2), and one in men with advanced prostate cancer (HERO).", "score": 0.926071, "arguments": [{"text": "men", "location": [7085, 7088], "entities": [{"type": "Person", "text": "women"}]}, {"text": "prostate cancer", "location": [7103, 7118], "entities": [{"type": "HealthCondition", "text": "prostate cancer"}]}]}, {"type": "hasAttribute", "sentence": "Myovant has initiated three clinical programs for relugolix consisting of five international Phase 3 clinical trials, two in women with heavy menstrual bleeding associated with uterine fibroids ( LIBERTY 1 and 2), two in women with pain associated with endometriosis (SPIRIT 1 and 2), and one in men with advanced prostate cancer (HERO).", "score": 0.833615, "arguments": [{"text": "HERO", "location": [7120, 7124], "entities": [{"type": "Person", "text": "HERO"}]}, {"text": "prostate cancer", "location": [7103, 7118], "entities": [{"type": "HealthCondition", "text": "prostate cancer"}]}]}, {"type": "managerOf", "sentence": "Takeda Pharmaceuticals International AG granted Myovant an exclusive, worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries where Takeda retains exclusive rights) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide.", "score": 0.679646, "arguments": [{"text": "Takeda", "location": [7316, 7322], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "Pharmaceuticals International AG", "location": [7323, 7355], "entities": [{"type": "Organization", "text": "Pharmaceuticals International AG"}]}]}, {"type": "affectedBy", "sentence": "Takeda Pharmaceuticals International AG granted Myovant an exclusive, worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries where Takeda retains exclusive rights) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide.", "score": 0.469702, "arguments": [{"text": "Takeda", "location": [7316, 7322], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "granted", "location": [7356, 7363], "entities": [{"type": "EntertainmentAward", "text": "granted"}]}]}, {"type": "partOfMany", "sentence": "In addition, Myovant has appointed industry veterans Myrtle Potter , Mark Guinan , and Frank Torti , M.D., to Myovant's Board of Directors, and Ms. Potter has been appointed Chairman of the Board.", "score": 0.842806, "arguments": [{"text": "Myrtle Potter", "location": [677, 690], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, {"text": "veterans", "location": [668, 676], "entities": [{"type": "Person", "text": "veterans"}]}]}, {"type": "agentOf", "sentence": "Takeda Pharmaceuticals International AG granted Myovant an exclusive, worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries where Takeda retains exclusive rights) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide.", "score": 0.923796, "arguments": [{"text": "Pharmaceuticals International AG", "location": [7323, 7355], "entities": [{"type": "Organization", "text": "Pharmaceuticals International AG"}]}, {"text": "granted", "location": [7356, 7363], "entities": [{"type": "EntertainmentAward", "text": "granted"}]}]}, {"type": "agentOf", "sentence": "Takeda Pharmaceuticals International AG granted Myovant an exclusive, worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries where Takeda retains exclusive rights) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide.", "score": 0.499432, "arguments": [{"text": "Myovant", "location": [7364, 7371], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc. investors@myovant.com\nMedia Contact"}]}, {"text": "granted", "location": [7356, 7363], "entities": [{"type": "EntertainmentAward", "text": "granted"}]}]}, {"type": "locatedAt", "sentence": "Takeda Pharmaceuticals International AG granted Myovant an exclusive, worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries where Takeda retains exclusive rights) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide.", "score": 0.793107, "arguments": [{"text": "countries", "location": [7484, 7493], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Asian", "location": [7478, 7483], "entities": [{"type": "GeopoliticalEntity", "text": "Asian"}]}]}, {"type": "locatedAt", "sentence": "Takeda Pharmaceuticals International AG granted Myovant an exclusive, worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries where Takeda retains exclusive rights) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide.", "score": 0.252388, "arguments": [{"text": "countries", "location": [7484, 7493], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "where", "location": [7494, 7499], "entities": [{"type": "Facility", "text": "where"}]}]}, {"type": "locatedAt", "sentence": "Takeda Pharmaceuticals International AG granted Myovant an exclusive, worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries where Takeda retains exclusive rights) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide.", "score": 0.322552, "arguments": [{"text": "Takeda", "location": [7500, 7506], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "where", "location": [7494, 7499], "entities": [{"type": "Facility", "text": "where"}]}]}, {"type": "employedBy", "sentence": "Over time, Myovant intends to expand its development pipeline to include other potential treatments for women's health and endocrine diseases.", "score": 0.307066, "arguments": [{"text": "women", "location": [7727, 7732], "entities": [{"type": "Person", "text": "women"}]}, {"text": "its", "location": [7660, 7663], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc. investors@myovant.com\nMedia Contact"}]}]}, {"type": "hasAttribute", "sentence": "Over time, Myovant intends to expand its development pipeline to include other potential treatments for women's health and endocrine diseases.", "score": 0.66745, "arguments": [{"text": "women", "location": [7727, 7732], "entities": [{"type": "Person", "text": "women"}]}, {"text": "diseases", "location": [7756, 7764], "entities": [{"type": "HealthCondition", "text": "prostate cancer"}]}]}, {"type": "hasAttribute", "sentence": "For more information, please visit Myovant's website at www.myovant.com .", "score": 0.698574, "arguments": [{"text": "Myovant", "location": [7801, 7808], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc. investors@myovant.com\nMedia Contact"}]}, {"text": "www.myovant.com", "location": [7822, 7837], "entities": [{"type": "Web", "text": "www.myovant.com"}]}]}, {"type": "hasAttribute", "sentence": "Forward-Looking Statements This press release contains forward-looking statements, including without limitation: Myovant's focus on developing and commercializing innovative therapies for the treatment of women's health and endocrine diseases; and the statements and Quote: related to the timing of reporting clinical trial results.", "score": 0.80934, "arguments": [{"text": "women", "location": [8045, 8050], "entities": [{"type": "Person", "text": "women"}]}, {"text": "diseases", "location": [8074, 8082], "entities": [{"type": "HealthCondition", "text": "prostate cancer"}]}]}, {"type": "agentOf", "sentence": "Factors that could cause or contribute to such differences include, but are not limited to, those identified herein, and those discussed in the section titled \"Risk Factors\" set forth in Myovant's Quarterly Report on Form 10-Q which was filed with the Securities and Exchange Commission on August 7, 2018 , and other filings that Myovant makes with the SEC from time to time.", "score": 0.890088, "arguments": [{"text": "Myovant", "location": [9322, 9329], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc. investors@myovant.com\nMedia Contact"}]}, {"text": "Report", "location": [9342, 9348], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "partOfMany", "sentence": "In addition, Myovant has appointed industry veterans Myrtle Potter , Mark Guinan , and Frank Torti , M.D., to Myovant's Board of Directors, and Ms. Potter has been appointed Chairman of the Board.", "score": 0.977454, "arguments": [{"text": "Mark Guinan", "location": [693, 704], "entities": [{"type": "Person", "text": "Mark Guinan"}]}, {"text": "veterans", "location": [668, 676], "entities": [{"type": "Person", "text": "veterans"}]}]}, {"type": "agentOf", "sentence": "These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.", "score": 0.811261, "arguments": [{"text": "investors", "location": [9931, 9940], "entities": [{"type": "Person", "text": "investors"}]}, {"text": "cautioned", "location": [9945, 9954], "entities": [{"type": "EventCommunication", "text": "cautioned"}]}]}, {"type": "managerOf", "sentence": "Investor Contact : Frank Karbe Chief Financial Officer Myovant Sciences, Inc. investors@myovant.com Media Contact : Julie Normart W2O pure jnormart@w2ogroup.com 415.946.1087 SOURCE Myovant Sciences, Ltd. Related Links http://www.myovant.com", "score": 0.454384, "arguments": [{"text": "Chief Financial Officer", "location": [10199, 10222], "entities": [{"type": "Person", "text": "Frank Karbe"}]}, {"text": "Myovant Sciences, Inc. investors@myovant.com\nMedia Contact", "location": [10223, 10281], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc. investors@myovant.com\nMedia Contact"}]}]}, {"type": "hasAttribute", "sentence": "Investor Contact : Frank Karbe Chief Financial Officer Myovant Sciences, Inc. investors@myovant.com Media Contact : Julie Normart W2O pure jnormart@w2ogroup.com 415.946.1087 SOURCE Myovant Sciences, Ltd. Related Links http://www.myovant.com", "score": 0.660514, "arguments": [{"text": "Ltd.\nRelated Links", "location": [10367, 10385], "entities": [{"type": "Organization", "text": "Ltd.\nRelated Links"}]}, {"text": "http://www.myovant.com", "location": [10386, 10408], "entities": [{"type": "Web", "text": "http://www.myovant.com"}]}]}], "keywords": [{"text": "Vice President", "sentiment": {"score": -0.412232, "label": "negative"}, "relevance": 0.980647}, {"text": "forward-looking statements", "sentiment": {"score": -0.340174, "label": "negative"}, "relevance": 0.784113}, {"text": "Senior Vice President", "sentiment": {"score": -0.350266, "label": "negative"}, "relevance": 0.774577}, {"text": "Executive Vice President", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.612494}, {"text": "Myovant Sciences", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.611412}, {"text": "Chief Financial Officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.586024}, {"text": "endocrine diseases", "sentiment": {"score": -0.540317, "label": "negative"}, "relevance": 0.582653}, {"text": "Ms. Potter", "sentiment": {"score": 0.788622, "label": "positive"}, "relevance": 0.576429}, {"text": "Dr. Torti", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.569371}, {"text": "Primary Care Marketing", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.535235}, {"text": "clinical-stage biopharmaceutical company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.532542}, {"text": "Chief Executive Officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518039}, {"text": "Officer Myovant Sciences", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.491788}, {"text": "Roivant Sciences", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.486665}, {"text": "New Myovant Directors", "sentiment": {"score": 0.724216, "label": "positive"}, "relevance": 0.481957}, {"text": "clinical trials", "sentiment": {"score": -0.302514, "label": "negative"}, "relevance": 0.481213}, {"text": "innovative therapies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.474038}, {"text": "technical operations", "sentiment": {"score": 0.021767, "label": "positive"}, "relevance": 0.472401}, {"text": "Mr. Nornhold", "sentiment": {"score": -0.412232, "label": "negative"}, "relevance": 0.464928}, {"text": "Chief Commercial Officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.460101}, {"text": "Ms. Sablich", "sentiment": {"score": 0.355856, "label": "positive"}, "relevance": 0.453687}, {"text": "Impax Laboratories", "sentiment": {"score": -0.350266, "label": "negative"}, "relevance": 0.453272}, {"text": "U.S. Quality Operations", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.437157}, {"text": "Chief Operating Officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.434749}, {"text": "Urovant Sciences", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.433774}, {"text": "Axovant Sciences", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.433747}, {"text": "Chief Procurement Officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.427621}, {"text": "management team", "sentiment": {"score": 0.486571, "label": "positive"}, "relevance": 0.427589}, {"text": "United States", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.427559}, {"text": "actual results", "sentiment": {"score": -0.340174, "label": "negative"}, "relevance": 0.427398}, {"text": "Green State University", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.426453}, {"text": "Global Quality Affairs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.42547}, {"text": "veterans Myrtle Potter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.425174}, {"text": "Amneal Pharmaceuticals", "sentiment": {"score": -0.432699, "label": "negative"}, "relevance": 0.425082}, {"text": "risk factors", "sentiment": {"score": -0.468341, "label": "negative"}, "relevance": 0.424757}, {"text": "Lynn Seely", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.421971}, {"text": "Roivant Pharma", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.421711}, {"text": "Vaccines Commercial Strategies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.421216}, {"text": "vaccines business areas", "sentiment": {"score": -0.323443, "label": "negative"}, "relevance": 0.420653}, {"text": "Olin Business School", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.420477}, {"text": "Roivant family", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.420169}, {"text": "Medco Health Solutions", "sentiment": {"score": 0.480265, "label": "positive"}, "relevance": 0.419428}, {"text": "ongoing global Phase", "sentiment": {"score": -0.302514, "label": "negative"}, "relevance": 0.418144}, {"text": "clinical trial results", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.416644}, {"text": "Duke University Center", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.416272}, {"text": "clinical trial research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.415772}, {"text": "multinational clinical trials", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.415046}, {"text": "Harvard Business School", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.414726}, {"text": "numerous healthcare companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.41382}, {"text": "Global Medicines Commercialization", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.412658}]}, "extracted_metadata": {"sha1": "158a2d82fd9d1d0cb2b7d162c248e2f2b4cf2f81", "filename": "1541604886465.zip-cc8af4660247de96656b6c29934d9b4a.xml", "file_type": "json"}, "external_links": ["http://studio-5.financialcontent.com/prnews?Page=Quote&Ticker=MYOV", "http://www.myovant.com/"], "title": "Myovant Strengthens Management Team and Adds New Directors to the Board", "forum_title": "All Biotechnology News and Press Releases from PR Newswire"}, {"id": "HI-pyylaG5JFLP-FNvatDM1I5xwcAN3S_7LweFP7ZS0f9ZoYdDB9bIHAZt0broHl", "result_metadata": {"score": 33.10667}, "author": "www.4-traders.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0.328886, "label": "positive"}, "text": "Barclays", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.751332, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "TAKEDA PHARMACEUTICAL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.916551}, {"text": "Barclays", "sentiment": {"score": 0.328886, "label": "positive"}, "relevance": 0.775237}, {"text": "MarketScreener", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.576364}]}, "crawl_date": "2018-11-07T15:10:17Z", "url": "https://www.marketscreener.com/BARCLAYS-9583556/news/Barclays-Form-8-3-TAKEDA-PHARMACEUTICAL-CO-LTD-27564159/", "host": "marketscreener.com", "text": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC. are being disclosed: Name of offeror/offeree in relation to whose TAKEDA PHARMACEUTICAL CO LTD relevant securities this from relates: 2.", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-07T00:00:00Z", "enriched_text": {"entities": [{"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS PLC", "relevance": 0.770054, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Barclays PLC.", "relevance": 0.671152, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.623102, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SHIRE PLC", "relevance": 0.540198, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": -0.285234, "label": "negative"}, "text": "Class of Product Nature", "relevance": 0.524551, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.516667, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.470404, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Large Holdings Regulatory Operations", "relevance": 0.429553, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.413018, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,255,100 1.29%", "relevance": 0.413018, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,521,600 1.32%", "relevance": 0.413018, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,941,600 1.38%", "relevance": 0.413018, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,048,100 1.39%", "relevance": 0.413018, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,784,586 1.48%", "relevance": 0.413018, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "12,185,115 1.53%", "relevance": 0.413018, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,354,286 4.20%", "relevance": 0.413018, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,381,815 4.20%", "relevance": 0.413018, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.413018, "type": "Quantity"}], "sentiment": {"document": {"score": 0.108646, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "POSITIONS OF THE PERSON", "keywords": [{"text": "POSITIONS"}, {"text": "PERSON"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "33,354,286 4.20% 33,381,815 4.20% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}], "entities": [{"type": "Quantity", "text": "33,354,286 4.20"}, {"type": "Quantity", "text": "33,381,815 4.20"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,048,100 1.39% 12,185,115 1.53% (2) Cash-settled derivatives: 11,784,586 1.48% 10,255,100 1.29% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% TOTAL: 33,354,286 4.20% 33,381,815 4.20% All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors' and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors' and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Class of relevant security Nature", "keywords": [{"text": "relevant security Nature"}, {"text": "Class"}]}, "sentence": " Class of relevant security Nature of dealing e.g. subscription, conversion", "object": {"text": "e.g. subscription, conversion", "keywords": [{"text": "e.g. subscription"}, {"text": "conversion"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "Irrevocable commitments and letters of intent", "keywords": [{"text": "Irrevocable commitments"}, {"text": "intent"}, {"text": "letters"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities", "keywords": [{"text": "option arrangement"}, {"text": "relevant securities"}, {"text": "indemnity"}, {"text": "agreement"}]}, "action": {"verb": {"text": "include", "tense": "future", "negated": true}, "text": "included", "normalized": "include"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any other person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "to: (i) the voting rights of any relevant securities under any option", "keywords": [{"text": "voting rights"}, {"text": "relevant securities"}, {"text": "option"}], "entities": []}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "020 3134 7213 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " YES Date of disclosure: 7 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "The Panel's Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "disclosure requirements"}, {"text": "relation"}, {"text": "consultation"}, {"text": "Code"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "details", "keywords": [{"text": "details"}]}, "sentence": " Full details should be given so that the nature of the interest or position can be fully understood: It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.", "object": {"text": "on a Supplemental Form (Open Positions)", "keywords": [{"text": "Supplemental Form"}, {"text": "Open Positions"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "to provide", "normalized": "to provide"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel's Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "disclosure requirements"}, {"text": "relation"}, {"text": "consultation"}, {"text": "Code"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "Barclays plc", "keywords": [{"text": "Barclays plc"}], "entities": [{"type": "Company", "text": "BARCLAYS PLC", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}]}, "sentence": " Barclays plc published this content on 07 November 2018 and is solely responsible for the information contained herein.", "object": {"text": "this content", "keywords": [{"text": "content"}]}, "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}, {"subject": {"text": "by Public", "keywords": [{"text": "Public"}]}, "sentence": " Distributed by Public, unedited and unaltered, on 07 November 2018 15:02:09 UTC", "object": {"text": "09 UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "Distributed", "tense": "past"}, "text": "Distributed", "normalized": "Distributed"}}], "concepts": [{"text": "Option", "relevance": 0.979191, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.739863, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.698956, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Put option", "relevance": 0.623507, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Stock", "relevance": 0.507268, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Option style", "relevance": 0.411368, "dbpedia_resource": "http://dbpedia.org/resource/Option_style"}, {"text": "Options", "relevance": 0.407483, "dbpedia_resource": "http://dbpedia.org/resource/Options"}, {"text": "Moneyness", "relevance": 0.379208, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}, {"text": "Security", "relevance": 0.349173, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "Bond", "relevance": 0.325895, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "December", "relevance": 0.314324, "dbpedia_resource": "http://dbpedia.org/resource/December"}, {"text": "Barclays", "relevance": 0.312, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}, {"text": "Contract", "relevance": 0.311696, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Unit type", "relevance": 0.303501, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}], "categories": [{"score": 0.573244, "label": "/real estate/buying and selling homes"}, {"score": 0.478604, "label": "/finance/financial news"}, {"score": 0.447825, "label": "/finance/investing"}], "relations": [{"type": "employedBy", "sentence": "Sale 18,700 4,626.1604 JPY Ordinary NPV Sale 83,000 4,625.4807 JPY Ordinary NPV Sale 171,600 4,625.7646 JPY Ordinary NPV Sale 226,600 4,623.9324 JPY Ordinary NPV Sale 230,200 4,623.0638 JPY Ordinary NPV Sale 422,400 4,623.7852 JPY (b) Cash-settled derivative transactions Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV CFD Long 4,400 4,561.5438 JPY Ordinary NPV SWAP Expires 06/12/2018 Long 466,100 4,562.0000 JPY Ordinary NPV CFD Short 15,000 4,628.0000 JPY Ordinary NPV SWAP Expires 06/11/2018 Short 466,100 4,650.0000 JPY (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American,", "score": 0.551117, "arguments": [{"text": "Cash", "location": [4827, 4831], "entities": [{"type": "Person", "text": "Cash"}]}, {"text": "Product Nature", "location": [4873, 4887], "entities": [{"type": "Organization", "text": "Product Nature", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "timeOf", "sentence": "View source version on businesswire.com: https://www.businesswire.com/news/home/20181107005584/en/ BARCLAYS PLC Source: BARCLAYS PLC Attachments Original document Permalink Disclaimer Barclays plc published this content on 07 November 2018 and is solely responsible for the information contained herein.", "score": 0.709802, "arguments": [{"text": "07 November 2018", "location": [10179, 10195], "entities": [{"type": "Date", "text": "07 November 2018"}]}, {"text": "published", "location": [10153, 10162], "entities": [{"type": "EventCommunication", "text": "published"}]}]}, {"type": "agentOf", "sentence": "Sale 18,700 4,626.1604 JPY Ordinary NPV Sale 83,000 4,625.4807 JPY Ordinary NPV Sale 171,600 4,625.7646 JPY Ordinary NPV Sale 226,600 4,623.9324 JPY Ordinary NPV Sale 230,200 4,623.0638 JPY Ordinary NPV Sale 422,400 4,623.7852 JPY (b) Cash-settled derivative transactions Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV CFD Long 4,400 4,561.5438 JPY Ordinary NPV SWAP Expires 06/12/2018 Long 466,100 4,562.0000 JPY Ordinary NPV CFD Short 15,000 4,628.0000 JPY Ordinary NPV SWAP Expires 06/11/2018 Short 466,100 4,650.0000 JPY (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American,", "score": 0.499051, "arguments": [{"text": "i", "location": [5257, 5258], "entities": [{"type": "Person", "text": "JPY Ordinary NPV Sale"}]}, {"text": "Writing", "location": [5260, 5267], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "employedBy", "sentence": "European etc. Expiry date Option money paid/ received per unit (ii) Exercise Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) 4.", "score": 0.582263, "arguments": [{"text": "Price", "location": [5857, 5862], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "unit", "location": [5867, 5871], "entities": [{"type": "Organization", "text": "Type e.g. American"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [6231, 6237], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [6248, 6255], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "YES Date of disclosure: 7 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.817481, "arguments": [{"text": "Rule 8", "location": [7156, 7162], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [7170, 7174], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "employedBy", "sentence": "Note 5(i) on Rule 8 of the Takeover Code (the 'Code') 1.", "score": 0.846433, "arguments": [{"text": "Rule 8", "location": [7602, 7608], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Takeover Code", "location": [7616, 7629], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [7237, 7261], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [7229, 7234], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [9748, 9772], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [9740, 9745], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [7396, 7401], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [7415, 7442], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [9907, 9912], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [9926, 9953], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "managerOf", "sentence": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC.", "score": 0.419441, "arguments": [{"text": "person", "location": [7678, 7684], "entities": [{"type": "Person", "text": "PERSON"}]}, {"text": "Barclays PLC", "location": [7710, 7722], "entities": [{"type": "Organization", "text": "BARCLAYS PLC\nAttachments\nOriginal", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "View source version on businesswire.com: https://www.businesswire.com/news/home/20181107005584/en/ BARCLAYS PLC Source: BARCLAYS PLC Attachments Original document Permalink Disclaimer Barclays plc published this content on 07 November 2018 and is solely responsible for the information contained herein.", "score": 0.986041, "arguments": [{"text": "Permalink Disclaimer\nBarclays plc", "location": [10119, 10152], "entities": [{"type": "Organization", "text": "BARCLAYS PLC\nAttachments\nOriginal", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "published", "location": [10153, 10162], "entities": [{"type": "EventCommunication", "text": "published"}]}]}], "keywords": [{"text": "JPY Ordinary NPV", "sentiment": {"score": -0.285234, "label": "negative"}, "relevance": 0.992107}, {"text": "Ordinary NPV Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.822548}, {"text": "Ordinary NPV Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.762172}, {"text": "Ordinary NPV Interests", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.506643}, {"text": "Ordinary NPV CFD", "sentiment": {"score": -0.285234, "label": "negative"}, "relevance": 0.503674}, {"text": "Ordinary NPV SWAP", "sentiment": {"score": -0.285234, "label": "negative"}, "relevance": 0.503246}, {"text": "USD Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.500774}, {"text": "securities Ordinary NPV", "sentiment": {"score": -0.285234, "label": "negative"}, "relevance": 0.500464}, {"text": "relevant securities", "sentiment": {"score": 0.229926, "label": "positive"}, "relevance": 0.482327}, {"text": "NPV Call Options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.459893}, {"text": "NPV Put Options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.446713}, {"text": "NPV CFD Short", "sentiment": {"score": -0.285234, "label": "negative"}, "relevance": 0.437391}, {"text": "Options Written", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.419061}, {"text": "relevant security", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.403669}, {"text": "supplemental form", "sentiment": {"score": 0.425721, "label": "positive"}, "relevance": 0.367731}, {"text": "open positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.362334}, {"text": "Product description e.g.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.356007}, {"text": "relevant security Product", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.355137}, {"text": "security Product description", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.354644}, {"text": "Market Surveillance Unit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.352746}, {"text": "short positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.351997}, {"text": "Options Purchased", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.351922}, {"text": "unit security securities", "sentiment": {"score": -0.285234, "label": "negative"}, "relevance": 0.351669}, {"text": "class", "sentiment": {"score": -0.268259, "label": "negative"}, "relevance": 0.350683}, {"text": "disclosure", "sentiment": {"score": 0.210866, "label": "positive"}, "relevance": 0.348787}, {"text": "securities ADR Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.338987}, {"text": "person", "sentiment": {"score": 0.210866, "label": "positive"}, "relevance": 0.33562}, {"text": "details", "sentiment": {"score": 0.0877267, "label": "positive"}, "relevance": 0.335334}, {"text": "TAKEDA PHARMACEUTICAL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.335153}, {"text": "new securities", "sentiment": {"score": 0.582177, "label": "positive"}, "relevance": 0.334935}, {"text": "Barclays PLC.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.334848}, {"text": "KEY INFORMATION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.333999}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.333916}, {"text": "number", "sentiment": {"score": -0.285234, "label": "negative"}, "relevance": 0.333742}, {"text": "relevant Purchase/sale Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.333469}, {"text": "additional class", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.333116}, {"text": "USD ADR Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.332749}, {"text": "Takeover Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.332619}, {"text": "monetary amounts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.332286}, {"text": "agreements", "sentiment": {"score": 0.0334629, "label": "positive"}, "relevance": 0.332235}, {"text": "relevant description reference", "sentiment": {"score": -0.285234, "label": "negative"}, "relevance": 0.332088}, {"text": "Short Positions Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.331754}, {"text": "relevant security Nature", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.331498}, {"text": "disclosure requirements", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.331452}, {"text": "stock-settled derivative positions", "sentiment": {"score": -0.27481, "label": "negative"}, "relevance": 0.331302}, {"text": "securities Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.331249}, {"text": "PUBLIC OPENING POSITION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.331066}, {"text": "cash-settled derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.330031}, {"text": "stock-settled derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.329867}, {"text": "e.g. call option", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.329707}]}, "extracted_metadata": {"sha1": "824e9883ad3f462dd7470dc5a56369bfed2e0885", "filename": "1541603417166.zip-a9f7c06f59bdd6b9afc7bef2426eb54b.xml", "file_type": "json"}, "external_links": ["http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.thetakeoverpanel.org.uk&esheet=51894309&newsitemid=20181107005584&lan=en-US&anchor=www.thetakeoverpanel.org.uk&index=2&md5=996edf9298ced549bdba5d34f6555a0d", "http://otp.investis.com/clients/uk/barclays1/rns/regulatory-story.aspx?cid=68&newsid=1205873", "https://www.businesswire.com/news/home/20181107005584/en/", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.thetakeoverpanel.org.uk&esheet=51894309&newsitemid=20181107005584&lan=en-US&anchor=www.thetakeoverpanel.org.uk&index=1&md5=e6ccf30097628a2c1e9b2ae77823ff69", "http://www.publicnow.com/view/259891249324171CC63A76BF03D01190F5790CF9"], "title": "Barclays : Form 8.3 - TAKEDA PHARMACEUTICAL CO LTD | MarketScreener", "forum_title": "Stock market news - Company News  - MarketScreener.com"}, {"id": "LS_uv3Dm9qnZdJKz_J7-visqI2nMuz-akUAvvana6j2aUJ2eVRSvqExh7O65KLKs", "result_metadata": {"score": 32.94609}, "author": "www.4-traders.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0.325017, "label": "positive"}, "text": "Barclays", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.725716, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "TAKEDA PHARMACEUTICAL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.967508}, {"text": "AMENDMENT | MarketScreener", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.828342}, {"text": "Barclays", "sentiment": {"score": 0.325017, "label": "positive"}, "relevance": 0.697545}]}, "crawl_date": "2018-11-08T12:51:48Z", "url": "https://www.marketscreener.com/BARCLAYS-9583556/news/Barclays-Form-8-3-TAKEDA-PHARMACEUTICAL-CO-LTD-AMENDMENT-27570553/", "host": "marketscreener.com", "text": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC. are being disclosed: Name of offeror/offeree in relation to whose TAKEDA PHARMACEUTICAL CO LTD relevant securities this from relates: 2.", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-08T00:00:00Z", "enriched_text": {"entities": [{"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS PLC", "relevance": 0.749883, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Barclays PLC.", "relevance": 0.641113, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.597344, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SHIRE PLC", "relevance": 0.53258, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.516667, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Class of Product Nature", "relevance": 0.509454, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.435359, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Large Holdings Regulatory Operations", "relevance": 0.4259, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.410617, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,569,600 1.33%", "relevance": 0.410617, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,285,826 1.42%", "relevance": 0.410617, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,344,341 1.42%", "relevance": 0.410617, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,909,404 1.50%", "relevance": 0.410617, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "13,320,114 1.68%", "relevance": 0.410617, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,199,767 4.17%", "relevance": 0.410617, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "421,110 0.05%", "relevance": 0.410617, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "989,600 0.12%", "relevance": 0.410617, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.410617, "type": "Quantity"}], "sentiment": {"document": {"score": 0.108646, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "POSITIONS OF THE PERSON", "keywords": [{"text": "POSITIONS"}, {"text": "PERSON"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "options) and agreements to purchase/sell: 10,569,600 1.33% 989,600 0.12% TOTAL: 33,199,767 4.17% 13,320,114 1.68% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "agreements"}, {"text": "options"}, {"text": "TOTAL"}], "entities": [{"type": "Quantity", "text": "10,569,600 1.33"}, {"type": "Quantity", "text": "13,320,114 1.68"}, {"type": "Quantity", "text": "33,199,767 4.17"}, {"type": "Quantity", "text": "989,600 0.12"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,344,341 1.42% 11,909,404 1.50% (2) Cash-settled derivatives: 11,285,826 1.42% 421,110 0.05% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,569,600 1.33% 989,600 0.12% TOTAL: 33,199,767 4.17% 13,320,114 1.68% All interests and all short positions should be disclosed.", "object": {"text": "Stock-settled derivatives", "keywords": [{"text": "Stock-settled derivatives"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "33,199,767 4.17% 13,320,114 1.68% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}], "entities": [{"type": "Quantity", "text": "13,320,114 1.68"}, {"type": "Quantity", "text": "33,199,767 4.17"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,344,341 1.42% 11,909,404 1.50% (2) Cash-settled derivatives: 11,285,826 1.42% 421,110 0.05% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,569,600 1.33% 989,600 0.12% TOTAL: 33,199,767 4.17% 13,320,114 1.68% All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors' and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors' and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Class of relevant security Nature", "keywords": [{"text": "relevant security Nature"}, {"text": "Class"}]}, "sentence": " Class of relevant security Nature of dealing e.g. subscription, conversion", "object": {"text": "e.g. subscription, conversion", "keywords": [{"text": "e.g. subscription"}, {"text": "conversion"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "Irrevocable commitments and letters of intent", "keywords": [{"text": "Irrevocable commitments"}, {"text": "intent"}, {"text": "letters"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities", "keywords": [{"text": "option arrangement"}, {"text": "relevant securities"}, {"text": "indemnity"}, {"text": "agreement"}]}, "action": {"verb": {"text": "include", "tense": "future", "negated": true}, "text": "included", "normalized": "include"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any other person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "to: (i) the voting rights of any relevant securities under any option", "keywords": [{"text": "voting rights"}, {"text": "relevant securities"}, {"text": "option"}], "entities": []}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "020 3134 7213 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " YES Date of disclosure: 8 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "The Panel's Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "disclosure requirements"}, {"text": "relation"}, {"text": "consultation"}, {"text": "Code"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "details", "keywords": [{"text": "details"}]}, "sentence": " Full details should be given so that the nature of the interest or position can be fully understood: It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.", "object": {"text": "on a Supplemental Form (Open Positions)", "keywords": [{"text": "Supplemental Form"}, {"text": "Open Positions"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "to provide", "normalized": "to provide"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel's Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "disclosure requirements"}, {"text": "relation"}, {"text": "consultation"}, {"text": "Code"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "Barclays plc", "keywords": [{"text": "Barclays plc"}], "entities": [{"type": "Company", "text": "BARCLAYS PLC", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}]}, "sentence": " Barclays plc published this content on 08 November 2018 and is solely responsible for the information contained herein.", "object": {"text": "this content", "keywords": [{"text": "content"}]}, "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}, {"subject": {"text": "by Public", "keywords": [{"text": "Public"}]}, "sentence": " Distributed by Public, unedited and unaltered, on 08 November 2018 12:23:09 UTC", "object": {"text": "09 UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "Distributed", "tense": "past"}, "text": "Distributed", "normalized": "Distributed"}}], "concepts": [{"text": "Option", "relevance": 0.974065, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.775305, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.71168, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Put option", "relevance": 0.616899, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Stock", "relevance": 0.613042, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Option style", "relevance": 0.432538, "dbpedia_resource": "http://dbpedia.org/resource/Option_style"}, {"text": "Derivative", "relevance": 0.425921, "dbpedia_resource": "http://dbpedia.org/resource/Derivative_(finance)"}, {"text": "Options", "relevance": 0.390147, "dbpedia_resource": "http://dbpedia.org/resource/Options"}, {"text": "Moneyness", "relevance": 0.381581, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}, {"text": "Security", "relevance": 0.357589, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "Barclays", "relevance": 0.3414, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}, {"text": "Bond", "relevance": 0.330724, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Contract", "relevance": 0.326258, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}], "categories": [{"score": 0.575672, "label": "/real estate/buying and selling homes"}, {"score": 0.476772, "label": "/finance/financial news"}, {"score": 0.447184, "label": "/finance/investing"}], "relations": [{"type": "agentOf", "sentence": "settled derivative transactions Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV SWAP Long 53 4,659.5340 JPY Ordinary NPV SWAP Long 112 4,686.1295 JPY Ordinary NPV SWAP Long 225 4,686.7046 JPY Ordinary NPV SWAP Long 281 4,691.8119 JPY Ordinary NPV SWAP Long 300 4,704.1239 JPY Ordinary NPV SWAP Long 705 4,709.2790 JPY Ordinary NPV SWAP Long 1,417 4,693.5204 JPY Ordinary NPV SWAP Long 2,200 4,701.5000 JPY Ordinary NPV SWAP Long 2,227 4,654.8284 JPY Ordinary NPV SWAP Long 4,544 4,667.9176 JPY Ordinary NPV SWAP Long 6,947 4,686.3828 JPY Ordinary NPV SWAP Long 11,531 4,700.6271 JPY Ordinary NPV SWAP Long 22,958 4,705.2680 JPY Ordinary NPV CFD Short 1,400 4,675.4671 JPY Ordinary NPV SWAP Short 2,200 4,701.5000 JPY (c) Stock-settled derivative transactions (including options) (i) Writing, selling,", "score": 0.682599, "arguments": [{"text": "i", "location": [6305, 6306], "entities": [{"type": "Person", "text": "JPY Ordinary NPV SWAP Short"}]}, {"text": "Writing", "location": [6308, 6315], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [7279, 7285], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [7296, 7303], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "YES Date of disclosure: 8 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.817481, "arguments": [{"text": "Rule 8", "location": [8204, 8210], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [8218, 8222], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "employedBy", "sentence": "Note 5(i) on Rule 8 of the Takeover Code (the 'Code') 1.", "score": 0.846433, "arguments": [{"text": "Rule 8", "location": [8650, 8656], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Takeover Code", "location": [8664, 8677], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [8285, 8309], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [8277, 8282], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [10865, 10889], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [10857, 10862], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [8444, 8449], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [8463, 8490], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [11024, 11029], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [11043, 11070], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "managerOf", "sentence": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC.", "score": 0.419441, "arguments": [{"text": "person", "location": [8726, 8732], "entities": [{"type": "Person", "text": "PERSON"}]}, {"text": "Barclays PLC", "location": [8758, 8770], "entities": [{"type": "Organization", "text": "BARCLAYS PLC\nAttachments\nOriginal", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "managerOf", "sentence": "Sep 2019 Ordinary NPV Call Options Written -70,000 4598.0000 European 14 Jun 2019 Ordinary NPV Put Options Purchased -48,000 4625.0000 European 12 Oct 2018 Ordinary NPV Put Options Purchased -39,000 5781.0000 European 14 Dec 2018 Ordinary NPV Put Options Written 70,000 4598.0000 European 14 Jun 2019 Ordinary NPV Put Options Written 75,900 4286.5200 European 6 Sep 2019 Ordinary NPV Put Options Written 78,000 5781.0000 European 14 Dec 2018 Ordinary NPV Put Options Written 104,700 5065.8300 European 17 Apr 2019 Ordinary NPV Put Options Written 114,000 4750.0200 European 14 May 2019 Ordinary NPV Call Options Purchased 10,000,000 4528.6397 European 5 Oct 2018 Ordinary NPV Put Options Written 10,000,000 4528.6397 European 5 Oct 2018 3.", "score": 0.325547, "arguments": [{"text": "5", "location": [10436, 10437], "entities": [{"type": "Person", "text": "5"}]}, {"text": "European", "location": [10427, 10435], "entities": [{"type": "GeopoliticalEntity", "text": "European", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "agentOf", "sentence": "View source version on businesswire.com: https://www.businesswire.com/news/home/20181108005410/en/ BARCLAYS PLC Source: BARCLAYS PLC Attachments Original document Permalink Disclaimer Barclays plc published this content on 08 November 2018 and is solely responsible for the information contained herein.", "score": 0.986041, "arguments": [{"text": "Permalink Disclaimer\nBarclays plc", "location": [11236, 11269], "entities": [{"type": "Organization", "text": "BARCLAYS PLC\nAttachments\nOriginal", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "published", "location": [11270, 11279], "entities": [{"type": "EventCommunication", "text": "published"}]}]}, {"type": "timeOf", "sentence": "View source version on businesswire.com: https://www.businesswire.com/news/home/20181108005410/en/ BARCLAYS PLC Source: BARCLAYS PLC Attachments Original document Permalink Disclaimer Barclays plc published this content on 08 November 2018 and is solely responsible for the information contained herein.", "score": 0.709802, "arguments": [{"text": "08 November 2018", "location": [11296, 11312], "entities": [{"type": "Date", "text": "08 November 2018"}]}, {"text": "published", "location": [11270, 11279], "entities": [{"type": "EventCommunication", "text": "published"}]}]}], "keywords": [{"text": "JPY Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.93111}, {"text": "Ordinary NPV Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.597068}, {"text": "Ordinary NPV Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519388}, {"text": "Ordinary NPV SWAP", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.384288}, {"text": "NPV SWAP Long", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.356822}, {"text": "Ordinary NPV Interests", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.285142}, {"text": "USD Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.280337}, {"text": "securities Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.277755}, {"text": "Ordinary NPV CFD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.274744}, {"text": "relevant securities", "sentiment": {"score": 0.229926, "label": "positive"}, "relevance": 0.243285}, {"text": "NPV Call Options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.240597}, {"text": "NPV Put Options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.225527}, {"text": "NPV SWAP Short", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.222889}]}, "extracted_metadata": {"sha1": "45a8defa10f32a3467367cbad525778caf1305d2", "filename": "1541681508293.zip-d1cd739207c612d148860e82559ddf55.xml", "file_type": "json"}, "external_links": ["https://www.businesswire.com/news/home/20181108005410/en/", "http://www.publicnow.com/view/2F31B2332DDA4296AA4888EAC8992D4A6C67ED9E", "http://otp.investis.com/clients/uk/barclays1/rns/regulatory-story.aspx?cid=68&newsid=1206114"], "title": "Barclays : Form 8.3 - TAKEDA PHARMACEUTICAL CO LTD - AMENDMENT | MarketScreener", "forum_title": "Stock market news - Company News  - MarketScreener.com"}, {"id": "m4w5nzuhL8ThnRHF0uAlM5YKarCzrVI-Pf3sUE1N0gagMDrM7tVW7b4X3t-wo-Na", "result_metadata": {"score": 32.890762}, "author": "businesswire.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cholera", "relevance": 0.33, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "InfectiousDisease", "Disease"], "name": "Cholera", "dbpedia_resource": "http://dbpedia.org/resource/Cholera"}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [], "categories": [{"score": 0.593318, "label": "/health and fitness/disease"}, {"score": 0.478879, "label": "/health and fitness/disease/epidemic"}, {"score": 0.427229, "label": "/health and fitness/disease/cold and flu"}], "relations": [], "keywords": [{"text": "Trends Analysis Report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.969409}, {"text": "Cholera Vaccines", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.956389}, {"text": "Global Forecast", "sentiment": {"score": -0.486152, "label": "negative"}, "relevance": 0.77693}, {"text": "Market Size", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.670125}, {"text": "ResearchAndMarkets.com", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.605573}, {"text": "Dukoral", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.349835}, {"text": "Shanchol", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.349272}, {"text": "Vaxchora", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.348709}, {"text": "Share", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.347301}]}, "crawl_date": "2018-11-07T20:12:47Z", "url": "https://www.businesswire.com/news/home/20181107005549/en/Cholera-Vaccines-Dukoral-Shanchol-Vaxchora-Market-Size", "host": "businesswire.com", "text": "Takeda Pharmaceutical Co., Ltd.", "main_image_url": "https://mms.businesswire.com/media/20181107005549/en/371054/23/ResearchAndMarkets_800px.jpg", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-07T14:22:00-06:00", "enriched_text": {"entities": [{"count": 4, "sentiment": {"score": -0.379085, "label": "negative"}, "text": "cholera", "relevance": 0.916642, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "InfectiousDisease", "Disease"], "name": "Cholera", "dbpedia_resource": "http://dbpedia.org/resource/Cholera"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shantha Biotechnics Private Limited", "relevance": 0.409032, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Astellas Pharma, Inc", "relevance": 0.289975, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ResearchAndMarkets.com", "relevance": 0.283406, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "United Nations Organization", "relevance": 0.267764, "type": "Organization", "disambiguation": {"subtype": ["MembershipOrganization", "AwardWinner", "GovernmentalBody", "TouristAttraction"], "name": "United Nations", "dbpedia_resource": "http://dbpedia.org/resource/United_Nations"}}, {"count": 1, "sentiment": {"score": -0.459628, "label": "negative"}, "text": "Government of Haiti", "relevance": 0.252443, "type": "Organization"}, {"count": 1, "sentiment": {"score": -0.384021, "label": "negative"}, "text": "Global Task Force", "relevance": 0.248935, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0.329043, "label": "positive"}, "text": "DUBLIN", "relevance": 0.248768, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co.", "relevance": 0.248322, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": -0.384526, "label": "negative"}, "text": "USD", "relevance": 0.24751, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mitsubishi Tanabe Pharma Corporation", "relevance": 0.243346, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.237882, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.236676, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.234342, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": -0.317572, "label": "negative"}, "text": "Merck & Co.", "relevance": 0.232877, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Haitian Government", "relevance": 0.229544, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Competitive Landscape", "relevance": 0.227707, "type": "Facility"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.225252, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AstraZeneca", "relevance": 0.222265, "type": "Company", "disambiguation": {"subtype": [], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline", "relevance": 0.220055, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Laura Wood", "relevance": 0.218236, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Executive", "relevance": 0.214181, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Senior Press Manager", "relevance": 0.204189, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer", "relevance": 0.201192, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "PaxVax", "relevance": 0.198694, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GSK", "relevance": 0.175434, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "press@researchandmarkets.com", "relevance": 0.175434, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "48 hours", "relevance": 0.175434, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10-year", "relevance": 0.175434, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "2025", "relevance": 0.175434, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "8.2%", "relevance": 0.175434, "type": "Quantity"}], "sentiment": {"document": {"score": -0.1746, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "2025\" report", "keywords": [{"text": "report"}], "entities": [{"type": "Quantity", "text": "2025\""}]}, "sentence": "DUBLIN- The \"Cholera Vaccines Market Size, Share & Trends Analysis Report By Product (Dukoral, Shanchol, Vaxchora), By Region (North America, APAC, Europe, MEA, Latin America), And Segment Forecasts, 2018 - 2025\" report has been added to ResearchAndMarkets.com's offering.", "object": {"text": "added to ResearchAndMarkets.com's offering", "keywords": [{"text": "ResearchAndMarkets.com"}, {"text": "offering"}], "entities": [{"type": "Company", "text": "ResearchAndMarkets.com"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "DUBLIN- The \"Cholera Vaccines Market Size, Share & Trends Analysis Report By Product (Dukoral, Shanchol, Vaxchora), By Region (North America, APAC, Europe, MEA, Latin America), And Segment Forecasts, 2018 - 2025\" report", "keywords": [{"text": "Cholera Vaccines Market"}, {"text": "Trends Analysis Report"}, {"text": "Segment Forecasts"}, {"text": "Latin America"}], "entities": [{"type": "Location", "text": "DUBLIN", "disambiguation": {"subtype": ["City"]}}, {"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Quantity", "text": "2025\""}]}, "sentence": "DUBLIN- The \"Cholera Vaccines Market Size, Share & Trends Analysis Report By Product (Dukoral, Shanchol, Vaxchora), By Region (North America, APAC, Europe, MEA, Latin America), And Segment Forecasts, 2018 - 2025\" report has been added to ResearchAndMarkets.com's offering.", "object": {"text": "to ResearchAndMarkets.com's offering", "keywords": [{"text": "ResearchAndMarkets.com"}, {"text": "offering"}], "entities": [{"type": "Company", "text": "ResearchAndMarkets.com"}]}, "action": {"verb": {"text": "add", "tense": "past"}, "text": "has been added", "normalized": "have be add"}}, {"subject": {"text": "The global cholera vaccines market size", "keywords": [{"text": "global cholera vaccines"}, {"text": "market size"}], "entities": [{"type": "HealthCondition", "text": "cholera", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "InfectiousDisease", "Disease"], "name": "Cholera", "dbpedia_resource": "http://dbpedia.org/resource/Cholera"}}]}, "sentence": " The global cholera vaccines market size is expected to reach USD 117.1 million by 2025, exhibiting a CAGR of 8.2% during the forecast period.", "object": {"text": "USD 117.1 million", "keywords": [{"text": "USD"}], "entities": [{"type": "Location", "text": "USD", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "reach", "tense": "future"}, "text": "is expected to reach", "normalized": "be expect to reach"}}, {"subject": {"text": "a CAGR of 8.2%", "keywords": [{"text": "CAGR"}], "entities": [{"type": "Quantity", "text": "8.2"}]}, "sentence": " The global cholera vaccines market size is expected to reach USD 117.1 million by 2025, exhibiting a CAGR of 8.2% during the forecast period.", "action": {"verb": {"text": "exhibit", "tense": "present"}, "text": "exhibiting", "normalized": "exhibit"}}, {"subject": {"text": "Increase in number of initiatives and rising awareness about cholera", "keywords": [{"text": "cholera"}, {"text": "initiatives"}, {"text": "number"}, {"text": "awareness"}], "entities": [{"type": "HealthCondition", "text": "cholera", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "InfectiousDisease", "Disease"], "name": "Cholera", "dbpedia_resource": "http://dbpedia.org/resource/Cholera"}}]}, "sentence": " Increase in number of initiatives and rising awareness about cholera are major factors contributing toward market growth.", "object": {"text": "major factors contributing toward market growth", "keywords": [{"text": "major factors"}, {"text": "market growth"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "by cholera", "keywords": [{"text": "cholera"}], "entities": [{"type": "HealthCondition", "text": "cholera", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "InfectiousDisease", "Disease"], "name": "Cholera", "dbpedia_resource": "http://dbpedia.org/resource/Cholera"}}]}, "sentence": " Governments in regions affected by cholera are striving to eliminate the disease by developing a strong public health and sanitation infrastructure.", "object": {"text": "Governments in regions", "keywords": [{"text": "Governments"}, {"text": "regions"}]}, "action": {"verb": {"text": "affect", "tense": "past"}, "text": "affected", "normalized": "affect"}}, {"subject": {"text": "the Government of Haiti", "keywords": [{"text": "Haiti"}, {"text": "Government"}], "entities": [{"type": "Organization", "text": "Government of Haiti"}]}, "sentence": " In February 2013, the Government of Haiti launched a 10-year National Cholera Elimination Plan.", "object": {"text": "a 10-year National Cholera Elimination Plan", "keywords": [{"text": "10-year National Cholera"}, {"text": "Elimination Plan"}], "entities": [{"type": "Quantity", "text": "10-year"}]}, "action": {"verb": {"text": "launch", "tense": "past"}, "text": "launched", "normalized": "launch"}}, {"subject": {"text": "The United Nations Organization", "keywords": [{"text": "United Nations Organization"}], "entities": [{"type": "Organization", "text": "United Nations Organization", "disambiguation": {"subtype": ["MembershipOrganization", "AwardWinner", "GovernmentalBody", "TouristAttraction"], "name": "United Nations", "dbpedia_resource": "http://dbpedia.org/resource/United_Nations"}}]}, "sentence": " The United Nations Organization has made elimination of cholera a key UN priority and offers support to the Haitian Government by establishing a mechanism to respond to an alert within 48 hours, household visits, and sensitization campaigns.", "object": {"text": "made elimination of cholera a key UN priority", "keywords": [{"text": "key UN priority"}, {"text": "cholera"}, {"text": "elimination"}], "entities": [{"type": "HealthCondition", "text": "cholera", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "InfectiousDisease", "Disease"], "name": "Cholera", "dbpedia_resource": "http://dbpedia.org/resource/Cholera"}}, {"type": "Organization", "text": "United Nations Organization", "disambiguation": {"subtype": ["MembershipOrganization", "AwardWinner", "GovernmentalBody", "TouristAttraction"], "name": "United Nations", "dbpedia_resource": "http://dbpedia.org/resource/United_Nations"}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The United Nations Organization", "keywords": [{"text": "United Nations Organization"}], "entities": [{"type": "Organization", "text": "United Nations Organization", "disambiguation": {"subtype": ["MembershipOrganization", "AwardWinner", "GovernmentalBody", "TouristAttraction"], "name": "United Nations", "dbpedia_resource": "http://dbpedia.org/resource/United_Nations"}}]}, "sentence": " The United Nations Organization has made elimination of cholera a key UN priority and offers support to the Haitian Government by establishing a mechanism to respond to an alert within 48 hours, household visits, and sensitization campaigns.", "object": {"text": "elimination of cholera a key UN priority", "keywords": [{"text": "key UN priority"}, {"text": "cholera"}, {"text": "elimination"}], "entities": [{"type": "HealthCondition", "text": "cholera", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "InfectiousDisease", "Disease"], "name": "Cholera", "dbpedia_resource": "http://dbpedia.org/resource/Cholera"}}, {"type": "Organization", "text": "United Nations Organization", "disambiguation": {"subtype": ["MembershipOrganization", "AwardWinner", "GovernmentalBody", "TouristAttraction"], "name": "United Nations", "dbpedia_resource": "http://dbpedia.org/resource/United_Nations"}}]}, "action": {"verb": {"text": "make", "tense": "past"}, "text": "has made", "normalized": "have make"}}, {"subject": {"text": "The United Nations Organization", "keywords": [{"text": "United Nations Organization"}], "entities": [{"type": "Organization", "text": "United Nations Organization", "disambiguation": {"subtype": ["MembershipOrganization", "AwardWinner", "GovernmentalBody", "TouristAttraction"], "name": "United Nations", "dbpedia_resource": "http://dbpedia.org/resource/United_Nations"}}]}, "sentence": " The United Nations Organization has made elimination of cholera a key UN priority and offers support to the Haitian Government by establishing a mechanism to respond to an alert within 48 hours, household visits, and sensitization campaigns.", "object": {"text": "support to the Haitian Government", "keywords": [{"text": "Haitian Government"}, {"text": "support"}], "entities": [{"type": "Organization", "text": "Haitian Government"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "The United Nations Organization", "keywords": [{"text": "United Nations Organization"}], "entities": [{"type": "Organization", "text": "United Nations Organization", "disambiguation": {"subtype": ["MembershipOrganization", "AwardWinner", "GovernmentalBody", "TouristAttraction"], "name": "United Nations", "dbpedia_resource": "http://dbpedia.org/resource/United_Nations"}}]}, "sentence": " The United Nations Organization has made elimination of cholera a key UN priority and offers support to the Haitian Government by establishing a mechanism to respond to an alert within 48 hours, household visits, and sensitization campaigns.", "object": {"text": "a mechanism to respond to an alert within 48 hours, household visits, and sensitization campaigns", "keywords": [{"text": "sensitization campaigns"}, {"text": "household visits"}, {"text": "mechanism"}], "entities": [{"type": "Quantity", "text": "48 hours"}]}, "action": {"verb": {"text": "establish", "tense": "present"}, "text": "establishing", "normalized": "establish"}}, {"subject": {"text": "various research projects and studies, such as epidemiological and anthropological studies,", "keywords": [{"text": "various research projects"}, {"text": "anthropological studies"}]}, "sentence": " Furthermore, various research projects and studies, such as epidemiological and anthropological studies, are being conducted in Africa.", "object": {"text": "being conducted in Africa", "keywords": [{"text": "Africa"}], "entities": [{"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "various research projects and studies, such as epidemiological and anthropological studies,", "keywords": [{"text": "various research projects"}, {"text": "anthropological studies"}]}, "sentence": " Furthermore, various research projects and studies, such as epidemiological and anthropological studies, are being conducted in Africa.", "object": {"text": "conducted in Africa", "keywords": [{"text": "Africa"}], "entities": [{"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "being", "normalized": "be"}}, {"subject": {"text": "various research projects and studies, such as epidemiological and anthropological studies,", "keywords": [{"text": "various research projects"}, {"text": "anthropological studies"}]}, "sentence": " Furthermore, various research projects and studies, such as epidemiological and anthropological studies, are being conducted in Africa.", "action": {"verb": {"text": "conduct", "tense": "past"}, "text": "are being conducted", "normalized": "be be conduct"}}, {"subject": {"text": "using rapid diagnostics tests to detect Vibrio cholerae in samples of water to understand epidemic diffusion mechanisms and anticipate outbreaks", "keywords": [{"text": "epidemic diffusion mechanisms"}, {"text": "rapid diagnostics tests"}, {"text": "Vibrio cholerae"}, {"text": "outbreaks"}]}, "sentence": " Ongoing studies include using rapid diagnostics tests to detect Vibrio cholerae in samples of water to understand epidemic diffusion mechanisms and anticipate outbreaks.", "object": {"text": "Ongoing studies", "keywords": [{"text": "Ongoing studies"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "Ongoing studies", "keywords": [{"text": "Ongoing studies"}]}, "sentence": " Ongoing studies include using rapid diagnostics tests to detect Vibrio cholerae in samples of water to understand epidemic diffusion mechanisms and anticipate outbreaks.", "object": {"text": "rapid diagnostics tests", "keywords": [{"text": "rapid diagnostics tests"}]}, "action": {"verb": {"text": "use", "tense": "present"}, "text": "include using", "normalized": "include use"}}, {"subject": {"text": "rapid diagnostics tests", "keywords": [{"text": "rapid diagnostics tests"}]}, "sentence": " Ongoing studies include using rapid diagnostics tests to detect Vibrio cholerae in samples of water to understand epidemic diffusion mechanisms and anticipate outbreaks.", "object": {"text": "Vibrio cholerae", "keywords": [{"text": "Vibrio cholerae"}]}, "action": {"verb": {"text": "detect", "tense": "future"}, "text": "to detect", "normalized": "to detect"}}, {"subject": {"text": "Ongoing studies", "keywords": [{"text": "Ongoing studies"}]}, "sentence": " Ongoing studies include using rapid diagnostics tests to detect Vibrio cholerae in samples of water to understand epidemic diffusion mechanisms and anticipate outbreaks.", "object": {"text": "outbreaks", "keywords": [{"text": "outbreaks"}]}, "action": {"verb": {"text": "anticipate", "tense": "present"}, "text": "anticipate", "normalized": "anticipate"}}, {"subject": {"text": "The Cholera Platform", "keywords": [{"text": "Cholera Platform"}]}, "sentence": " The Cholera Platform is working with the Global Task Force for Cholera Control (GTFCC) WASH working group.", "object": {"text": "working with the Global Task Force for Cholera Control (GTFCC) WASH working group", "keywords": [{"text": "Global Task Force"}, {"text": "Cholera Control"}, {"text": "WASH"}, {"text": "GTFCC"}], "entities": [{"type": "Organization", "text": "Global Task Force"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "This association", "keywords": [{"text": "association"}]}, "sentence": " This association aims to develop a method for conducting case studies to control and prevent the disease.", "object": {"text": "to develop a method for conducting case studies to control and prevent the disease", "keywords": [{"text": "case studies"}, {"text": "method"}, {"text": "disease"}]}, "action": {"verb": {"text": "aim", "tense": "present"}, "text": "aims", "normalized": "aim"}}, {"subject": {"text": "This association", "keywords": [{"text": "association"}]}, "sentence": " This association aims to develop a method for conducting case studies to control and prevent the disease.", "object": {"text": "a method for conducting case studies to control and prevent the disease", "keywords": [{"text": "case studies"}, {"text": "method"}, {"text": "disease"}]}, "action": {"verb": {"text": "develop", "tense": "future"}, "text": "aims to develop", "normalized": "aim to develop"}}, {"subject": {"text": "This association", "keywords": [{"text": "association"}]}, "sentence": " This association aims to develop a method for conducting case studies to control and prevent the disease.", "object": {"text": "the disease", "keywords": [{"text": "disease"}]}, "action": {"verb": {"text": "prevent", "tense": "present"}, "text": "prevent", "normalized": "prevent"}}, {"subject": {"text": "Some of the key players", "keywords": [{"text": "key players"}]}, "sentence": " Some of the key players are Valneva SE; Shantha Biotechnics Private Limited; and PaxVax, Inc.", "object": {"text": "Valneva SE", "keywords": [{"text": "Valneva SE"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}], "concepts": [{"text": "Cholera", "relevance": 0.973136, "dbpedia_resource": "http://dbpedia.org/resource/Cholera"}, {"text": "Vibrio cholerae", "relevance": 0.716571, "dbpedia_resource": "http://dbpedia.org/resource/Vibrio_cholerae"}, {"text": "United Nations", "relevance": 0.636086, "dbpedia_resource": "http://dbpedia.org/resource/United_Nations"}, {"text": "GlaxoSmithKline", "relevance": 0.556018, "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}, {"text": "Epidemiology", "relevance": 0.555202, "dbpedia_resource": "http://dbpedia.org/resource/Epidemiology"}, {"text": "Emergent BioSolutions", "relevance": 0.5497, "dbpedia_resource": "http://dbpedia.org/resource/Emergent_BioSolutions"}, {"text": "Haiti", "relevance": 0.482701, "dbpedia_resource": "http://dbpedia.org/resource/Haiti"}, {"text": "Anthropology", "relevance": 0.462867, "dbpedia_resource": "http://dbpedia.org/resource/Anthropology"}, {"text": "Government", "relevance": 0.453387, "dbpedia_resource": "http://dbpedia.org/resource/Government"}, {"text": "Microbiology", "relevance": 0.412248, "dbpedia_resource": "http://dbpedia.org/resource/Microbiology"}, {"text": "The Key", "relevance": 0.407101, "dbpedia_resource": "http://dbpedia.org/resource/The_Key_(novel)"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.406859, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Trend", "relevance": 0.406762, "dbpedia_resource": "http://dbpedia.org/resource/Trend"}, {"text": "Politics of Haiti", "relevance": 0.396403, "dbpedia_resource": "http://dbpedia.org/resource/Politics_of_Haiti"}, {"text": "Latin America", "relevance": 0.395771, "dbpedia_resource": "http://dbpedia.org/resource/Latin_America"}, {"text": "Vibrio", "relevance": 0.38891, "dbpedia_resource": "http://dbpedia.org/resource/Vibrio"}], "categories": [{"score": 0.719586, "label": "/health and fitness/disease"}, {"score": 0.584195, "label": "/health and fitness/disease/epidemic"}, {"score": 0.217137, "label": "/business and industrial/pharmaceutical industry"}], "relations": [{"type": "locatedAt", "sentence": "Governments in regions affected by cholera are striving to eliminate the disease by developing a strong public health and sanitation infrastructure.", "score": 0.498338, "arguments": [{"text": "Governments", "location": [537, 548], "entities": [{"type": "GeopoliticalEntity", "text": "Governments"}]}, {"text": "regions", "location": [552, 559], "entities": [{"type": "Location", "text": "regions"}]}]}, {"type": "locatedAt", "sentence": "Governments in regions affected by cholera are striving to eliminate the disease by developing a strong public health and sanitation infrastructure.", "score": 0.591426, "arguments": [{"text": "cholera", "location": [572, 579], "entities": [{"type": "Person", "text": "cholera"}]}, {"text": "regions", "location": [552, 559], "entities": [{"type": "Location", "text": "regions"}]}]}, {"type": "hasAttribute", "sentence": "Governments in regions affected by cholera are striving to eliminate the disease by developing a strong public health and sanitation infrastructure.", "score": 0.694935, "arguments": [{"text": "cholera", "location": [572, 579], "entities": [{"type": "Person", "text": "cholera"}]}, {"text": "disease", "location": [610, 617], "entities": [{"type": "HealthCondition", "text": "disease"}]}]}, {"type": "partOfMany", "sentence": "Some of the key players are Valneva SE; Shantha Biotechnics Private Limited; and PaxVax, Inc. Key Topics Covered: Chapter 1 Executive Summary Chapter 2 Methodology and Scope Chapter 3 Cholera Vaccines Market Variables, Trends & Scope Chapter 4 Cholera Vaccines Market: Product Estimates & Trend Analysis Chapter 5 Cholera Vaccines Market: Regional Estimates & Trend Analysis Chapter 6 Competitive Landscape Shantha Biotechnics Private Limited Valneva SE PaxVax, Inc. Astellas Pharma, Inc. Merck & Co., Inc. GlaxoSmithKline plc (GSK) Pfizer, Inc. Takeda Pharmaceutical Co., Ltd. Emergent BioSolutions, Inc. AstraZeneca Mitsubishi Tanabe Pharma Corporation For more information about this report visit https://www.researchandmarkets.com/research/pv48bs/cholera_vaccines?w=4 Contacts ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Vaccines", "score": 0.867766, "arguments": [{"text": "Some", "location": [1543, 1547], "entities": [{"type": "Cardinal", "text": "Some"}]}, {"text": "players", "location": [1559, 1566], "entities": [{"type": "Person", "text": "players"}]}]}, {"type": "partOf", "sentence": "Some of the key players are Valneva SE; Shantha Biotechnics Private Limited; and PaxVax, Inc. Key Topics Covered: Chapter 1 Executive Summary Chapter 2 Methodology and Scope Chapter 3 Cholera Vaccines Market Variables, Trends & Scope Chapter 4 Cholera Vaccines Market: Product Estimates & Trend Analysis Chapter 5 Cholera Vaccines Market: Regional Estimates & Trend Analysis Chapter 6 Competitive Landscape Shantha Biotechnics Private Limited Valneva SE PaxVax, Inc. Astellas Pharma, Inc. Merck & Co., Inc. GlaxoSmithKline plc (GSK) Pfizer, Inc. Takeda Pharmaceutical Co., Ltd. Emergent BioSolutions, Inc. AstraZeneca Mitsubishi Tanabe Pharma Corporation For more information about this report visit https://www.researchandmarkets.com/research/pv48bs/cholera_vaccines?w=4 Contacts ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Vaccines", "score": 0.776782, "arguments": [{"text": "Merck & Co., Inc. GlaxoSmithKline plc", "location": [2032, 2069], "entities": [{"type": "Organization", "text": "Merck & Co., Inc. GlaxoSmithKline plc", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Regional Estimates & Trend Analysis\nChapter 6 Competitive Landscape\nShantha Biotechnics Private Limited Valneva SE PaxVax, Inc. Astellas Pharma, Inc.", "location": [1882, 2031], "entities": [{"type": "Organization", "text": "Regional Estimates & Trend Analysis\nChapter 6 Competitive Landscape\nShantha Biotechnics Private Limited Valneva SE PaxVax, Inc. Astellas Pharma, Inc."}]}]}, {"type": "employedBy", "sentence": "Some of the key players are Valneva SE; Shantha Biotechnics Private Limited; and PaxVax, Inc. Key Topics Covered: Chapter 1 Executive Summary Chapter 2 Methodology and Scope Chapter 3 Cholera Vaccines Market Variables, Trends & Scope Chapter 4 Cholera Vaccines Market: Product Estimates & Trend Analysis Chapter 5 Cholera Vaccines Market: Regional Estimates & Trend Analysis Chapter 6 Competitive Landscape Shantha Biotechnics Private Limited Valneva SE PaxVax, Inc. Astellas Pharma, Inc. Merck & Co., Inc. GlaxoSmithKline plc (GSK) Pfizer, Inc. Takeda Pharmaceutical Co., Ltd. Emergent BioSolutions, Inc. AstraZeneca Mitsubishi Tanabe Pharma Corporation For more information about this report visit https://www.researchandmarkets.com/research/pv48bs/cholera_vaccines?w=4 Contacts ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Vaccines", "score": 0.569111, "arguments": [{"text": "ResearchAndMarkets.com\nLaura Wood", "location": [2324, 2357], "entities": [{"type": "Person", "text": "ResearchAndMarkets.com\nLaura Wood"}]}, {"text": "Contacts", "location": [2315, 2323], "entities": [{"type": "Organization", "text": "Contacts", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "cholera vaccines market", "sentiment": {"score": -0.384526, "label": "negative"}, "relevance": 0.935028}, {"text": "global cholera vaccines", "sentiment": {"score": -0.384526, "label": "negative"}, "relevance": 0.677702}, {"text": "National Cholera Elimination", "sentiment": {"score": -0.459628, "label": "negative"}, "relevance": 0.598617}, {"text": "vaccines market size", "sentiment": {"score": -0.384526, "label": "negative"}, "relevance": 0.592507}, {"text": "Cholera Control", "sentiment": {"score": -0.384021, "label": "negative"}, "relevance": 0.525053}, {"text": "Cholera Platform", "sentiment": {"score": -0.384021, "label": "negative"}, "relevance": 0.52464}, {"text": "Vaccines Market Variables", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.479541}, {"text": "Trends Analysis Report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.446781}, {"text": "Shantha Biotechnics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.445376}, {"text": "Shantha Biotechnics Private", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.443106}, {"text": "strong public health", "sentiment": {"score": -0.373645, "label": "negative"}, "relevance": 0.430299}, {"text": "Mitsubishi Tanabe Pharma", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.42904}, {"text": "Valneva SE", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.42721}, {"text": "United Nations Organization", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.42565}, {"text": "various research projects", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.423825}, {"text": "epidemic diffusion mechanisms", "sentiment": {"score": -0.708769, "label": "negative"}, "relevance": 0.422489}, {"text": "Limited Valneva SE", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.420955}, {"text": "Global Task Force", "sentiment": {"score": -0.384021, "label": "negative"}, "relevance": 0.4196}, {"text": "rapid diagnostics tests", "sentiment": {"score": -0.708769, "label": "negative"}, "relevance": 0.417673}, {"text": "U.S./CAN Toll Free", "sentiment": {"score": 0.431954, "label": "positive"}, "relevance": 0.412485}, {"text": "Trend Analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.411497}, {"text": "report visit https://www.researchandmarkets.com/research/pv48bs/cholera_vaccines?w=4", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.410463}, {"text": "Senior Press Manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.41011}, {"text": "press@researchandmarkets.com", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.402427}, {"text": "Contacts ResearchAndMarkets.com", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.40239}, {"text": "market growth", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.386816}, {"text": "Vibrio cholerae", "sentiment": {"score": -0.708769, "label": "negative"}, "relevance": 0.37763}, {"text": "Latin America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.376237}, {"text": "anthropological studies", "sentiment": {"score": -0.254171, "label": "negative"}, "relevance": 0.374004}, {"text": "Segment Forecasts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.373204}, {"text": "forecast period", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.372878}, {"text": "Key Topics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.372457}, {"text": "key UN priority", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.371723}, {"text": "case studies", "sentiment": {"score": -0.447941, "label": "negative"}, "relevance": 0.371526}, {"text": "sensitization campaigns", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.371412}, {"text": "Emergent BioSolutions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.371001}, {"text": "sanitation infrastructure", "sentiment": {"score": -0.373645, "label": "negative"}, "relevance": 0.370341}, {"text": "Ongoing studies", "sentiment": {"score": -0.708769, "label": "negative"}, "relevance": 0.36985}, {"text": "Haitian Government", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.369826}, {"text": "major factors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.369577}, {"text": "Product Estimates", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.369455}, {"text": "key players", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.368266}, {"text": "Regional Estimates", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.368005}, {"text": "GMT Office", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.367687}, {"text": "Pharmaceutical Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.364836}, {"text": "E.S.T Office", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.364831}, {"text": "Executive Summary", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.36465}, {"text": "household visits", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.363329}, {"text": "Competitive Landscape", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.362845}]}, "extracted_metadata": {"sha1": "4aaad46d1fc7493f962c4d71b056fa021f90f497", "filename": "1541621567208.zip-dc8b31cd6515352bc4925acca2f74dfd.xml", "file_type": "json"}, "external_links": ["https://www.researchandmarkets.com/categories.asp?cat_id=747&campaign_id=pv48bs", "https://www.researchandmarkets.com/research/pv48bs/cholera_vaccines?w=4"], "title": "Cholera Vaccines (Dukoral, Shanchol, Vaxchora) Market Size, Share & Trends Analysis Report 2018 - Global Forecast to 2025 - ResearchAndMarkets.com", "forum_title": "All News | Business Wire"}, {"id": "enflJlrnPMUBUMjHaQmiO2qTd6vUQARSeBochuVlKGWDcqanUBhBff9Vaa5hFRIk", "result_metadata": {"score": 32.707436}, "author": "www.4-traders.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0.325017, "label": "positive"}, "text": "Barclays", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.725716, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "TAKEDA PHARMACEUTICAL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.910547}, {"text": "Barclays", "sentiment": {"score": 0.325017, "label": "positive"}, "relevance": 0.775237}, {"text": "AMENDMENT", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.639858}]}, "crawl_date": "2018-11-08T12:28:13Z", "url": "http://www.4-traders.com/BARCLAYS-9583556/news/Barclays-Form-8-3-TAKEDA-PHARMACEUTICAL-CO-LTD-AMENDMENT-27570553/", "host": "4-traders.com", "text": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC. are being disclosed: Name of offeror/offeree in relation to whose TAKEDA PHARMACEUTICAL CO LTD relevant securities this from relates: 2.", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-08T00:00:00+01:00", "enriched_text": {"entities": [{"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS PLC", "relevance": 0.749883, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Barclays PLC.", "relevance": 0.641113, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.597344, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SHIRE PLC", "relevance": 0.53258, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.516667, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Class of Product Nature", "relevance": 0.509454, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.435359, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Large Holdings Regulatory Operations", "relevance": 0.4259, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.410617, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,569,600 1.33%", "relevance": 0.410617, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,285,826 1.42%", "relevance": 0.410617, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,344,341 1.42%", "relevance": 0.410617, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,909,404 1.50%", "relevance": 0.410617, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "13,320,114 1.68%", "relevance": 0.410617, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,199,767 4.17%", "relevance": 0.410617, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "421,110 0.05%", "relevance": 0.410617, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "989,600 0.12%", "relevance": 0.410617, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.410617, "type": "Quantity"}], "sentiment": {"document": {"score": 0.108646, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "POSITIONS OF THE PERSON", "keywords": [{"text": "POSITIONS"}, {"text": "PERSON"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "options) and agreements to purchase/sell: 10,569,600 1.33% 989,600 0.12% TOTAL: 33,199,767 4.17% 13,320,114 1.68% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "agreements"}, {"text": "options"}, {"text": "TOTAL"}], "entities": [{"type": "Quantity", "text": "10,569,600 1.33"}, {"type": "Quantity", "text": "13,320,114 1.68"}, {"type": "Quantity", "text": "33,199,767 4.17"}, {"type": "Quantity", "text": "989,600 0.12"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,344,341 1.42% 11,909,404 1.50% (2) Cash-settled derivatives: 11,285,826 1.42% 421,110 0.05% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,569,600 1.33% 989,600 0.12% TOTAL: 33,199,767 4.17% 13,320,114 1.68% All interests and all short positions should be disclosed.", "object": {"text": "Stock-settled derivatives", "keywords": [{"text": "Stock-settled derivatives"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "33,199,767 4.17% 13,320,114 1.68% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}], "entities": [{"type": "Quantity", "text": "13,320,114 1.68"}, {"type": "Quantity", "text": "33,199,767 4.17"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,344,341 1.42% 11,909,404 1.50% (2) Cash-settled derivatives: 11,285,826 1.42% 421,110 0.05% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,569,600 1.33% 989,600 0.12% TOTAL: 33,199,767 4.17% 13,320,114 1.68% All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors' and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors' and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Class of relevant security Nature", "keywords": [{"text": "relevant security Nature"}, {"text": "Class"}]}, "sentence": " Class of relevant security Nature of dealing e.g. subscription, conversion", "object": {"text": "e.g. subscription, conversion", "keywords": [{"text": "e.g. subscription"}, {"text": "conversion"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "Irrevocable commitments and letters of intent", "keywords": [{"text": "Irrevocable commitments"}, {"text": "intent"}, {"text": "letters"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities", "keywords": [{"text": "option arrangement"}, {"text": "relevant securities"}, {"text": "indemnity"}, {"text": "agreement"}]}, "action": {"verb": {"text": "include", "tense": "future", "negated": true}, "text": "included", "normalized": "include"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any other person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "to: (i) the voting rights of any relevant securities under any option", "keywords": [{"text": "voting rights"}, {"text": "relevant securities"}, {"text": "option"}], "entities": []}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "020 3134 7213 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " YES Date of disclosure: 8 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "The Panel's Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "disclosure requirements"}, {"text": "relation"}, {"text": "consultation"}, {"text": "Code"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "details", "keywords": [{"text": "details"}]}, "sentence": " Full details should be given so that the nature of the interest or position can be fully understood: It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.", "object": {"text": "on a Supplemental Form (Open Positions)", "keywords": [{"text": "Supplemental Form"}, {"text": "Open Positions"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "to provide", "normalized": "to provide"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel's Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "disclosure requirements"}, {"text": "relation"}, {"text": "consultation"}, {"text": "Code"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "Barclays plc", "keywords": [{"text": "Barclays plc"}], "entities": [{"type": "Company", "text": "BARCLAYS PLC", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}]}, "sentence": " Barclays plc published this content on 08 November 2018 and is solely responsible for the information contained herein.", "object": {"text": "this content", "keywords": [{"text": "content"}]}, "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}, {"subject": {"text": "by Public", "keywords": [{"text": "Public"}]}, "sentence": " Distributed by Public, unedited and unaltered, on 08 November 2018 12:23:09 UTC", "object": {"text": "09 UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "Distributed", "tense": "past"}, "text": "Distributed", "normalized": "Distributed"}}], "concepts": [{"text": "Option", "relevance": 0.974065, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.775305, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.71168, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Put option", "relevance": 0.616899, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Stock", "relevance": 0.613042, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Option style", "relevance": 0.432538, "dbpedia_resource": "http://dbpedia.org/resource/Option_style"}, {"text": "Derivative", "relevance": 0.425921, "dbpedia_resource": "http://dbpedia.org/resource/Derivative_(finance)"}, {"text": "Options", "relevance": 0.390147, "dbpedia_resource": "http://dbpedia.org/resource/Options"}, {"text": "Moneyness", "relevance": 0.381581, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}, {"text": "Security", "relevance": 0.357589, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "Barclays", "relevance": 0.3414, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}, {"text": "Bond", "relevance": 0.330724, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Contract", "relevance": 0.326258, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}], "categories": [{"score": 0.575672, "label": "/real estate/buying and selling homes"}, {"score": 0.476772, "label": "/finance/financial news"}, {"score": 0.447184, "label": "/finance/investing"}], "relations": [{"type": "agentOf", "sentence": "settled derivative transactions Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV SWAP Long 53 4,659.5340 JPY Ordinary NPV SWAP Long 112 4,686.1295 JPY Ordinary NPV SWAP Long 225 4,686.7046 JPY Ordinary NPV SWAP Long 281 4,691.8119 JPY Ordinary NPV SWAP Long 300 4,704.1239 JPY Ordinary NPV SWAP Long 705 4,709.2790 JPY Ordinary NPV SWAP Long 1,417 4,693.5204 JPY Ordinary NPV SWAP Long 2,200 4,701.5000 JPY Ordinary NPV SWAP Long 2,227 4,654.8284 JPY Ordinary NPV SWAP Long 4,544 4,667.9176 JPY Ordinary NPV SWAP Long 6,947 4,686.3828 JPY Ordinary NPV SWAP Long 11,531 4,700.6271 JPY Ordinary NPV SWAP Long 22,958 4,705.2680 JPY Ordinary NPV CFD Short 1,400 4,675.4671 JPY Ordinary NPV SWAP Short 2,200 4,701.5000 JPY (c) Stock-settled derivative transactions (including options) (i) Writing, selling,", "score": 0.682599, "arguments": [{"text": "i", "location": [6305, 6306], "entities": [{"type": "Person", "text": "JPY Ordinary NPV SWAP Short"}]}, {"text": "Writing", "location": [6308, 6315], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [7279, 7285], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [7296, 7303], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "YES Date of disclosure: 8 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.817481, "arguments": [{"text": "Rule 8", "location": [8204, 8210], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [8218, 8222], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "employedBy", "sentence": "Note 5(i) on Rule 8 of the Takeover Code (the 'Code') 1.", "score": 0.846433, "arguments": [{"text": "Rule 8", "location": [8650, 8656], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Takeover Code", "location": [8664, 8677], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [8285, 8309], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [8277, 8282], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [10865, 10889], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [10857, 10862], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [8444, 8449], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [8463, 8490], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [11024, 11029], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [11043, 11070], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "managerOf", "sentence": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC.", "score": 0.419441, "arguments": [{"text": "person", "location": [8726, 8732], "entities": [{"type": "Person", "text": "PERSON"}]}, {"text": "Barclays PLC", "location": [8758, 8770], "entities": [{"type": "Organization", "text": "BARCLAYS PLC\nAttachments\nOriginal", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "managerOf", "sentence": "Sep 2019 Ordinary NPV Call Options Written -70,000 4598.0000 European 14 Jun 2019 Ordinary NPV Put Options Purchased -48,000 4625.0000 European 12 Oct 2018 Ordinary NPV Put Options Purchased -39,000 5781.0000 European 14 Dec 2018 Ordinary NPV Put Options Written 70,000 4598.0000 European 14 Jun 2019 Ordinary NPV Put Options Written 75,900 4286.5200 European 6 Sep 2019 Ordinary NPV Put Options Written 78,000 5781.0000 European 14 Dec 2018 Ordinary NPV Put Options Written 104,700 5065.8300 European 17 Apr 2019 Ordinary NPV Put Options Written 114,000 4750.0200 European 14 May 2019 Ordinary NPV Call Options Purchased 10,000,000 4528.6397 European 5 Oct 2018 Ordinary NPV Put Options Written 10,000,000 4528.6397 European 5 Oct 2018 3.", "score": 0.325547, "arguments": [{"text": "5", "location": [10436, 10437], "entities": [{"type": "Person", "text": "5"}]}, {"text": "European", "location": [10427, 10435], "entities": [{"type": "GeopoliticalEntity", "text": "European", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "agentOf", "sentence": "View source version on businesswire.com: https://www.businesswire.com/news/home/20181108005410/en/ BARCLAYS PLC Source: BARCLAYS PLC Attachments Original document Permalink Disclaimer Barclays plc published this content on 08 November 2018 and is solely responsible for the information contained herein.", "score": 0.986041, "arguments": [{"text": "Permalink Disclaimer\nBarclays plc", "location": [11236, 11269], "entities": [{"type": "Organization", "text": "BARCLAYS PLC\nAttachments\nOriginal", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "published", "location": [11270, 11279], "entities": [{"type": "EventCommunication", "text": "published"}]}]}, {"type": "timeOf", "sentence": "View source version on businesswire.com: https://www.businesswire.com/news/home/20181108005410/en/ BARCLAYS PLC Source: BARCLAYS PLC Attachments Original document Permalink Disclaimer Barclays plc published this content on 08 November 2018 and is solely responsible for the information contained herein.", "score": 0.709802, "arguments": [{"text": "08 November 2018", "location": [11296, 11312], "entities": [{"type": "Date", "text": "08 November 2018"}]}, {"text": "published", "location": [11270, 11279], "entities": [{"type": "EventCommunication", "text": "published"}]}]}], "keywords": [{"text": "JPY Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.93111}, {"text": "Ordinary NPV Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.597068}, {"text": "Ordinary NPV Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519388}, {"text": "Ordinary NPV SWAP", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.384288}, {"text": "NPV SWAP Long", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.356822}, {"text": "Ordinary NPV Interests", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.285142}, {"text": "USD Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.280337}, {"text": "securities Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.277755}, {"text": "Ordinary NPV CFD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.274744}, {"text": "relevant securities", "sentiment": {"score": 0.229926, "label": "positive"}, "relevance": 0.243285}, {"text": "NPV Call Options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.240597}, {"text": "NPV Put Options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.225527}, {"text": "NPV SWAP Short", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.222889}]}, "extracted_metadata": {"sha1": "4821f1517f199c5366552385844aa2badfea74dc", "filename": "1541680093567.zip-1b19471e9cc72d75cded530d1b448b4b.xml", "file_type": "json"}, "external_links": ["https://www.businesswire.com/news/home/20181108005410/en/", "http://www.publicnow.com/view/2F31B2332DDA4296AA4888EAC8992D4A6C67ED9E", "http://otp.investis.com/clients/uk/barclays1/rns/regulatory-story.aspx?cid=68&newsid=1206114"], "title": "Barclays : Form 8.3 - TAKEDA PHARMACEUTICAL CO LTD - AMENDMENT", "forum_title": "Markets : News, Latest News - Marketscreener.com"}, {"id": "Cu_3r9eaKNy2PRc7-hpSBiW1SWbe9dscAMCidTwdgjbtht4dRYgsYFUPIR8fn8jq", "result_metadata": {"score": 32.497795}, "author": "businesswire.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS PLC", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "UK", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["Country"]}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Barclays", "relevance": 0.972986, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}, {"text": "United Kingdom", "relevance": 0.700474, "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.5607, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.6964, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.412502, "label": "/law, govt and politics/government"}], "relations": [], "keywords": [{"text": "BARCLAYS PLC UK", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.901143}, {"text": "TAKEDA PHARMACEUTICAL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.587635}, {"text": "Regulatory Announcement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.506342}, {"text": "Amendment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.302334}]}, "crawl_date": "2018-11-08T14:48:50Z", "url": "https://www.businesswire.com/news/home/20181108005414/en/BARCLAYS-PLC-UK-Regulatory-Announcement-Form-8.3", "host": "businesswire.com", "text": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC. are being disclosed: Name of offeror/offeree in relation to whose TAKEDA PHARMACEUTICAL CO LTD relevant securities this from relates: 2.", "main_image_url": "http://www.businesswire.com/images/bwlogo_square.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-08T12:16:00-06:00", "enriched_text": {"entities": [{"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Barclays PLC.", "relevance": 0.744283, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.71112, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SHIRE PLC", "relevance": 0.577055, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Class of Product Nature", "relevance": 0.571543, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS", "relevance": 0.55166, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.542896, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Contacts BARCLAYS PLC", "relevance": 0.526865, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.51284, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Large Holdings Regulatory Operations", "relevance": 0.469755, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.452922, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,255,300 1.29%", "relevance": 0.452922, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,521,600 1.32%", "relevance": 0.452922, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,941,600 1.38%", "relevance": 0.452922, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,660,864 1.49%", "relevance": 0.452922, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,775,786 1.48%", "relevance": 0.452922, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "12,185,679 1.53%", "relevance": 0.452922, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,382,579 4.20%", "relevance": 0.452922, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,958,250\n4.30%", "relevance": 0.452922, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.452922, "type": "Quantity"}], "sentiment": {"document": {"score": 0.106395, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "POSITIONS OF THE PERSON", "keywords": [{"text": "POSITIONS"}, {"text": "PERSON"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "all short positions", "keywords": [{"text": "short positions"}]}, "sentence": " 4.30% 33,382,579 4.20% All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Class of relevant security Nature", "keywords": [{"text": "relevant security Nature"}, {"text": "Class"}]}, "sentence": " Class of relevant security Nature of dealing e.g. subscription, conversion", "object": {"text": "e.g. subscription, conversion", "keywords": [{"text": "e.g. subscription"}, {"text": "conversion"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "Irrevocable commitments and letters of intent", "keywords": [{"text": "Irrevocable commitments"}, {"text": "intent"}, {"text": "letters"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities", "keywords": [{"text": "option arrangement"}, {"text": "relevant securities"}, {"text": "indemnity"}, {"text": "agreement"}]}, "action": {"verb": {"text": "include", "tense": "future", "negated": true}, "text": "included", "normalized": "include"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any other person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "to: (i) the voting rights of any relevant securities under any option", "keywords": [{"text": "voting rights"}, {"text": "relevant securities"}, {"text": "option"}], "entities": []}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "020 3134 7213 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " YES Date of disclosure: 8 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "details", "keywords": [{"text": "details"}]}, "sentence": " Full details should be given so that the nature of the interest or position can be fully understood: It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.", "object": {"text": "on a Supplemental Form (Open Positions)", "keywords": [{"text": "Supplemental Form"}, {"text": "Open Positions"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "to provide", "normalized": "to provide"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Receipt", "keywords": [{"text": "Receipt"}]}, "sentence": " Short Name: BARCLAYS PLC Category Code: RET Sequence Number: 658991 Time of Receipt (offset from UTC): 20181108T115546+0000 Contacts BARCLAYS PLC", "object": {"text": "from UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "offset", "tense": "past"}, "text": "offset", "normalized": "offset"}}], "concepts": [{"text": "Option", "relevance": 0.978134, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.739318, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.697238, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Put option", "relevance": 0.62152, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Stock", "relevance": 0.506292, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Option style", "relevance": 0.410843, "dbpedia_resource": "http://dbpedia.org/resource/Option_style"}, {"text": "Options", "relevance": 0.405718, "dbpedia_resource": "http://dbpedia.org/resource/Options"}, {"text": "Moneyness", "relevance": 0.378821, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}, {"text": "Security", "relevance": 0.348345, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "Contract", "relevance": 0.329883, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Bond", "relevance": 0.325077, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Unit type", "relevance": 0.302841, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "United States dollar", "relevance": 0.299693, "dbpedia_resource": "http://dbpedia.org/resource/United_States_dollar"}, {"text": "Barclays", "relevance": 0.295658, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}], "categories": [{"score": 0.5853, "label": "/real estate/buying and selling homes"}, {"score": 0.46493, "label": "/finance/financial news"}, {"score": 0.449162, "label": "/finance/investing"}], "relations": [{"type": "agentOf", "sentence": "JPY Ordinary NPV Sale 3,200 4,593.4218 JPY Ordinary NPV Sale 5,000 4,618.5000 JPY Ordinary NPV Sale 5,800 4,591.7931 JPY Ordinary NPV Sale 7,300 4,620.4246 JPY Ordinary NPV Sale 7,800 4,617.1794 JPY Ordinary NPV Sale 9,100 4,623.8131 JPY Ordinary NPV Sale 19,500 4,627.0000 JPY Ordinary NPV Sale 35,000 TRANSFER Ordinary NPV Sale 87,500 4,612.3805 JPY Ordinary NPV Sale 112,200 4,600.9073 JPY Ordinary NPV Sale 209,800 4,609.0734 JPY Ordinary NPV Sale 405,800 4,600.0931 JPY Ordinary NPV Sale 405,900 4,599.9152 JPY (b) Cash-settled derivative transactions Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV CFD Long 27,900 4,595.0000 JPY (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling,", "score": 0.682599, "arguments": [{"text": "i", "location": [5354, 5355], "entities": [{"type": "Person", "text": "JPY Ordinary NPV Sale"}]}, {"text": "Writing", "location": [5357, 5364], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [6328, 6334], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [6345, 6352], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "YES Date of disclosure: 8 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.817481, "arguments": [{"text": "Rule 8", "location": [7253, 7259], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [7267, 7271], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "employedBy", "sentence": "Note 5(i) on Rule 8 of the Takeover Code (the \"Code\") 1.", "score": 0.522588, "arguments": [{"text": "Rule 8", "location": [7699, 7705], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Takeover Code", "location": [7713, 7726], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [7334, 7358], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [7326, 7331], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [9845, 9869], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [9837, 9842], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [7493, 7498], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [7512, 7539], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [10004, 10009], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [10023, 10050], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "managerOf", "sentence": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC.", "score": 0.419441, "arguments": [{"text": "person", "location": [7775, 7781], "entities": [{"type": "Person", "text": "PERSON"}]}, {"text": "Barclays PLC", "location": [7807, 7819], "entities": [{"type": "Organization", "text": "Barclays PLC", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Sep 2019 Ordinary NPV Call Options Written -70,000 4598.0000 European 14 Jun 2019 Ordinary NPV Put Options Purchased -39,000 5781.0000 European 14 Dec 2018 Ordinary NPV Put Options Written 70,000 4598.0000 European 14 Jun 2019 Ordinary NPV Put Options Written 75,900 4286.5200 European 6 Sep 2019 Ordinary NPV Put Options Written 78,000 5781.0000 European 14 Dec 2018 Ordinary NPV Put Options Written 104,700 5065.8300 European 17 Apr 2019 Ordinary NPV Put Options Written 114,000 4750.0200 European 14 May 2019 Ordinary NPV Call Options Purchased 10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Call Options Written -10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Put Options Purchased -10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Put Options Written 10,000,000 4620.0372 European 6 Nov 2018 3.", "score": 0.30982, "arguments": [{"text": "6", "location": [9339, 9340], "entities": [{"type": "Person", "text": "6"}]}, {"text": "European", "location": [9330, 9338], "entities": [{"type": "GeopoliticalEntity", "text": "European", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "basedIn", "sentence": "Short Name: BARCLAYS PLC Category Code: RET Sequence Number: 658991 Time of Receipt (offset from UTC): 20181108T115546+0000 Contacts BARCLAYS PLC", "score": 0.626381, "arguments": [{"text": "UTC", "location": [10150, 10153], "entities": [{"type": "Organization", "text": "UTC"}]}, {"text": "Receipt", "location": [10129, 10136], "entities": [{"type": "GeopoliticalEntity", "text": "Receipt"}]}]}], "keywords": [{"text": "Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.951075}, {"text": "JPY Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.903293}, {"text": "Ordinary NPV Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.735859}, {"text": "Ordinary NPV Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.721929}, {"text": "Ordinary NPV Interests", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.414571}, {"text": "TRANSFER Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.412242}, {"text": "USD Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.408187}, {"text": "securities Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.406588}, {"text": "relevant securities", "sentiment": {"score": 0.229926, "label": "positive"}, "relevance": 0.395538}, {"text": "NPV Call Options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.361899}, {"text": "NPV Put Options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.348899}, {"text": "Options Written", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.318242}, {"text": "relevant security", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.312391}, {"text": "supplemental form", "sentiment": {"score": 0.425721, "label": "positive"}, "relevance": 0.262607}, {"text": "short positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.260197}, {"text": "open positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.257594}, {"text": "unit security securities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.257252}, {"text": "Product description e.g.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.25589}, {"text": "relevant security Product", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.25497}, {"text": "class", "sentiment": {"score": -0.251285, "label": "negative"}, "relevance": 0.254712}, {"text": "security Product description", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.254512}, {"text": "Market Surveillance Unit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.253713}, {"text": "USD ADR Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.252772}, {"text": "Options Purchased", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.251532}, {"text": "number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.240433}, {"text": "securities ADR Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.239415}, {"text": "person", "sentiment": {"score": 0.210866, "label": "positive"}, "relevance": 0.235664}, {"text": "USD ADR Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.235378}, {"text": "TAKEDA PHARMACEUTICAL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.235139}, {"text": "new securities", "sentiment": {"score": 0.582177, "label": "positive"}, "relevance": 0.234873}, {"text": "Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.234639}, {"text": "Barclays PLC.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.234551}, {"text": "KEY INFORMATION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.234374}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.234072}, {"text": "disclosure", "sentiment": {"score": 0.210866, "label": "positive"}, "relevance": 0.233878}, {"text": "relevant Purchase/sale Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.233623}, {"text": "additional class", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.233184}, {"text": "details", "sentiment": {"score": 0.0877267, "label": "positive"}, "relevance": 0.233162}, {"text": "monetary amounts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.232972}, {"text": "Takeover Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.232615}, {"text": "derivative transactions", "sentiment": {"score": -0.412596, "label": "negative"}, "relevance": 0.232306}, {"text": "relevant description reference", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.231948}, {"text": "Short Positions Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.231875}, {"text": "PUBLIC OPENING POSITION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.231435}, {"text": "relevant security Nature", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.231347}, {"text": "stock-settled derivative positions", "sentiment": {"score": -0.27481, "label": "negative"}, "relevance": 0.231296}, {"text": "securities Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.231101}, {"text": "cash-settled derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.230698}, {"text": "stock-settled derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.229814}, {"text": "e.g. call option", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.229638}]}, "extracted_metadata": {"sha1": "a68577532b69703112607ce8ab8064a47427877e", "filename": "1541688530237.zip-65e7c1b1760723ea9a05e13825fb3582.xml", "file_type": "json"}, "title": "BARCLAYS PLC UK Regulatory Announcement: Form 8.3 - TAKEDA PHARMACEUTICAL CO LTD - Amendment", "forum_title": "All News | Business Wire"}]}